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CHAPTER 1 
 
General Introduction 
  
Bone 
Bone is a complex and dynamic tissue, which is naturally remodeled throughout entire life. It is a natural 
composite material, which by weight contains about 60% mineral, 30% matrix and 10-20.% water [1]. The 
matrix primarily consists of collagen, responsible for the tensile strength. The mineral component of bone is 
mainly calcium phosphate, which confers the compressive strength [2]. In the body, bone tissue serves as 
number of functions, such as providing mechanical support, protection of the vital organs, acting as 
calcium/mineral reservoir [3], and serving as a niche for bone marrow cells and hematopoiesis. 
1. Tissue Engineering 
Organ and tissue loss, or failure resulting from an injury or other type of damage, is a major human health 
problem. Tissue or organ transplantation is a standard therapy to treat patients suffering from such conditions, 
but remains severely limited by donor shortage. Other available therapies including surgical reconstruction, 
drug therapy, synthetic prostheses, and medical devices are not limited by supply, but they do have other 
problems. For example, synthetic prostheses and medical devices are not able to replace all the functions of a 
damaged or lost organ or tissue. The efforts to address these problems and limitations have elicited the 
development of new biomaterials and alternative therapies. Tissue engineering has emerged as a promising 
alternative approach to treat the loss or malfunction of a tissue or organ without the limitations of current 
therapies.  Tissue engineering involves the expansion of cells from a small biopsy, followed by the culturing of 
the cells in temporary three-dimensional scaffolds to form the new organ or tissue, possibly in the presence of 
stimulating growth factors. By using the patient's own cells, this approach has the advantages of autografts, but 
without the problems associated with adequate supply [4]. 
 
2. Bone Biomaterials 
Regarding bone tissue engineering as a whole, currently emphasis is put on the development of instructive 
materials and synthetic scaffolds for bone tissue regeneration as promising alternatives to overcome the 
problems associated with routine therapeutic solutions (i.e. autografts, allografts). Theoretically, the ideal bone 
graft should be osteogenic, biocompatible, biodegradable, able to provide structural support, easy to use and 
cost-effective. A composite graft usually  combines an osteoconductive matrix with bioactive agents that 
provide osteoinductive and osteogenic properties [5]. A number of three-dimensional porous scaffolds 
fabricated from various biodegradable materials have been developed and used for tissue engineering of bone 
tissue. 
 
3. Bone Biomaterials Imaging  
The growing complexity of bone substitute materials as mentioned above, also supports the need for advanced 
techniques for accurate and reproducible morphological and functional characterization. Functionality of 
substitute materials is usually assessed by monitoring the interactions between the scaffold and the 
surrounding environment, including bone formation throughout the defect area, vascular ingrowth, scaffold 
resorption, bone remodeling and restoration of mechanical properties [6]. Although preliminary in vitro studies 
are appropriate for demonstrating initial proof of concept, these parameters must ultimately be tested in vivo. 
Thus, the evaluation of any novel implant material or tissue engineered construct commonly relies mainly on 
histological examination, even though it is now obvious that more sensitive, quantitative, and non-invasive 
methods are needed. Therefore, imaging technologies have gained interest in the past decade [7], advances in 
bone engineering,   currently underline the limits of simple x-ray imaging. Although, advanced follow-up 
methods are pivotal to develop. With regard to bone applications, imaging systems can be categorized into 
generally morphological/anatomical or functional imaging techniques: ultrasound (US), magnetic resonance 
imaging (MRI) and computed tomography (CT) are usually used for anatomical imaging, while  optical imaging 
(OI)  (fluorescence and bioluminescence), positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) are usually used for metabolic imaging [8]. Moreover, dedicated preclinical 
  
scanners have become available, with sensitivity and resolution even higher than clinical scanners, thus 
favoring a quick translation from preclinical to clinical applications.  
 
4. Objectives of the thesis 
The overall objectives of this thesis were to investigate imaging-based strategies to enhance Calcium 
Phosphate-to-bone contrast, and to monitor the osteogenic performance of synthetic materials throughout the 
implantation period. Animal models were also used to identify the optimal combinations of defect model and 
imaging modality, depending on the specific applications. 
 
More specifically, the following research questions were covered:   
  
1. What is the current state of the art in  bone  and biomaterial imaging? 
2. Is Magnetic Resonance Imaging suitable for the imaging of bone and Calcium Phosphate-based 
materials? 
3. How can the Calcium Phosphate cement-to-bone contrast be enhanced in both CT and MRI? 
4. How can an MR contrast agent be upgraded to theranostic agent to promote bone regeneration? 
5. Are Positron Computed Tomography and/or Single Photon Computed Tomography suitable to 
measure bone healing?  
6. Is Positron Computed Tomography suitable to discriminate bone healing response in the presence of 
different synthetic bone substitutes, as well as supra-physiological healing induced by growth factors 
(BMP-2) ? 
7. What is the influence of formulation and storage conditions on rhBMP-2 bioactivity? 
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CHAPTER 2 
 
Preclinical Imaging in Bone Tissue Engineering 
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1. Introduction 
Bone imaging found its origin in 1895, when the existence of X-rays was first demonstrated by 
Wilhelm Röntgen. Since then, bone has remained the most commonly imaged tissue, and thus  
developments in the field of bone medical imaging have been most evident compared to other fields 
of medical imaging [1]. These developments have resulted in sustained knowledge of bone anatomy, 
physiology and pathophysiology, either at the tissue, cell, or molecular level, but in term also 
constantly arising new and more challenging questions.   
Regarding bone tissue engineering as a whole, currently emphasis is put on the development of 
instructive materials and synthetic scaffolds for bone tissue regeneration as promising alternatives to 
overcome the problems associated with routine therapeutic solutions (i.e. autografts, allografts). The 
growing complexity of such alloplastic bone substitute materials though, supports the need for 
advanced techniques for accurate, reproducible and morphological and functional characterization. 
Functionality of substitute materials is usually assessed by monitoring the interactions between the 
scaffold and the surrounding environment. Such measures include bone formation throughout the 
defect area, vascular ingrowth, scaffold resorption, bone remodeling and restoration of mechanical 
properties [2]. Although preliminary in vitro studies are appropriate for demonstrating initial proof of 
concept, these parameters must ultimately be tested in vivo. Thus, the evaluation of any novel 
implant material or tissue engineered construct commonly relies mainly on histological examination. 
Despite histology is still considered as final proof, it is now obvious that more sensitive, quantitative, 
real-time and non-invasive methods are needed. Therefore, imaging technologies have gained 
interest in the past decade [3].  
Besides the clinically established methods, X-Ray Computed Tomography (CT), Magnetic Resonance 
Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography 
(SPECT) and Ultrasound (US), more recent imaging tools like molecular ultrasound, high field MRI, 
Photoacoustics and Optical Imaging (OI)  are also currently in the stage of development. Dedicated 
scanners for small animal imaging (mice/rats) are now available for all the aforementioned 
modalities, with time and spatial resolution comparable to, or even higher than clinical scanners.  
Preclinical imaging is defined as the visualization of biochemical, physiological and anatomical 
phenomena in living animals for research purposes [4]. The application of longitudinal studies, and 
the use of healthy sites within each animal as inherent control, offers scientific and statistical 
benefits while simultaneously reducing the number of animals required [5], compared to classical 
histological assessments. With regard to bone applications, imaging systems (Figure 1) can be 
categorized into generally morphological/anatomical or functional imaging techniques: US, MRI and 
CT are usually used for anatomical imaging, while  OI  (fluorescence and bioluminescence), PET and 
SPECT are usually used for metabolic imaging [6]. 
 
  
 
 
Figure 1. The tissue engineering approach typically involves a combination of biomaterials, cells, and inducible factors that 
are expected to generate tissues following implantation in vivo. The imaging techniques showed here have all been 
successfully applied, based on their characteristics (i.e. spatial resolution), to evaluate specific aspects of bone tissue 
engineering applications. 
CT could be regarded as the gold standard for bone imaging and many of its strengths and applications have 
been reviewed elsewhere [7, 8, 9, 10]. Therefore, in the present manuscript, only the most recent 
breakthrough CT applications will be discussed. Instead, the innovative approaches from other modalities, 
commonly restricted to soft tissue imaging (e.g. MRI and ultrasound), will be here presented as alternative 
and/or support to CT imaging for bone tissue engineering applications.  
Although each imaging modality relies on a different physical principle, the critical requirement for any useful 
medical imaging technology is contrast, i.e. the target structure in the body should report a different signal 
compared to its surrounding. Contrast may either be classified as being endogenous or exogenous. A major 
example of endogenous contrast is the difference between signal from bone and surrounding soft tissue in X-
ray imaging. Exogenous contrast, instead, is created by administering a foreign substance, usually called tracer, 
probe or contrast agent, depending on the respective imaging modality [11].  
 
In the next paragraphs, the main features and disadvantages of each imaging modality summarized in Table 1, 
will be discussed in regard to bone regenerative technologies. Moreover, characteristics and availability of 
contrast agents/probes/radiotracers will be explored and noticeable applications to bone substitutes and 
biomaterials characterization will be reported. 
 
  
 
 
Table 1. Strengths and weaknesses of imaging modalities. 
 
2. Nuclear Imaging 
Nuclear medicine imaging is based on the detection of radioactive biologically active substances, which  
biodistribution, physiological uptake, and pathophysiologic behavior reflect a particular body function or 
metabolism. Upon radioactive decay the tracer emits photons (or positrons) that can be detected and  mapped 
as a function of time and space [12]. 
 
Nuclear Imaging radiotracers 
 
Targeting agents for nuclear imaging are called tracers, as only traces of these compounds (picomolar amounts) 
are usually enough to be detected. When designing a nuclear imaging tracer, some basic requirements have to 
be achieved [13, 14]: 
- A radioactive tracer is a biological compound in which one or more atoms are replaced by a radioisotope 
which should behave identically as the biological compound. 
- The radioactivity should not change chemical and physical properties of the targeted molecule, nor affect 
the surrounding physiological environment. 
- The tracer should be present in a very low concentration so that it does not perturb the 
biological process under study. 
- The concentration of the radiolabeled compound should be maintained during the investigational period. 
- The accumulation and retention of the tracer should correlate with biological responses specific to the 
system under study. 
- The minimum amount of activity necessary to allow accurate measurements and counting rates in the 
samples should be employed.  
 
Radioactive tracers decay by emitting either gamma rays or positrons (which annihilate generating gamma 
rays), respectively detected by SPECT and PET (Figure 2a and b). These two major nuclear imaging modalities 
will be described in the next paragraphs. 
 
  
 
 
Figure 2. Schematic representation of PET and SPECT principle (a) In PET, the radiotracer accumulates in the tissue to be 
studied and decays by emitting a positron (β+). Within a very short travelling range, the positron collides and annihilates 
with an electron (e-), simultaneously releasing two gamma rays (photons) into opposite directions. These two photons are 
detected by a series of detectors and processed as specific signal coincidence. (b) In SPECT, the accumulated radiotracer 
directly emits photons in all directions. These photons are restricted by a collimator, so that each point in the image 
corresponds to a unique point in the source. Without the presence of the collimator in front of the detectors, the final 
image would be indistinct. (c) 18F physiological bone uptake in a rat. 18F signal (red) is overlapped on a 3D Computed 
Tomography scan. 
 
2.1 PET  
 
Radioisotopes with a deficit of neutrons decay by emitting a positron, for example Oxygen-15 (
15
O), Nitrogen-
13 (
13
N), Carbon-11 (
11
C), Fluorine-18 (
18
F), Iodine 124 (
124
I). The released positron can only travel over a very 
short range through tissues before meeting an electron and annihilating. The annihilation produces two gamma 
rays (photons) which are emitted in opposite direction (with precise energy of 511 keV) and detected in PET as 
coincidence by opposite detectors. Only simultaneously detected photons with a 180˚ angle between the 
trajectories are considered as real coincidences. This peculiarity allows the reduction of most unspecific signals 
while overcoming the use of collimators, as are necessary for SPECT (described below) [15]. Many PET isotopes 
have relatively short half-lives which, for the most commonly used radionuclides, range from ~2 min of 
15
O to 
~110 min of 
18
F. These must be produced on-site in a cyclotron, or at least nearby (so-called satellite PET 
centres), when only 
18
F is used. For this reason PET is the most costly of all the major medical imaging 
techniques.  
  
Concerning bone applications,  the most widely used tracer is 
18
F-Fluoride (
18
F). Its specific and rapid bone 
uptake (Figure 2c), together with its rapid blood clearance, results in a high bone-to-background ratio within 
less than one hour following intravenous administration. 
18
F-Fluoride became widely used for skeletal scintigraphy after its introduction by Blau and others in the early 
1960s and was approved for clinical use by the U.S. Food and Drug Administration in 1972 [16]. Currently, 
nearly all 
18
F used for clinical and preclinical applications is produced in a cyclotron using a one-step reaction 
with isotopically enriched (≥ 95%) 
18
O water as the target: 
 
18
O + p = 
18
F + n. 
Several curies of 
18
F can be produced using short irradiation times (2 h) with beam currents (<100 µA) that are 
achievable with clinical cyclotrons. The 
18
F that is produced in this reaction is collected as 
18
F-fluoride by 
passage of the irradiated water through an ion-exchange column. If the 
18
F-fluoride is to be used for bone 
scanning, no further chemical processing is required. 
Imaging can most optimally be performed less than 1 h after 
18
F-Fluoride administration, as tracer retention by 
the bone is a two-phase process. First, the 
18
F- ion exchanges for an OH- ion on the surface of the 
hydroxyapatite matrix of bone. In the second phase, the 
18
F- ion migrates into the crystalline matrix of bone, 
where it is retained until the bone is remodeled [17].  
Living bone is a dynamic tissue, as throughout the skeleton, and especially at areas of repair, bone  is constantly 
being resorbed and deposited in the process of remodeling. Thus, for clinicians, areas of increased uptake of 
18
F-fluoride in the skeleton reflect sites of increased blood flow and bone remodeling,  by means of enhanced 
osteoblast activity and enhanced osteoid production. These areas of enhanced 
18
F-fluoride incorporation are 
usually indication of metastatic activity. If on the one hand 
18
F-fluorodeoxyglucose (FDG) is the most used 
reporter of the presence of tumor metastasis, on the other hand, 
18
F- Fluoride (or Sodium Fluoride, 
18
F-NaF) is 
the most sensitive tracer to detect early bone lesions and areas of active bone healing due to the locally 
increased remodeling activity.  
A recent study from Hsu et al. sought to compare the two tracers and to determine the utility of 
18
F-fluoride, 
which localizes in regions of high osteoblastic activity, and 
18
F-FDG, an indicator of enhanced cellular glucose 
consumption, in assessing bone healing in a rat femural fracture model. Fracture healing was assessed with 
18
F-
fluoride, and 
18
F-FDG PET scans over a period of 4 weeks. While 
18
F scans revealed progressively increased 
signal uptake at the union site during fracture repair, 
18
F-FDG scans were not helpful in differentiating 
metabolic activity between successful and delayed bone healing [18]. 
Adult stem cells are promising therapeutic agents for skeletal regeneration. Their follow-up in terms of homing 
to the injured site and biological activity should be validated to support their in vivo application. PET can be 
used as validation method, as in the study of Lee et al., where a population of systemically administered 
adipose-derived multipotent cells (ADMCs) was tracked in a mouse model of skeletal injury. 
18
F- fluoride PET 
imaging proved that the cells could migrate and home to the site of the femural injury, where they promoted 
healing of the damaged tissue [19]. Similarly, Lin et al. used 
18
F-NaF PET as quantitative tool to show that bone 
marrow-derived Mesenchymal Stem Cells (BMSCs) expressing the bone morphogenetic protein BMP-2 and the 
vascular endothelial growth factor (VEGF) contributed to the repair of critical-sized femoral [20] as well as 
calvarial defects in rabbits [21]. After transplantation, 
18
F-NaF PET analyses demonstrated that the sustained 
BMP2/VEGF expression remarkably ameliorated both the angiogenesis and regeneration of the bone defects, 
when compared with the control groups. 
Defined by reduced bone strength and increased bone mass loss, osteoporosis is frequently linked with bone 
quality deterioration. Dai et al. used 
18
F- NaF PET to analyze the impact of osteoporosis on the occurrence of 
microdamage, by observing the change in 
18
F-fluoride uptake in the tibia of ovariectomized rats after fatigue 
loading. As result, a significant PET signal was detected in areas of bone microdamage, later identified and 
confirmed by histomorphometric measurements [22]. 
Blood flow also plays a fundamental role in new bone production and repair but, due to the high density of 
bone, it is generally difficult to quantify with X-ray-based techniques. The study of Tomlinson et al., presents a 
valid PET-based modeling technique to evaluate blood flow and fluoride metabolism in a pre-clinical stress 
  
fracture model of osteogenesis in rats. Bone formation was induced by forelimb compression in adult rats and 
15
O-water and 
18
F-fluoride PET imaging were used to evaluate blood flow and fluoride kinetics 7 days after 
loading. 
15
O water was modeled using a one-compartment, two-parameter model, while a two-compartment, 
three-parameter model was used to model the kinetics of 
18
F-fluoride. Results indicated a significant increase in 
blood flow and kinetics, in addition to increased fluoride incorporation into the bone [23].  
 
Gallium 68 tracers 
Despite 
18
F is the far most common PET radioisotope, the dependence on a cyclotron and the complex 
chemistry associated with incorporation of the tracer into the molecules of interest, limits the use of 
18
F-based 
tracers. Gallium 68 (
68
Ga) is another positron emitter (half life of 68 minutes) produced by a 
68
Germanium/
68
Gallium generator, which makes its production independent of an onsite cyclotron [23]. 
Therefore, 
68
Ga-labeled bone imaging agents are currently the object of extensive preclinical research. New 
promising bone seeking agents have been created by labeling bisphosphonates with 
68
Ga using different 
chelators. Recent examples of those first tracers are a 
68
Ga-labeled NOTA-conjugated bisphosphonate (
68
Ga-
NOTA-BP) synthesized by Suzuki et al. [24] or a 
68
Ga-TRAP-conjugated bisphosphonate synthesized by Notni et 
al. [25].  
2.2  SPECT  
 
SPECT tracers are isotopes that decay, while producing gamma rays emitted in random direction. Imaging is 
performed by using a gamma camera to acquire multiple 2-D images (projections), from multiple angles. In 
order to detect the direction from which the signal originates, a collimator is used. Images are then 
reconstructed using tomographic reconstruction algorithms, yielding a 3-D dataset. Technetium-99m (
99m
Tc), 
iodine-123 (
123
I), iodine-131 (
131
I), iodine-125 (
125
I) and indium-111 (
111
I) linked to target molecules are the main 
clinically and preclinically employed tracers [26]. SPECT isotopes generally have relatively long half-lives 
(ranging from 6 hours for 
99m
Tc to 60 days for 
125
I) which allow for longitudinal studies. Furthermore, synthesis 
does not require an on-site cyclotron, thus offering greater accessibility and making the method, generally, less 
expensive compared to PET [27]. Currently available small-animal SPECT can provide spatial resolutions up to 
200 micrometer, while sensitivity, resolution and field of view are dependent upon the pinhole collimator of 
the instrument which influences the number of detected or rejected gamma rays. 
Concerning bone related applications, 
99m
Tc is the most widely used radionuclide, clinically and preclinically. 
99m
Tc is a very versatile radioisotope. It is easy to produce in a generator, by decay of 
99
Molybdenum (Mo).  
99
Mo → 
99m
Tc + e− + γ. The molybdenum isotope has a half-life of approximately 66 hours and the generator 
has a useful life of 1-2 weeks. Most commercial 
99m
Tc generators use column chromatography, in which 
99
Mo in 
the form of molybdate, is adsorbed onto acid alumina. When the 
99
Mo decays it forms 
99m
Tc-pertechnetate, 
which is eluted from the solid phase of the generator with saline.  
In the early 1970s, 
99m
Tc-labeled polyphosphates and pyrophosphate were introduced as bone-imaging agents, 
but were later abandoned in favor of the more specific 
99m
Tc-labeled bisphosphonates which chelate 
99m
Tc-
technetium quite efficiently, while maintaining their hydroxyapatite (HA) binding properties [28]. Currently, 
methylene diphosphonate (
99m
Tc-MDP) and  hydroxymethylene diphosphonate (
99m
Tc-HDP) are the only 
99m
Tc-
based radiopharmaceuticals approved for bone imaging. Both tracers selectively bind to HA: accumulation is 
considered to the result of both chemical adsorption onto the surface, as well as incorporation into the 
crystalline structure [29]. 
99m
Tc-MDP is often used in preclinical bone tissue engineering studies, especially to evaluate bone defect repair 
following implantation of diverse engineered scaffolds. For example, Lindsey et al. described the characteristics 
of bone healing in a femoral segmental defect reconstructed with a titanium cage in a canine model. 
99m
Tc-
MDP scanning was performed to quantitatively and qualitatively assess the biologic activity of the specimens 
up to 18 weeks.  Results confirmed a sustained biological activity throughout the whole specimen, supporting 
  
the hypothesis that the cages promote confluent bone healing across the entire defect [30]. In the same way, a 
prevascularized tissue engineered scaffold, containing a co-culture of mesenchymal stem cells (MSCs) and 
MSC-derived endothelial cells (ECs) in porous b-tricalcium phosphate ceramic (b-TCP) was evaluated for the 
ability to repair large segmental ulnar defects in rabbits. Examination by 
99m
Tc-MDP SPECT, as well as X-ray, 
histological analysis, and biomechanical tests were used to evaluate repair and the vascularization of the 
implants. The results of the SPECT analyses demonstrated that osteogenesis and vascularization were more 
pronounced in the prevascularized bone group compared to the controls, indicating the effectiveness of the 
approach [31]. 
As 
99m
Tc-MDP  shows  limitations to both pharmacokinetic and chemical stability, current research efforts focus 
on the synthesis and preclinical evaluation of novel 
99m
Tc-bisphosphonates complexes. The aim is to produce a 
tracer with enhanced specific uptake in the bone, while lowering serum proteins binding and soft tissue uptake 
[32, 33]. As example, the group of Lin et al. substituted MDP with a zoledronic acid (ZL) derivative, 1-hydroxy-3-
(1H-imidazol-1-yl)propane-1,1-diyldiphosphonic acid (IPrDP), which was successfully labeled with 
99m
Tc and 
tested in mice. Biodistribution of 
99m
Tc-IPrDP showed significant advantages over 
99m
Tc-ZL and 
99m
Tc-MDP in 
terms of bone resorption, clearance from soft tissues and faster specific accumulation, which leads to faster 
acquisition procedures, as it allows images to be acquired at earlier time points [34].  
One of the other major applications of SPECT in bone tissue engineering is the labeling of active molecules, 
such as growth factors, in order to monitor their release from implanted scaffold materials. The release of the 
growth factor can be traced longitudinally and its biological effect (i.e. bone formation) can be monitored, thus 
this strategy holds great potential for the optimization of growth factor delivery vehicles [35]. This approach 
was used by van de Watering et al. to evaluate both in vitro and in vivo release kinetics of bone morphogenetic 
protein-2 (BMP-2) loaded into calcium phosphate cement (CPC) scaffolds. The protein was either (i) loaded 
onto poly(d,l-lactic-co-glycolic acid) (PLGA) microparticles, (ii) incorporated into the liquid phase of the CPC, or 
(iii) absorbed to the surface of preset, porous CPC. The efficacy of the different loading methods in terms of 
release and osteoinductive capacity of the obtained scaffolds was then evaluated using (125)I-labeled BMP-2 in 
vitro and in a subcutaneous rat model in vivo over a period of 28 days [39]. The same method has also been 
used to monitor the release of BMP-2 release from an hyaluronan-based hydrogel system [36] and the release 
of vascular endothelial growth factor (VEGF) and platelet derived growth factor-BB (PDGF-BB) from a platelet-
rich plasma (PRP) gel membrane [37], among many other examples. 
3. Magnetic Resonance Imaging (MRI) 
MRI is a form of Nuclear Magnetic Resonance (NMR) based upon the proton movement of the hydrogen atoms 
(H
+
), abundant as water in tissues. Protons are positively charged particles that spin in random directions in the 
absence of an external magnetic field. When a strong magnetic field is applied, however, the protons align and 
result in a net magnetization vector. When hit with precise radio frequency (RF) pulses, the magnetization 
vector resonates and flips from the longitudinal to the transverse plane. Once the frequency is turned off, the 
transverse component (T2) decays and the longitudinal component (T1) recovers, a brief radio signal is 
emitted. Its intensity reflects the number of protons in a particular slice of tissue. Endogenous contrast arises 
because different tissues have different decay and recovery times (T2 and T1 values). Thus, MRI works 
particularly well to discriminate different soft tissues as well as abnormalities within the same tissue. 
Still, in regards to low-water containing tissues like bone, important considerations have to be made.  
Cortical bone contains approximately 20% water by volume [38] and most of it resides in the microscopic pores 
of the Haversian and the lacunocanalicular systems. In conjuction, a smaller fraction is bound to collagen and 
the matrix substrate, or embedded in the crystals of the apatite mineral [39]. The bone water protons possess 
extremely short transverse relaxation times (T2 ≤ 500 µsec).  Their signal is, therefore, not detectable with 
standard imaging pulse sequences in which echo times are typically on the order of milliseconds. Thus, in 
classical MRI, the bony structures appear dark (Figure 3a).  Based on this loss of signal, MRI has been used to 
assess growth and development of bone in preclinical studies with an indirect method, namely by monitoring 
the disappearance of MR signal in proton density MR images and correlating this to the newly formed bone 
  
appearance [40, 41, 42, 43], or to validate cell-seeding procedures and assess the fate of the transplanted cells 
in vivo, in 3D porous scaffolds [44, 45]. 
However, recently developed MR imaging techniques which employ radial read-outs in conjunction with short-
duration radiofrequency pulses enable the signal acquisition to start tens of microseconds after excitation and, 
therefore, to directly visualize bone [46].  These ultrafast MR imaging sequences are not widely available yet 
and require special high-speed imaging hardware, which is currently mainly applied to small animal devices 
[47]. Animal MRI systems were initially constructed using lower field strength magnets, such as 2T. However, 
developments in the design of superconducting magnets have led to higher field strength instruments, such as 
4.7T, 7T, and 11.7T and thereby to spatial resolution in the range of 10-100 µm [48]. In the last decade,  and 
especially in the last few years, dedicated sequences with ultrashort echo times have been developed in order 
to reduce as much as possible T2 signal decay and loss of data. The most promising, and more often applied to 
direct hard tissue imaging, are Ultrashort Echo Time (UTE), Zero Echo Time (ZTE) (Figure 3B), and SWeep 
Imaging with Fourier Transformation (SWIFT). 
 
 
 
Figure 3. 2D MR images of a rat femoral condyle. (a) Conventional MR imaging. Due to the low amount of water and the 
low T2 relaxation time, bone tissue appears dark. (b) Zero echo-time imaging allows the detection of signal components 
with T2 relaxation times on the order of only a few hundred microseconds, allowing detailed bone imaging. 
 
3.1 UTE  
 
The echo time (TE) is defined as the interval between the end of the radio frequency (RF) pulse and the 
beginning of the sampling window (15), and accordingly to the standard definition, it is considered as ultrashort 
within a range of 0.05 - 0.50 ms [49].  Ultrashort echo-time imaging allows the detection of signal components 
with T2 relaxation times on the order of only a few hundred microseconds (i.e. cortical bone, dentine, enamel, 
tendons, ligaments and periosteum).  
The achievable echo time for UTE imaging methods is mainly determined by the transmit/receive switching 
times of the coils, which are typically in the order of 100 µs, but can be shortened by the use of dedicated 
hardware. Moreover, to minimize the short T2 signal decay prior to acquisition, the duration of the RF 
excitation pulse and the echo time must be reduced. This can be done by using fast switching coils which 
ensure a minimal TE and minimize signal decay, and by starting the sampling simultaneously with the rising 
slope of the readout gradient [50, 51]. 
As key elements in bone tissue engineering, imaging of bone substitute materials for both anatomical 
visualization and material characterization would be desirable. The measurement of bone water located into 
the material’s pores has been recently used to estimate a range of mechanical properties [52]. One approach is 
to use adiabatic inversion to null long T2* components surrounding the CPC. In this example, a two-
dimensional UTE pulse sequence with a minimal nominal echo time of 8 µseconds was used together with 
bicomponent analysis to quantify the bound and free water in cortical bone using a clinical 3T scanner. Total 
water concentration was measured using a three-dimensional UTE sequence together with a reference water 
phantom. UTE-MR measures of water content (total, free, and bound), T2* (short and long), and short and long 
  
T2* fractions were compared with porosity assessed with µCT, as well as elastic (modulus, yield stress, and 
strain) and failure (ultimate stress, failure strain, and energy) properties. Results suggest that UTE-MR 
measures are indeed sensitive to the structure and failure properties of human cortical bone, and may provide 
a novel way of evaluating cortical bone quality [53].  
 
3.2 ZTE 
 
The UTE technique enables particularly short TE, since after the excitation pulse, data acquisition is started 
immediately. Still, the challenge of the UTE sequence is that acquiring data during gradient ramping can lead to 
major image distortions. ZTE imaging overcomes this problem as the echo time can even be reduced to zero by 
switching on the projection gradient even before applying the RF pulse [54]. This approach still implies a 
certain, although very limited, initial loss of data during transmit/receive switching, which might result in image 
artifacts. Different methods and algebraic reconstructions have been implemented to address this initial gap 
[55, 56, 57]. Still, as gradients are already on when the RF pulse is applied, limitation in bandwidth and duration 
of the pulses may occur. As further and improved alternative, Sweep imaging with Fourier transformation 
(SWIFT), allows to reach higher signal-to-noise ratios compared to the other sequences. 
 
3.3 SWIFT 
 
SWIFT uses a swept RF excitation pulse and nearly simultaneous acquisition, performed within the RF gaps, to 
obtain images with essentially zero TE in the presence of field gradients. This allows to reduce losses due to T2 
signal decay and, unlike the UTE technique, SWIFT demand on the scanner’s gradient hardware are greatly 
reduced. With simultaneous RF excitation and signal acquisition, SWIFT produces less distortion in the presence 
of materials that have magnetic susceptibility, and is less sensitive to motion artifacts [58, 59].  
As example of preclinical application, this technique has been used to detect areas of calcification (commonly 
found in several metabolic disorders) in the brain, in rat models of status epilepticus and traumatic brain injury. 
Calcifications were detected in phase and imaginary SWIFT images based on their dipole like magnetic field 
disturbances. In magnitude SWIFT images, calcifications were distinguished as hypointense and hyperintense. 
Hypointense calcifications showed large crystallized granules with few surrounding inflammatory cells, while 
hyperintense calcifications contained small granules with the presence of more inflammatory cells. The size of 
the calcifications in SWIFT magnitude images correlated with that in Alizarin stained histological sections [60].  
One of the newest and most promising application of SWIFT, is in clinical dentistry. The possibility to perform 
simultaneous three-dimensional hard and soft tissue imaging of teeth in clinically relevant scanning times, 
without subjecting patients to ionizing radiation, represent a big improvement in diagnostic imaging. The study 
of Idiyatullin et al. [58], among others, aimed to assess the feasibility of SWIFT to visualize dental tissues, in 
vitro in a 9.4T system and in vivo using a 4T system. SWIFT images were compared with traditional two-
dimensional radiographs, three-dimensional cone-beam computed tomography (CBCT), gradient-echo MR 
imaging technique, and histological sections. A resolution of 100 microns could be obtained from in vitro teeth 
and SWIFT also identified the presence and extent of dental caries and fine structures of the teeth, including 
cracks and accessory canals, which are not visible with existing clinical radiography techniques. 
 
3.4 
31
P 
 
Typically, MRI detects only the signal from free water, using a single nuclear isotope (
1
H). Extending the reach 
of MRI to combine UTE and nuclear magnetic resonance (NMR) spectroscopy, other elements  like phosphorus 
(
31
P) can also be detected. 
31
P is particularly abundant in both bone mineral and cell membranes and MR 
images have been used to reveal the 
31
P density in bone samples, and to detect early signs of new 
mineralization, in vitro and in vivo in several preclinical studies [61, 62].  
  
Since the technique is capable of quantitatively distinguish the phosphates in artificial scaffolds from the ones 
in natural newly formed bone, 
31
P solid-state NMR spectroscopy also represents a quantitative tool to detect 
the formation of newly deposited bone matrix within artificial bone grafts. One example is the study from 
Weber et al. who evaluated the formation of extracellular matrix in poly(D,L-lactide-co-glycolide) (PLGA) bone 
implants. To this end, porous PLGA matrices were implanted into rat tibiae and analysed by NMR after 2, 4 or 8 
weeks. The inorganic component of the matrix, bioapatite, could be detected by 
31
P NMR spectroscopy and 
differentially quantified within the inorganic extracellular matrix formed de novo versus the native bone [63].  
 
3.5 Exogenous contrast in bone MRI 
 
When endogenous tissue contrast is not present, or not sufficient to clearly identify the target tissue, 
exogenous contrast agents (CA) have to be used. Upon accumulation in tissues, such CAs cause significant 
alterations in the local T1 and/or T2 and are usually divided into 2 main categories based on the relaxation 
process they affect. T1-alteration causes a positive and increased signal intensity (i.e. Gadolinium and 
Manganese ions), while T2-affected images appear darker, with decreased signal intensity (i.e. Iron-based 
agents). 
The combination of contrast agents and the above described acquisition methods could provide not only 
anatomical but also functional information due to the fact that bone seeking probes of many types can be 
labeled with MR detectable tags (eg, Gd, 
19
F, Fe) and thereafter be used as molecular probes.  
Several types of compounds exhibit strong affinity for bone tissue, including heavy metals, tetracyclines, and 
bisphosphonates [64]. The latter are the most used and well described in literature. Bone binding mainly occurs 
by physisorption (weak intermolecular interactions) and/or chemisorption (strong interactions through 
covalent bonds) [65].  
Bisphosphonate moieties are often incorporated as side chain in macrocyclic molecules, commonly 
polyaminopolycarboxylates analogs (e.g. DOTA, DTPA, NOTA). The macrocyclic structure is then maintained by 
the presence of a lanthanide metal ion (most commonly gadolinium, which is the gold standard T1 affecting 
agent), which gives the contrast and is linked into the central cavity.  
Several attempts have been made in order to optimize kinetic stability and relaxivity of the resulting 
complexes. These properties are often significantly decreased upon adsorption on the hydroxyapatite surface 
[66]. 
One important aspect, with the use of a CA based on gadolinium, still is the clearance from the skeleton 
following the binding. In most cases the clearance is too slow, increasing the risk of localized lanthanides-
related toxicity [67]. 
Differently, the Iron oxide-based T2-affecting contrast agents, were never used directly as targeting probes. Still 
they find extensive use in labeling and tracking, for instance to visualize the fate of stem cells within bone 
engineered constructs and scaffolds. Among others, a recent example comes from the work of Lalande et al. 
Their study aimed to validate cell-seeding procedures in 3D porous scaffolds and to assess the fate of human 
Adipose Derived Stem Cells (hADSCs) transplanted in vivo.  hADSCs were isolated, labelled with Ultra Small 
Super Paramagnetic Iron Oxide (USPIO)-rhodamine and seeded within a 3D porous polysaccharide-based 
scaffold. MR imaging was then performed in vitro and in vivo, in a subcutaneous  model in mice, up to 28 days 
after implantation. Results showed that USPIO were efficiently internalized by hADSCs and generated a high 
T2* contrast. Moreover, in vivo, cells remained detectable over the entire observational period and could 
migrate from the scaffold, colonizing the surrounding area [68].  
When looking at the other main aspect of bone tissue engineering, the biomaterial scaffold, also potential 
applications of CAs exist. For instance, polymer materials like the conventional bone cements cannot be 
detected directly in MRI [69]. These biomaterials mainly consist of water-free matrix, (e.g. hydrophobic 
polymethylmethacrylate (PMMA), calcium phosphate, etc) and thus conventionally in MRI can only be detected 
indirectly as a lack of signal. The clear identification and differentiation of materials and surrounding structures 
could, for instance, be the base for safe MR-guided material injections. Only an MR-visible scaffold can cope 
  
with complications, like leakage, and improve postoperative diagnostics in treated bones. For this purpose, 
several bone substitute have been combined with MRI-contrast agents for signal induction [70, 71]. 
In the case of orthopedic cements, for instance, the work of Sun et al. [70], presents a good example of the 
combination of this widely used material with the two most common clinical MR contrast agents, USPIO 
(Sinerem
®
) and gadopentetatedimeglumine Gd-DTPA (MagneVist
®
). MR Zero Echo Time (ZTE) imaging was 
performed in vitro and in vivo, up to 8 weeks after the implantation of the CPCs in a femoral condyle defect 
model in rats. In the presence of both contrast agents and over the entire observational period, CPCs could be 
visualized as areas of hypointensity.  
Still, despite the contrast enhancement, the incorporation of both contrast agents (with the exception of the 
lowest concentration, 1% w/w, of Gd-DTPA) negatively  affected the mechanical properties of the cement. This 
phenomenon is often described in literature and  strategies to preserve the physico-mechanical behavior of the 
implanted material should also be taken into account. A possible strategy to overcome this problem has been 
presented by Ventura et al. In this study, inert silica beads were used as vector for the encapsulation of 
contrast-enhancing agents, thus minimizing aspecific reactivity. The study aimed to evaluate the feasibility of a 
dual contrast agent (DCA), traceable with both CT and MRI as enhancer of CPC/bone tissue contrast. Colloidal 
Gold and Superparamagnetic Iron oxide particles (SPIO) were encapsulated into the silica beads. The bead 
suspension was incorporated into the calcium phosphate cements which were then tested in vitro and in vivo in 
a femoral condyle defect model in rats. The mechanical properties of the cements, were not significantly 
altered and, CT and ZTE-MR imaging performed over a period of 8 weeks, showed a short-term CT contrast 
enhancement but a long-term MR effect. Due to the inert behavior of the carrier, we assume that the DCA 
could be incorporated within virtually any kind of ceramic or polymer-based materials [72]. 
 
4. Optical Imaging 
 
Different from most of the other imaging methods, endogenous sources of optical contrast from small animal 
tissue are not routinely in the scope of pre-clinical studies. Therefore, fluorescent probes have to be introduced 
exogenously and, due to the spatial and temporal resolutions of Optical Imaging instruments, submicromolar 
concentrations are usually sufficient [73]. 
OI has rapidly gained popularity in preclinical imaging because this technology is non-invasive, longitudinal, 
radioactivity free, relatively economical, and images interpretation is generally straightforward. These 
combined properties also allow for high-throughput approaches. Optical imaging has excellent sensitivity (in 
the p-mol concentration range) as well as high specificity. As potential disadvantage, anatomical resolution is 
relatively poor (1mm) due to scattering of light in tissue. Light absorption by tissue limits detection to a couple 
of centimeters in tissue depth. Therefore, despite being the oldest between all imaging modalities, it is 
minimally used in the clinic and translational applications are questionable or at least still under development. 
Only recent advances in optical imaging probes and animal models now allow to image bone and bone related 
processes, providing functional information together with the structural information, commonly acquired with 
X-ray-based techniques [74].  Optical imaging can be divided in bioluminescence imaging (BLI) and fluorescence 
imaging (FLI), which both will shortly be described in the next two chapters (Figure 4a). 
 
4.1 Bioluminescence imaging 
Bioluminescence refers to the enzymatic generation of visible light by living organisms. The most commonly 
used bioluminescent reporter gene for research purposes is luciferase, derived from the firefly Photinus pyralis. 
This enzyme catalyses the transformation of its substrate D-luciferin into oxoluciferin, in an oxygen and ATP-
dependent process, leading to emission of photons at wavelengths from 500 to 620nm, with sufficient intensity 
to cross animal tissues, including bone [75]. 
For instance, effective bioluminescent imaging in bone can be achieved by using transgenic mice harboring the 
luciferase reporter gene, downstream of an osteogenesis specific promoter [76]. Several Luciferase transgenic 
  
animal models are available to investigate a number of bone tissue engineering related processes and include 
BMP-4-luciferase mice [77], bone sialoprotein (BSP)-luciferase mice [78], bone specific enhancer of the mouse 
collagen type I-luciferase mice [79], human osteocalcin (hOC)-luciferase mice [80], etc.  
As previously mentioned, in vivo evaluation of seeding, proliferation and osteogenic differentiation of 
mesenchymal stem cells within different 3D scaffolds represent an essential step in bone tissue engineering 
and several examples have been reported in literature [81, 82]. One of these is the study from Dègano et al., 
who used bioluminescence imaging, together with bone densitometry and histology, to analyze the bone 
regeneration capacity of human bone marrow and adipose tissue mesenchymal stem cells, seeded in an 
osteoconductive arginine-glycine-aspartate (RGD) crosslinked hydrogel scaffold. Combinations of scaffold with 
and without labeled cells were implanted in mouse calvarial defects, and monitored over a 12 week period. 
Results showed that luciferase labeled stem cells could be monitored in vivo through a prolonged period, 
during which hBMSCs showed  better survival as compared to the hAMSCs [83]. Apart from Luciferase itself, a 
class of enzyme-activated probes or activity-based “smart probes”  is also available and provides functional 
information on local enzymatic activity. As example, a pH-activatable probe proved to be a powerful tool for 
the selective in vivo detection of low-pH regions created by bone-resorbing osteoclasts [84].  
 
4.2  Fluorescence imaging  
In contrast to BLI, FLI is not based on the production of photons by an enzymatic reaction. Instead, a 
fluorescent compound, or fluorophore can be excited by photons of a certain wavelength from an external light 
source. Upon relaxation to its ground state, the fluorophore emits photons at a different wavelength and this is 
the signal which is used for imaging [85].  
Several classes of fuorophores have been reported but, for bone tissue engineering purposes, tetracyclines  
probably represent the most important members, due to their ability to target and bind bone. Polychrome 
sequential labeling with tetracyclines is a standard technique for the investigation of bone formation and 
regeneration processes in vivo, allowing longitudinal morphometric measurements. It is based on the injection 
of different tetracycline at different time points. As the tetracyclines target the new forming bone, this will end 
up carrying different labels, reflecting the time of deposition [86]. Despite the application advantages, 
tetracyclines should be used cautiously due to the potential and still unclear side effects on bone remodeling 
[87].  
Less debated bone seeking molecules, like bisphosphonates, can also be linked to fluorophores to visualize the 
process of bone regeneration in vivo. As example, the study from Wen et al. used fluorescently labeled 
pamidronate to prove the skeletal biodistribution of intravenously injected bisphosphonate is anatomic site-
dependent in a rat model system.  The systemic injection of the fluorescent bisphosphonate was followed by in 
vivo whole body fluorimetry and demonstrated regional differences in both uptake and release of 
bisphosphonates from oral, axial, and appendicular bones [88]. 
Still, when using fluorescence for in vivo imaging, tissue absorbance, scattering and auto-fluorescence (mostly 
in the green part of the spectrum) can become a problem, especially when imaging structures that are located 
deeper in the animal. Near infrared (NIR) light causes hardly any auto-fluorescence,  light penetration is 
improved, while tissue absorption and scattering are greatly reduced. For these reasons, the most recently 
developed fuorophores work mostly in the so called optical window (Figure 4 b),  the near infrared region of 
the spectrum. Some of the bisphosphonate-targeted NIR fluorophores for use in small animal imaging are 
Pam78 [89], IRDye 800 CW [90], OsteoSense680 and OsteoSense750 [91], which are all commercially available 
[75].  
 
  
 
 
Figure 4. (a) Representation of Bioluminescence and Fluorescence imaging reporters. Luciferase enzymes, commonly 
expressed by engineered cells, catalyze the production of light photons from the injected substrate luciferin, in the 
presence of ATP and oxygen. Fluorescence imaging requires light of appropriate wavelength to interact and excite the 
reporter molecule, which emits light with a defined wavelength, specific for each reporter or dye. (b) The absorption 
spectra of major tissue light absorbers haemoglobin and water. In the optical window there is little single-photon 
absorption. (c) A photograph and a fluorescence image of a mouse with a subcutaneous tumor that received a tumor-
targeting compound labeled with the fluorescent dye IRdye800CW. 
 
4.3 Fluorescent computed tomography 
The availability of more, and more specific NIR targeting probes contributes to overcome most of the 
drawbacks caused by the limited tissue penetration depth of light. Still, planar imaging cannot quantify 
fluorescence or provide depth or size information. Fluorescence molecular tomography (FMT) imaging is a 
novel modality used for localization and absolute quantification of fluorescent probes in tissues.  
In principle, tissues are illuminated at different points or projections and the collected light is used for image 
reconstruction, in combination with a mathematical formulation that describes photon propagation in tissues, 
in which they are still highly scattered [92]. FMT is mainly used in combination with NIR probes. Still the 
observed light intensity in images does not actually represent true fluorochrome distribution, but a mixed 
effect of fluorescence photons and their modification by the optical properties of tissue. A promising way to 
account for this limit is to combine FMT with CT (or MRI), enabling the co-registration of anatomical and 
  
molecular information, and the design of absorption/scattering maps corrections [93]. To examine the 
performance of a new hybrid FMT-XCT system in challenging deep regions, bone growth and remodeling 
studies were performed after systemic administration of the NIR bisphosphonate (pamidronate) imaging agent, 
OsteoSense
TM
 in a mouse model of osteogenesis imperfecta [94] or following the implantation of genetically 
modified MSCs. In the latter example, murine mesenchymal stem cells overexpressing the osteogenic gene 
BMP2 were implanted into the thigh muscle and into a radial non-union bone defect model in mice. Real-time 
imaging of bone formation was performed following systemic administration of OsteoSense
TM
. The mice 
underwent imaging on days 7, 14, and 21 post-implantation. Mice injected with mMSCs overexpressing BMP2, 
into the thigh muscle showed a significant fluorescent signal, whereas little or no signal could be detected in 
mice injected with MSCs which did not overexpress BMP2. The inclusion of XCT information into the FMT 
inversion highly improved the quality of the outcome [95].  
  
4.4 Scaffold Characterization 
A full characterization of bone substitute materials is routinely performed prior to the implantation. Still, post-
implantation follow up and in vivo characterization would also be desirable to determine the material 
performance. Specifically for chemical and structural characterization of 3D scaffold materials, different OI 
techniques are available for application in vivo. These most prominently are Optical Coherence Tomography 
(OCT) and Raman Spectroscopy.  Depending on the specific application, OCT can be further divided into 
Structural OCT, which monitors cell dynamics and cell-material interactions, OCT elastography, which generates 
maps of strain to reflect the spatially dependent biomechanical properties, and spectroscopic OCT to 
differentiate different cell types [96].  
Raman Spectroscopy is used to determine the vibrational and rotational modes of molecules and compounds 
based on inelastic scattering phenomena, thus to gather information on the organic and mineral states of the 
material, without the addition of chemical or fluorescent markers. Bone structure generates strong Raman 
bands, which can be associated with the quantities of phosphate, carbonate and collagen components, as well 
as less intense collagen bands associated with collaged amino acids, notably proline, hydroxyproline and 
phenylalanine. These individual components can be used to determine the composition of the carbonated 
apatite and octacalcium phosphate within the bone matrix, which are used as bone health markers. Previous 
research using samples from both animal models and ex vivo human patients has shown that it is even possible 
to determine disease states and bone maturation from Raman scattering data [97, 98].  A purely visual 
approach is to directly label  the scaffold with fluorescent probes, in order to monitor its degradation and 
substitution with newly growth bone over time [99, 100]. 
While, as previously described, OI generally detects light from the visible or near-infrared spectra, it is worth to 
mention that recent innovative studies reported the possibility of detecting common radionuclides like 18F-
FDG, 18F-Na or 90Y by commercially available OI instruments. To do so, Liu et al. surveyed the detectability of 
varying amounts of commonly used radionuclides by an IVIS Spectrum OI system. These radionuclides included 
β+ emitters (
18
F and 
64
Cu), β− emibers (
131
I, 
90
Y, and 
177
Lu), and γ emitters (
111
In and 
99m
Tc). With the exception 
of 
99m
Tc, all tested radionuclides provided optical signals with good sensitivity with 1–5 min acquisition time 
[101]. 
 
4.5 Fourier Transform Infrared Spectroscopy 
Similarly to Raman spectroscopy, Fourier transform infrared (FTIR) spectroscopy is based on the principle that 
all chemical bonds undergo vibrations that encompass a variety of motions of the atomic groupings within the 
molecular framework. These include bond stretching, angle bending, wagging (change in angle between a bond 
and a plane), and twisting (change in angle between two planes). If a particular motion is accompanied by a 
dipole moment change, when illuminated with infrared (IR) radiation, it will absorb at a specific infrared 
frequency. The wavelengths of many IR absorption bands are characteristic of specific types of chemical bonds, 
therefore IR spectroscopy is often used to identify compounds. Furthermore, in the IR, shifts in band intensities 
  
and positions are also caused by changes in the environment of the molecule, enabling descriptions of 
variations in these environments [102, 103]. In regards to bone related applications, FTIR has been especially 
applied to establish bone quality and explore tissue variability, as FTIR spectra can provide information on all 
bone tissue components. Information are currently available from both the mineral and matrix (i.e. collagen) 
components.  With FTIR, the relative amount, molecular nature, distribution and orientation of the 
components of connective tissues can be evaluated at a pixel resolution of 6.25 um and a spatial resolution of 
1.3–13 microns [104, 105].  
The major bone and bone material parameters that can be determined by FTIR spectroscopy are (i) mineral to 
matrix ratio, (ii) mineral maturity/crystallinity, and (iii) collagen maturity, mostly aimed to provide insights into 
molecular changes that occur in diseases of connective or collagen-based tissues, including osteoarthritis, 
osteoporosis, osteogenesis imperfecta, osteopetrosis and pathologic calcifications. Moreover, these technique 
has also been used to probe chemical changes associated with load, disuse, and micro-damage in bone, and 
with degradation and repair in cartilage [106].  
Due to the strong absorbance of water in the infrared, tissues are commonly dehydrated before analysis, so 
that the water spectrum is not observed. For FTIR measurement of bone, light is usually passed through thin 
and transparent section of 2–3 µm, for which the tissue must be embedded in a hard resin such as polymethyl 
methacrylate or glycol methacrylate, whereas for measurements of tissue engineered bone structures, most 
often, implant scaffold compositions are evaluated as homogenized samples [107].  
In bone tissue engineering, FTIR applications have been reported in regards to the characterization and 
assessment of the quality of the mineral formed on different materials [108, 109], for example by monitoring 
the nucleation and growth of calcium phosphate on amine-, carboxyl- and hydroxyl-silane self-assembled 
monolayers [110]. In the same way, another recent study used FTIR Imaging to localize where hydroxyapatite 
formed on bioglass templates, placed in a saline solution [111]. 
The quality of biomaterial-to-surrounding tissue contact could also be assessed, as shown in the study of 
Schmitt et al., where the crystallization process was monitored at the polymer/calcium-phosphate and bone 
tissue interface [112]. The applications of FTIR microspectroscopy to the study of injectable composite for bone 
and dental surgery for analyses of bone and dental implant materials have been reviewed in [113]. In 
conclusion, FTIR micro-spectroscopy is not a routine pre-clinical screening tool yet, unless non-invasive 
methodologies can be developed, because up to this moment bone biopsies are required. On the other hand, it 
is a powerful research tool, providing unique insights into the pathophysiology of musculoskeletal diseases 
[106]. 
5. Ultrasound 
Ultrasound refers to sound waves that are not detectable by the human ear implying waves with frequencies 
greater than 20,000 cycles/ sec (Hz) [102]. Diagnostic ultrasound commonly uses frequencies between 2 and 15 
MHz (2*106 and 15*106 cycles/sec) with a resolution up to 200 µm, whereas with ultrasonic microimaging and 
small animal imaging high frequency systems (25-82.5MHz), a resolution of 30 µm at a maximum depth of 15 
mm is now reality. It is worth to clarify that the higher the frequency, the better the resolution, but at the same 
time the lower the depth of ultrasound penetration gets. While before the early 1990s, research applications of 
ultrasound were limited primarily to larger animal species, advances in ultrasound imaging technology during 
the last decades and the increased interest in small animal imaging  have made it possible for dedicated 
commercially available systems to obtain accurate and reliable images of small animals too.  
The transducer, placed on the skin, is the vital part of an ultrasound system as it alternatingly produces and 
receives the ultrasonic waves [114]. The waves are commonly generated by the piezoelectric effect, the 
piezoelectric crystals composing the transducer vibrate when exposed to electrical stimuli generating sound 
waves which can be directed, through the tissues, to the target site. Depending on the nature of the tissue, the 
waves can be absorbed, reflected, scattered, etc, as summarize in Figure 5.  
   
  
 
Figure 5. Interaction of ultrasounds with tissues. The interaction of US waves with organs and tissues encountered along 
the ultrasound beam can be described in terms of attenuation, absorption, reflection, scattering, refraction and diffraction. 
When two tissues with different properties (mainly density) are located next to each other, an acoustic impedance 
mismatch is created and the sound waves are reflected. The greater the acoustic mismatch, the more sound waves are 
reflected and return to the transducer. 
At the most commonly used frequencies, the transmission throughout tissues is mostly dependent on the 
acoustic impedance of each tissue which strictly correlates with its density. When two tissues with different 
densities are located next to each other, an acoustic impedance mismatch is created and it causes the 
reflection of the sound waves. The greater the acoustic mismatch, or difference in tissue densities, the more 
sound waves are reflected and return to the transducer. Here, the interaction with the piezoelectric crystals 
produces electrical signals processed by the CPU, thus generating the final image [115]. As all previously 
described modalities, ultrasounds also allow 3D volumetric reconstructions from multiple 2D images. In the 
image, areas with large tissue density differences, and hence more reflected sound waves, are generally seen 
as bright. Hard tissues like bone have a much larger acoustic impedance than soft tissue resulting in a very 
bright reflection. Since almost all energy is reflected, the sound waves will barely propagate in the bone itself, 
resulting in a dark appearance (Figure 6).  
  
                                    
Figure 6. 2D Ultrasound image of a mouse leg. The image was obtained with a clinical 10 MHz linear array transducer. The 
bright reflections are the result of the larger acoustic impedance of bone compared to the surrounding soft tissue. Given 
the reflection of almost all energy, the sound waves barely propagate in the bone tissue which appears dark. 
5.1 Contrast-enhanced Ultrasound Imaging 
Because ultrasound waves are highly reflected by gas-filled structures, tissue contrast can be enhanced by the 
use of micro- or nanobubbles filled with inert gas, acting as contrast agent. The bubbles increase the amount of 
reflected signal, thus structures in which these bubbles are presented can be identified. It has even been 
suggested that such gas containers can be used, after destruction at high acoustic powers, for drug delivery or 
gene therapy [116]. Non-targeted microbubble contrast agents are, in general, purely intravascular, therefore 
molecular imaging principally targets antigens expressed within the vascular compartment and reflects spatial 
and temporal tissue perfusion. Researchers and industry are currently working on expanding the application 
range, mainly through new target molecules, but the possibility of producing extravasating contrast bubbles 
should also be considered [117]. 
5.2 Bone quality and fracture healing evaluation 
In recent years, ultrasound has emerged as promising alternative to X-ray and CT methods for assessing bone 
growth, fracture healing and bone thinning due to osteoporosis, by overcoming some of their disadvantages 
such as ionizing radiation, relatively expensive cost, and limited information on mineralization of the bone 
[118]. The majority of the work has been performed by quantitative ultrasounds (QUS), in which low frequency 
techniques are used to estimate ultrasound parameters related to the bone density and composition, with high 
accuracy, in 2D and 3D. Ultrasound imaging results were found to be in good agreement with corresponding x-
ray imaging and optical imaging results, in vitro [119] and in vivo, to discriminate, for example, the bone loss 
and to predict the mechanical and microarchitectural properties of cancellous bone in a rat model of 
osteopenia [120]. Based on the results, QUS has recently been suggested as an alternative method for the 
diagnosis of osteoporosis [121].  
In terms of fracture healing evaluation, Ultrasound Axial Transmission (UAT) has been proposed as preferential 
diagnostic technique. Typically, a transmitter and a receiver are placed in direct contact with the skin on each 
side of the fracture site and the emitted ultrasonic waves propagate from the transmitter to the receiver along 
the longitudinal axis of bone. Quantitative ultrasound parameters have been reported to be sensitive to callus 
changes during the regeneration process and throughout the different healing stages. The differences in the 
properties between the callus tissue and the cortical bone mainly affect ultrasounds velocity, wave 
attenuation, velocity dispersion [122, 123].  
  
The ability of quantitative ultrasound to monitor the healing process has been investigated through animal 
[124] and clinical studies over a long period, proving that US permits diagnosis at least as precise as CT [125]. 
5.3 Material characterization 
Ultrasonic testing is one of the widely used non-destructive testing (NDT) methods for material 
characterization since, as previously mentioned, ultrasonic testing parameters are significantly affected by 
changes in micro structural or mechanical properties of materials. Specifically, when the ultrasonic wave 
propagates through the medium, part of its energy is attenuated through thermal loss, scattering, absorption, 
etc. The coefficient of ultrasonic attenuation and the ultrasonic velocity correlates with some important 
properties as (i) microstructure (grain size, texture, density), (ii) mechanical properties (tensile strength, shear 
strength, hardness, inclusion content, elastic modulus, fracture toughness, yield strength, tensile strength), (iii) 
discontinuity (porosity, creep damage, fatigue damage) [126]. So far, ultrasonic measurement have been used 
for the characterization of several materials like ceramic composites, polymers and composite materials like 
Chitosan/nano-hydroxyapatite-Collagen (CS/nHAC) [127], underling the potential to noninvasively and 
nondestructively monitor and evaluate the in vivo formation and characteristics of injectable bone scaffolds.  In 
the latter example, the potential of ultrasound for the quantitative in vivo evaluation of tissue development in 
a CS/nHAC scaffold was investigated. The CS/nHAC scaffold was injected into rat subcutaneous tissue and 
monitored for 28 days using diagnostic ultrasounds. Results demonstrated that it was possible to evaluate the 
volume, stiffness, and blood supply of the injectable bone scaffold and, in comparison to the CS, the CS/nHAC 
scaffold showed greater stiffness, lower degradation rate, and better blood supply. 
Ultrasonic material characterization has also been used to qualify and monitor the entire setting process of 
injectable bone cements. Compared to the existing method (namely the Gillmore needle test) it offers strong 
advantages over subjectivity, reproducibility, non destructive analytical method and the possibility to follow 
the whole process over time [128, 129].  
Of course, tissue engineering scaffolds are not used alone but in combination with cells like MSCs. The 
possibility of evaluate the actual number of cells within the scaffolds after cell seeding, was also explored. Bone 
marrow derived MSCs were seeded onto β-tricalcium phosphate (β-TCP) scaffolds. 24 h after seeding 1.0x106, 
1.5x106, 2.0x106, and 1.0x107 cells/mL, the seeding density was measured by ultrasound and reported as 
2.8±1.5x105, 3.4±2.3x105, 3.7±1.0x105, and 3.7±1.8x105, respectively, indicating that even when one regular 
cell-seeding concentration was applied to the b-TCP, the actual number of cells in the individual BMSC/b-TCP 
composites varied considerably. Results underlined the effective correlation between the ultrasound amplitude 
and actual number of cell, promoting ultrasounds devices as valuable tools for orthopedic surgeons who will be 
able to choose composites that contain favorable number of cells right before implantations [130]. 
 
6. Advances in Computed Tomography 
X-ray computed tomography is an anatomical imaging modality which uses X-ray attenuation data acquired at 
multiple viewing angles to reconstruct a 3D representation of the imaged specimen, characterizing the spatial 
distribution of tissues density or contrast agents. Small animal CT scanners provide detailed anatomic 
information at resolutions down to 20µm (down to 5 μm; although new generation on nano-scanners can go 
down below 1 μm), even though soft tissue and bone substitute materials contrast remains poor (Figure 7), 
requiring the incorporation of contrast agents [131, 72]. As most common set-up for small animal scanners, the 
examined subject is placed in the centre and the X-ray detector and radiation source is mounted in a gantry 
that rotates around it.  
Micro-CT has been used for a wide range of preclinical bone studies, including bone quality and density [1], 
bone repair during fracture healing and different stages of callus formation [132, 133, 134], vessel formation in 
the wound healing environment [135], bone changes influenced by metabolic disorders, e.g. osteoporosis [136] 
and constant improvements are achieved on materials characterization and performance evaluation [8].  
  
Although, as stated in the introductory paragraphs, the focus of this review is not on CT techniques, recently, a 
number of new contrast methodologies have emerged to expand X-rays applications to functional imaging 
other than structural imaging. Some of these new approaches will be discussed in the following paragraphs and 
include synchrotron X-rays radiation imaging, and time-lapse CT also used as combination with fluorescence 
and optical luminescence. 
 
 
Figure 7. microCT scan of a rat femoral condyle. (a) 3D reconstruction model. (b) 2D slices of a healthy femoral condyle, 
versus (c) a condyle containing a calcium phosphate-based implant (indicated by the red arrows).    
6.1 Synchrotron radiation micro-CT 
Synchrotron X-rays bring several advantages compared to conventional X-ray sources: as the use of a 
monochromatic X-ray source instead of a polychromatic beam allows the achievement of very high photon flux 
and spatial resolution, improves the signal to noise ratio (SNR) while simultaneously reducing acquisition times, 
beam hardening and cone-beam artifacts. Still, the major advantage comes from the simultaneous analysis of 
bone morphometry and bone mineralization [137].  
In a circular accelerator such as a synchrotron, electrons are deviated by magnetic fields which cause their 
acceleration followed by the emission of electromagnetic waves also known as synchrotron radiation light. The 
wide range of wavelengths covered by the emitted radiation allows studying different properties of materials 
at different scales, as well as follow chemical reactions on a very short time scale.  
While most bone-related studies were performed after animal sacrifice, the feasibility of imaging small animals 
in vivo with synchrotron radiation micro-CT was firstly demonstrated by Kinney et al. in 1998 in a rat model of 
osteoporosis. Ovariectomized rats were subjected to estrogen treatment in order to providing data on the 
earliest manifestations of estrogen loss. Results demonstrated that estrogen replacement therapy could 
restore bone mass to baseline levels, did not recover the trabecular connectivity, but still recovered the original 
structural modulus of elasticity [138]. Despite the exponential growth of applications, the high radiation dose in 
a synchrotron set-up remains a major limitation for in vivo applications and since 1998 only few animal studies 
have been reported [140, 139]. 
6.2 X-rays microfluorescence 
Among X-ray methods based on synchrotron radiation, X-ray microfluorescence (μXRF) has been successfully 
applied in several fields of research, such as material, archeological and biological sciences, as it can supply 
important information about the sample’s chemical properties. 
When the X-rays beam reaches a sample, the interaction via photoelectric effect with the material surface 
results in a specific radiation characteristic of the atoms present in the sample. This emitted radiation is called 
X-ray fluorescent radiation and it is unique for each material. When X-ray fluorescence is associated with a 
synchrotron radiation source, high energy, tunability and polarization of the X-rays can be achieved. To 
mention one example, an X-ray microfluorescence system was implemented to study the bone mineral content 
and distribution in bone sites of human and animal samples with and without bone disorders. The presence of 
several elements like iron, copper and zinc, in addition to calcium and phosphorous, was observed. Their 
  
distribution appeared to be were different and heterogeneous within the analyzed samples and in healthy 
versus compromised conditions. Despite the promising results, in vivo studies have not been reported yet 
[141]. 
6.3 Time-Lapse in vivo CT and multimodal imaging 
The outcomes of dynamic bone activity are traditionally measured by two-dimensional snapshots of single time 
points, which do not allow any assessment of temporal rates of bone remodeling. Alternatively,  a recently 
developed time-lapse CT approach, investigated non-destructive time-lapsed in vivo measurements based on 
image registration of two subsequent scans of the same animal. Bone areas only present in the earlier 
measurement were considered resorbed bone volumes, while areas only present in the latter measurement 
corresponded to formed bone volumes. This approach was first used to monitor how mouse tail vertebrae 
adapt to cyclic mechanical loading, induced on the sixth caudal vertebra of C57BL/6 mice through pins in the 
adjacent vertebrae at either 8 N or 0 N (control) three times a week for 5 min over a total of 4 weeks. Results 
showed how bone formation is increased while resorption sites are reduced over time, leading to an overall 
increase in bone strength [142]. The same approach was then used to investigate whether postmenopausal 
osteoporosis could be modeled in caudal vertebrae of C57Bl/6 mice. Mice were ovariectomized or sham-
operated and monitored with in vivo μCT on the day of surgery and every 2 weeks after, up to 12 weeks. The 
evaluation of temporal changes in remodeling rates showed an immediate increase in bone resorption and a 
delayed increase in bone formation [143].  
CT imaging also offers a great potential for complementary imaging data registration which can be applied to 
radionuclide, optical and MR imaging as well as histology. Registration methods need constant improvements 
and can generally be performed either after or before scanning (through reference frames) and can be done 
manually or automatically, depending on the availability of software and  algorithms. The most accurate 
registrations are achieved by combining two modalities in one scanner for simultaneous images acquisition. 
The main disadvantage of simultaneous imaging devices though, is a loss of the flexible choice of scanner 
geometry. 
6.1 Radiation Dose 
The effect of ionizing radiation in rodents has been well studied after micro-CT and the lethal dose in mice, 
which is typically expressed as LD50/30 (whole-body radiation dose that would kill 50% of exposed animals 
within 30 days) is in the range 5 to 7.6 Gy. The typical whole-body radiation dose for a 3D scan is far below the 
lethal dose and ranges from 0.017 to 0.78 Gy. Still, in case of musculoskeletal applications, higher resolutions 
may be required, resulting in increased exposure. An increase in resolution from 1.0 mm to 0.5 mm has to be 
paid for by a 16-fold increase in exposure dose. Depending on the diagnostic demand, however, X-ray dose can 
be decreased while maintaining high spatial resolution by reducing other image quality parameters such as 
image noise and soft-tissue contrast, which is commonly accepted in case of bone imaging [144]. Still, since the 
main advantage of in vivo small animal CT lies in the fact that follow-up studies can be performed, the dose 
effects could become relevant and several radiation effects have been described even on bone growth. To 
mention one,  the work from Boyd et al. [145] has used the non-irradiated controlateral limb as a control in 
three inbred strains of mice measured weekly for 4 weeks, it was found that the bone volume ratio of the 
irradiated limbs was decreased by at most 3%. 
7. Conclusions 
In conclusion, the increasing use and constant evolution of imaging technology in animal models supports its 
prominent role in translational research for bone and bone regenerative approaches. With ongoing 
developments in small animal preclinical scanners, particularly CT and MR instruments, imaging of bone 
structures and bone substitute biomaterials can be achieved down to the micro and nano-structural level. On 
  
the other hand, the implementation of PET and SPECT and optical imaging in the bone tissue engineering 
preclinical field provides significant potential for investigating the dynamics of bone metabolic and functional 
processes at the molecular and cellular levels with the ability to monitor the effectiveness of novel therapeutic 
targets or biomaterial performance. New tracers and contrast agents are being developed as biomarkers for 
specific targets, which can provide further insights on bone related mechanisms and regenerative therapies. 
Ongoing research is focusing on integrating different imaging modalities and thus obtaining complementary 
data, with the aim of facilitating successful translational applications from anatomical to  functional endpoints, 
to improve the efficacy in musculoskeletal preclinical studies.  
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1. Introduction  
To heal bone tissue loss and damage, autologous grafting remains the preferred clinical option. However auto-
graft material is scarce, thus the implantation of synthetic bone grafts at the site of injury is sometimes 
necessary [1]. Among a large number of available bone substitutes, calcium phosphate cement (CPC) best 
resembles the matrix of natural bone. The high similarity of CPC to natural bone promotes bone regeneration, 
but also results in low contrast between CPC and native bone tissue in X-ray and CT imaging. Therefore, it 
remains difficult to monitor the degradation of the cements and regeneration of bone tissue, hampering the 
evaluation of repair procedures. A strategy to overcome this problem is the addition of contrast agents to CPC. 
For example, contrast agents with iodine, barium and tantalum have been utilized in X-ray to increase 
radiopacity of CPCs, which allowed discriminating them from bone tissue [2, 3, 4, 5]. X-ray imaging provides 
adequate resolution with high throughput at low cost, but with relatively poor contrast and potential radiation 
damage [6]. MRI is a non-invasive, radiation-free, high-resolution technique, which however is mostly 
optimized to visualize soft tissues. The MR signals are generated from the proton spins in water molecules, if 
placed in a strong magnetic field, by a radiofrequency (RF) pulse. In an explorative animal study, it was shown 
that MRI could be a valuable tool in bone tissue engineering [7]. However, due to a relatively low content of 
water protons and their ultra-short T2 relaxation (e.g. cortical bone has a mean T2 value of 500 μs or less [8]), 
MR imaging of rigid tissue and solid material is still challenging. Some approaches that have been proposed to 
image hard tissues are solid-state and single point MR techniques [9,10], but these are unfavorable for in vivo 
applications due to long acquisition times. Following improvements in hardware and MR methods, an echo 
time of less than hundreds of μs could be reached by UTE imaging either employing a short nonselective RF 
excitation pulse with 3D radial sampling or using a two half-pulse FID acquisition [11,12]. Suppression of long-
T2 spins from soft tissue have further improved and extended this technique and its derivatives [13,14]. More 
recently a no-echo-time method called SWIFT (sweep imaging with Fourier transformation) was introduced, 
which acquires data quasi-simultaneously with the excitation pulse, using adiabatic pulses. It already has been 
applied in imaging of bone samples and thermoplastic objects [15, 16]. Another approach without echo time 
spin evolution is zero echo time (ZTE) MR [17, 18, 19, 20]. It is closely related to UTE and has been 
implemented on small animal MR systems [21]. A hard RF pulse is applied to accomplish spatially non-selective 
excitation that covers the full frequency bandwidth spanned by the read out gradient. Excitation as well as 
acquisition is both in the presence of a constant gradient used for purely frequency encoding by 3D radial 
center-out k-space trajectories. Thus these recently developed MR methods offer new options to image bone, 
and might also be applicable to examine bone filler material.  
The aim of this study was to explore bone and CPC imaging by the ZTE method, and to evaluate the 
incorporation of two clinical MRI contrast agents, ultra-small particles of iron oxide (USPIO) and gadopentetate 
dimeglumine (Gd-DTPA). This included the determination of useful contrast levels for in vivo experiments, the 
characterization of changes in the properties of CPC after addition of contrast agents, the measurement of T1 
and T2* relaxation times of materials and surrounding bone, and finally monitoring the substitutes’ 
degradation in an in vivo experiment. 
2. Materials and Methods 
Injectable CPC preparation and contrast agents incorporation Calcium phosphate cement consisted of 85% α-
tricalcium phosphate, 10% dicalcium phosphate dihydrate and 5% hydroxyapatite. The liquid applied to make 
cement was a sterilized 2 wt% (weight percentage) aqueous solution of sodium phosphate (Na2HPO4). 
Poly(lactic-co-glycolic acid) particles (PLGA ,Purasorbs, Purac, Gorinchem, the Netherlands) with a lactic-to-
glycolic-acid ratio of 50:50 was used for microparticle preparation (Habraken et al. 2006). PLGA was mixed with 
the cement powder at 20 wt% to create micro-porosity. The mixture was sterilized using gamma radiation with 
25 KGy (Isotron B.V., Ede, The Netherlands). After adding a filtered sterilized (0.2 μm filter) 2% aqueous 
solution of sodium phosphate to the PLGA/CPC powder, the mixture was put into a 2-mL syringe (BD Plastipak, 
Becton Dickinson S.A., Madrid, Spain) with a closed tip. These components were shaken for 20 seconds with a 
  
mixing apparatus (Silamat, Vivadent, Schaan, Liechtenstein) to generate injectable CPC. For the incorporation 
of USPIO (Sinerem®), it was directly added to the liquid Na2HPO4 solution with cement before mixing. From a 
USPIO solution of 21 mg/ml, 120 μL and 600 μL were applied for 1 wt% and 5 wt% USPIO-CPC respectively. Gd-
DTPA particles (MagneVist®) were incorporated within the cement powder after freeze drying, 6 μL and 30 μL 
were taken from a solution of 469 mg/ml to make 1 wt% and 5 wt% Gd-DTPA-CPC respectively.  
CPC characterization  
The solidification times measurement and compression tests to examine clinical handling proprieties of the CPC 
were performed as follows: Setting time is the time required to reach a certain compressive strength [22]. 
Initial and final setting time of different formulations were assessed by using custom available Gillmore needles 
(ASTM C266). Pre-set scaffolds at a size of 3 mm (diameter) x 6 mm (height) were made from a plastic mould. 
Samples from each formulation were mixed and injected into the mould, and then both initial and final setting 
times were determined. Tests were performed at room temperature.  
For compression tests, samples were placed in a testing bench (858 MiniBionixII®, MTS, Eden Prairie, MN, USA) 
and compressive strength and E-modulus in the longitudinal direction (parallel to the long axis) of the 
specimens were measured at 0.5 mm/min crosshead speed. For both tests, data are presented as mean ± 
standard deviation. Significant differences were determined by analysis of variance (ANOVA). Calculations were 
performed using GraphPad Instat® (GraphPad Software, San Diego, CA). All differences were considered 
significant at P-values <0.05. 
In vitro and ex vivo test of CPC repaired bone  
For in vitro tests bone blocks of 1.5 cm3 were harvested from pig bone. A cylindrical defect of 3 mm in depth 
and diameter was drilled using a dental bur and dental drills. Defects were then filled with injectable CPC. The 
filler material was tested with contrast agent (USPIO or Gd-DTPA) in different concentrations (1% and 5%) for 
each formulation. CPC without contrast agents were applied as control. Photos of bone blocks were taken, and 
then the MR images were acquired. The feasibility to use USPIO as contrast agent for localization of bone filler 
was also tested on a rat cadaver. A cylindrical defect of 3 mm depth and diameter was drilled in the femoral 
condyle, and subsequently this defect was repaired with CPC containing 1 wt% USPIO. 
In vivo animal model  
National guidelines for care and use of laboratory animals were obeyed with approval of the Experimental 
Animal Ethical Committee of the University Medical Center Nijmegen (RU-DEC 2010-225). In two healthy adult 
male Wistar rats, weighting 250-300g, femoral condyle defects were created. The first rat had a defect in one 
leg repaired by CPC and one healthy leg, while the second rat had a defect in one leg repaired with Gd-DTPA-
CPC and a defect on the other leg left unrepaired. The Gd-DTPA concentration was 1 wt% of the cement 
powder. Surgery was performed under general inhalation anesthesia (Isoflurane) and sterile conditions. 
Animals were immobilized and legs were shaved, washed and disinfected before surgery. The knee joint 
became totally exposed after a longitudinal parapatellar incision. At the femoral intercondylar notch a 
cylindrical defect of 3.0 mm depth and diameter was prepared using a dental bur and continuous external 
cooling with saline. Defects were then filled with the proper material or left unrepaired before closing.  
T1 and T2* measurement using UTE  
The UTE sequence (see Fig.1 for basic pulse sequence) was applied to measure T1 (spin-lattice relaxations time) 
and T2* (relaxation due to spin-spin interactions and field inhomogeneities), of two bone samples (harvested 
from the rat leg) with defects which had been repaired with CPC and Gd-DTPA-CPC respectively. The standard 
parameters were: TR=8 ms, FOV=30*30*30 mm, matrix size: 128*128*128, and 8 averages. In order to 
  
measure T2* values, several images were obtained with different echo times. As femoral head and CPCs bone 
fillers have extremely short T2* relaxation time, echo times were mostly chosen in the initial signal decay part 
after the 5° excitation pulse, i.e. at 40, 60, 80, 100, 200, 400, 600, 800 and 1000 μs. 
Assuming a mono-exponential decay the signal intensity (STE) is related to the echo time (TE) according to the 
equation [23, 24]:  
STE=S0×e-TE/T2*+C  
S0 is the initial value of signal intensity and C is the background noise. By fitting this equation to the 
experimental data, the T2* relaxation time was calculated. For T1 measurements, the variable flip angle 
method [25] was applied. The steady state signal achieved when TR>>T2*, result in the following equation for 
signal intensity: Sα=NM0e-TE/T2* sinα(1-e-TR/T1) 1-cosα(e-TR/T1). 
N represent a constant, M0 is the net magnetization at thermal equilibrium and α is the flip angle. This 
equation can be rearranged to: Sα/sinα=e-TR/T1Sα/tanα+NM0e-Te/T2*(1-e-TR/T1) Linear regression is 
independent of N, T2* and TE allowing the calculation of T1. By using variable flip angles (α=2.5°, 5°, 7.5°, 10°, 
12.5°), TE=0.04ms and other standard parameters in UTE, images with signal intensity as a function of T1 were 
obtained. Regions of interests (ROIs) were manually outlined on the bone filler and about the same number of 
pixels on femoral head using Paravision 5.1(Bruker, Biospin, Germany). Average signal intensities of a selected 
region on UTE images were calculated using the same program, and then processed in GraphPad Prism® 
(GraphPad Software, San Diego, CA, USA). 
MR imaging  
MR imaging of bone samples was performed on an 11.7T MR system (Biospec, Bruker, Germany) with a home-
built Helmholtz coil, with a size of 3*3 cm. The standard ZTE imaging (pulse sequence diagram is shown in 
Figure 1) was done with 200 kHz bandwidth, pulse length=0.002 ms, TR=4 ms, FOV = 50*50*50 mm, matrix 
size:128*128*128, 1 average and a total acquisition time of 3 mins 27 secs. Conventional MR imaging of bone 
was acquired with 3D RARE, with FOV = 50*50*50 mm, TE/TR=35.7 ms/1000 ms, RARE factor=16, and 
acquisition time of 8 mins 32 secs. ZTE imaging of cadaver rats were performed on the same MR system and 
using the same acquisition parameters. For in vivo experiments, ZTE imaging was done right after surgery and 8 
weeks post operation on 2 animals with similar parameters as in the standard acquisition protocol, but with 
TR=8 ms, 4 averages and a total acquisition time around 30 minutes. Because the use of a ZTE sequence, other 
rigid material such as the animal bed, and holders, water heating system and RF coil housing may give 
background signal. Therefore, proton free materials were applied wherever possible.  
 
  
Figure 1. Left: 3D UTE sequence, 3D radial sampling applied after nonselective RF excitation pulse, TE min=t pulse/2+delay. 
Delay is the time to switch from transmit to receive mode. Right: ZTE pulse sequence, excitation and acquisition are both in 
the presence of constant gradient, with an effective echo time of zero. 
In vivo CT imaging  
For comparison with MRI, the non-defect leg was imaged on a small animal scanner (Inveon®, Siemens 
Preclinical Solutions, Knoxville, TN, USA). Scans were performed under general inhalation anesthesia 
(Isoflurane). The animal was placed in a supine position in the scanner and images were acquired over ~6 
minutes (spatial resolution 30.04 μm, 80 kV, 500 μA, exposure time 1000 ms, frame average by 1). CT values of 
air (-1000 HU) and water (0 HU) were applied to calibrate the image values in Hounsfield units, while the bone 
mineral density values provided a linear calibration for bone mineral density values. CT images were 
reconstructed using a modified cone-beam algorithm [26]. 
3. Results  
CPC characterization For CPC doped with USPIO at concentrations of 1 wt% and 5 wt%, the initial and final 
setting times were substantially prolonged compared to normal CPC (Table 1). For the formulations with 1 wt% 
and 5 wt% Gd-DTPA no significant change in final setting times compared to normal CPC was observed. 
Compression tests of CPC with 5% Gd-DPTA and 5% USPIO showed a significant decrease of the peak load 
(Table 1). In contrast, adding 1% Gd-DPTA and 1% USPIO did not result in a significant change. In conclusion, 
the setting time and the mechanical properties of CPC were not affected by adding 1% Gd-DTPA. 
 
Table 1. Setting time and compression test. To determine the setting time a standard Gillmore test was used, initial needle 
diameter 1/12 inch, Weight ¼ lb; Final needle diameter 1/24 inch, Weight ¼ lb. 
In vitro and ex vivo imaging of repaired bone 
Visual inspection of pig bone blocks repaired with pure CPC revealed a white lesion with a sharp edge, making 
the cement easily discernible from bone (Fig. 2A). In MR images there was little contrast between bone and 
CPC, even in images obtained by ZTE (Fig 2E). For the Gd-DTPA incorporated CPCs filler, visual inspection 
showed the same contrast as for pure CPC (Fig 2B), but with enhanced contrast in ZTE imaging (Fig. 2F). Finally, 
with USPIO incorporation the lesion became black (Fig. 2C, D) and showed large effects on ZTE images, due to 
the so-called “blooming effect” of the iron oxide particles (Fig. 2G, H). 
  
 
Figure 2. Macroscopic views and MR images of bone samples with defect in bone blocks repaired by CPCs. The lesions with 
bone filler material are indicated by red arrows in the pictures (top, A-D) and by blue arrows in the MRI’s, which were 
obtained by ZTE imaging (bottom, E-H). A, E. No contrast agent; B, F. with Gd-DTPA 1wt%; C, G. with USPIO 1wt%; D, H. 
with USPIO 5 wt%; note the stronger blooming effect with 5 wt% USPIO (H). 
To test the feasibility of applying USPIO as a contrast agent in animal experiments, an ex-vivo experiment was 
performed on bone defect repaired by 1 wt% USPIO tagged CPCs, since the lower concentration had less effect 
on the properties of CPC. On conventional MRI, bone and normal CPC both appear dark (Fig. 3A), with little 
bone detail. In contrast, bone structure is clearly seen on the ZTE images (Fig. 3B). However the strong 
blooming effect rendered the precise localization of USPIO-CPC filler cumbersome, also in ZTE imaging(Fig. 3B). 
 
Figure 3. Ex-vivo MR images of 2 rat legs with repaired defects. A: bone and CPC appear dark and no detail is apparent in 
conventional MR imaging (3D RARE). B: ZTE image of the bone defect repaired by USPIO-CPC, bone details and lesion site 
can be discerned. Note however the strong blooming effect (arrow). 
T1 and T2* measurement of bone and bone fillers  
Using 3D UTE at different echo times T2* relaxation times were assessed. The signal decay in these 
measurements were fitted with a mono-exponential function (see Fig. 4) resulting in T2* relaxation 
times of 597±19 μs for bone, 442±22 μs for CPC and 226±18 μs for Gd-DTPA-CPCs. For the T1 
measurements the variable flip angle method was used. This resulted in T1 relaxation time of 
474.19±28 ms for bone, 527±29 ms for CPC and 336.44±25 ms for Gd-DTPA loaded CPCs. Thus T1 and 
T2* values were both shortened due to Gd-DTPA incorporation.  
  
 
Figure 4. Signal intensity plotted versus TE in UTE acquisition of bone and CPC materials. All curves are 
normalized to 100 % signal intensity at the first measurement point of bone. Dashed and dotted line (black): fit 
of T<sub>2</sub>* decay of CPC. Dotted line (green): fit of bone T<sub>2</sub>* decay. Red line: fit of 
T<sub>2</sub>* decay of 1 wt% Gd-DTPA loaded CPC. 
In vivo imaging of CPC repaired femoral condyle defects  
On ZTE images of the rat leg without defect, bone and surrounding tissues were clearly distinguishable (Fig. 
5A). Despite that the resolution of the image of rat condyle measured by ZTE MRI was lower than those 
obtained by CT (Fig. 5B), it has sufficient image quality to provide complementary structural diagnostic 
information on bone and surrounding soft tissue like muscles and meniscus. 
 
Figure 5. A: ZTE image of healthy rat condyle, soft tissues like muscles are surrounding the bone structure. B: In 
vivo CT of the same body part. 
For in vivo assessment of contrast enhancement in ZTE imaging of repaired bone lesions we selected CPC 
doped with 1% Gd-DTPA, as this formulation had similar mechanical properties as normal CPC (without Gd-
DTPA). Lesions filled with the contrast agent loaded CPC showed a decreased signal intensity compared to the 
surrounding bone tissue (Fig. 6A,B), reflecting the shortened relaxation times. The shape and location of the 
filler material were clearly visible. This contrast decreased after 8 weeks, but it was still possible to differentiate 
the lesion location from bone (Fig. 6C). Lesions filled with normal CPC showed little contrast with bone on ZTE 
images immediately post-operation. This contrast was further degraded 8 weeks later, so that the lesion was 
virtually invisible (Fig. 6D,E). 
  
 
Figure 6. In vivo ZTE MR images of femoral condyle defects in rat leg. A. Femor with bone defect filled with Gd-DTPA-CPC. B. 
Zoomed part of image in A, only showing the femoral condyle. D. Same condyle, 8 weeks after the first scan (image B). C. 
Condyle from another rat, with defect filled with CPC without contrast added. E. Same condyle 8 weeks after first scan 
(image C). Arrows indicate position of lesion with CPC + 1% Gd-DTPA (red) and CPC without contrast agent (blue). 
4. Discussion  
In this study we demonstrated that bone defects repaired by calcium phosphate cement (CPC) could be 
distinguished from surrounding bone on MR images by using a ZTE sequence and mixing the CPC with a 
contrast agent. Among the contrast formulations tested the clinical approved Gd-DTPA at 1 wt% appeared to 
be most practical. This would enable the evaluation of bone regeneration in studies to optimize procedures for 
lesion repair. CT has been used in the past in the imaging of repaired bone lesions. To distinguish bone defects 
filled with CPC from surrounding tissue this also requires a contrast enhancer (radiopacifier), such as 
tantalumpentoxide [27]. Especially in longitudinal CT studies the accumulation of radiation becomes of concern 
[28]. Therefore, MRI has attracted attention as an alternative in the imaging of bone and hard tissue. For 
example, T1-weighted MR imaging on bone implants with gadolinium-based contrast clearly demonstrated the 
potential of MRI to study bone formation [29] and gadoterate meglumine was developed to enhance MRI of 
bone cement [30]. However, none of these experiments demonstrated in-vivo MR imaging of the material yet. 
Furthermore, as only conventional MRI was used signal intensity was not optimal. Since both bone and CPC 
have very short T2 values (<1 ms), it is problematic to visualize these materials with conventional MRI, as signal 
rapidly disappears in the echo times of several ms or more. A UTE sequence provides the possibility to obtain 
MR images at echo time below 1 ms [12], but this sequence has some intrinsic problems, like errors from eddy-
currents generated by the gradient ramps, which need to be corrected by k-space trajectory measurements; 
additionally the ramp reduces the signal to noise ratio [21]. Therefore, the use of ZTE imaging, which samples 
signal without an echo time delay, was explored to visualize bone and CPC at optimal signal strength. In this 
study, it was shown that with ZTE indeed good images of bone and CPC could be obtained. And a comparison 
with CT shows that interesting complementary information of bone may be obtained. In practice, both UTE and 
ZTE suffer from dominating signals of long T2 spin systems, in particular of soft tissue [31], and optimally need 
a long T2 suppression element in the pulse sequence to reduce this problem. An advantage of the UTE 
sequence is its flexibility which allows to filter out signals of species with extremely short T2* values if needed 
(e.g. background signal from coil housing). The similar T1 and T2* values of bone and CPC preclude their 
discrimination by ZTE MRI based on relaxation properties alone. Therefore the additions of Gd-DTPA and USPIO 
as MR contrast agents to CPC were explored. By far the strongest effects was seen with USPIO’s, but the region 
occupied by the filler was heavily overestimated due to blooming effects, which made precise localization of 
the defect difficult. This is also expected to interfere with the proper quantitative assessment of CPC 
degeneration and bone regeneration by ZTE imaging. Another problem with USPIO addition was the 
  
detrimental effect on the solidification time and mechanical properties of the CPC. By lowering the iron 
concentration and using alternate types of iron oxide based contrast agent with less susceptibility effects, it 
might be possible to minimize both the blooming problem and the detrimental effects on CPC properties and 
meet the requirements for in vivo use. For the other contrast agent tested in this study, Gd-DTPA, a decrease in 
mechanical strength and setting times at a concentration of 5% was also observed, but not at 1%. Therefore 
the addition of 1 wt% Gd-DTPA to CPC was selected for testing in vivo and it was demonstrated that this 
enhanced the MR visibility of lesions repaired with CPC in the time immediately post-operation. The lower 
signal intensity reflects a shorter T2* of CPC. Contrast became less after 8 weeks; likely because of CPC 
degradation, resulting in loss and dilution of the contrast agent. This was proven by histology as will be 
demonstrated in a separate manuscript. The use of gadolinium in contrast agents is associated with the risk of 
nephrogenic systemic fibrosis (NSF) [32]. The commonly applied dose of Gd-DTPA in the clinic is 0.1 mmol/kg 
(0.2 ml/kg) [33]. In this study, the amount we injected was 6 μL (in Gd-DTPA-CPC), which results in less than 
0.03 ml/kg in the rat body. Locally Gd-DTPA in CPC will be at relatively high concentration and slowly released 
in the body. In the future, with fine-tuning of contrast agent formulations, more optimal MR acquisition 
parameter values and suppression of long T2 signals are expected to further improve the contrast between 
bone and CPC. Also the usage of iron oxide contrast at low dose is an option, especially if the signal intensity 
change can be correlated with its concentration [34]. In principle also other MR approaches have potential to 
visualize repaired bone lesions like the use of 19F nuclei in contrast material [35] or the application of 31P MR 
to differentiate between natural and synthetic hydroxyapatite [36]. In conclusion, this study reported on the 
first in vivo MR imaging of a CPC repaired lesion in bone, using a ZTE acquisition sequence and clinically 
approved Gd-DTPA for enhanced contrast. This offers a novel radiation free method to visualize CPC 
degradation and bone regeneration in preclinical experiments. 
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1. Introduction 
The increasing incidence of bone treatment procedures keeps a high pressure on the development and 
optimization of substitutes for bone regeneration [1]. Several synthetic bone substitutes are currently 
available, organic, inorganic, polymer or ceramic-based materials. Among those, calcium phosphate cements 
(CPCs) represent a category which closely resembles the structure and composition of natural bone. The 
excellent biocompatibility of CPC and osteoconductive properties can be further enhanced by the introduction 
of structural macroporosity eg. by incorporation of microparticles. The (pre)clinical application of such cements 
has been demonstrated in vivo, eg. in a rat skull augmentation model [2], alveolar bone regeneration model in 
beagle dogs [3], maxillary sinus floor augmentation in sheep  [4] and a critical-sized  cranial defect model in rats 
[5]. Despite their wide use and characterization, less achievements have been reported in the field of in vivo 
visualization and follow-up methods. Plain radiography (X-rays) and Computed Tomography (CT) are the most 
employed techniques. On the other hand, recent developments in the field of MRI open the way to a 
completely new scenario of high resolution bone visualization applications [6, 7, 8].  
A common problem of all imaging modalities remains the high similarity between CPCs and the mineral phase 
of the bone, which makes it difficult, if not impossible, to clearly discriminate the materials [9]. Several 
opacifiers have already been proposed to enhance the contrast of CPCs for CT (i.e. barium sulfate, tantalum 
oxide) and MRI (Iron Oxide Particles, gadolinium) [10, 11, 12]. As a negative side effect, all above mentioned 
compounds have shown to interact with CPCs, negatively affecting both physical and mechanical properties, 
even at very low concentrations [13]. Moreover, a major drawback for their in vivo application arises from the 
lack of information regarding behaviour and metabolic destiny of heavy metal compounds following the 
degradation of the CPC material [14, 15].  
In this study, we have developed a new nanocomposite which is a silica-based, dual contrast agent, detectable 
with both CT and MRI. The specific formulation of such beads, combined with the chemical inertness and 
biocompatibility of silica, should allow the maintainance of  the positive visualization effects of the selected 
contrast agents (colloidal gold and SPIO), while at the same time reducing unspecific reactivity, inflammatory 
tissue reactions and alteration of the physico-mechanical properties of the CPC. Colloidal gold and iron oxide 
nanoparticles were selected as embedded agents for, respectively, CT and MR imaging, as both compounds are 
widely characterized and approved for clinical use [16, 17]. After in vitro characterization, the developed 
contrast agent was tested in vivo, in a femoral condyle defect model in rats. Effects were monitored by 
scanning  the same animals with both CT and MRI up to 8 weeks post-surgery. Finally histology was performed 
to prove the biocompatibility of the product. 
2. Materials and Methods  
2.1 Implant materials 
CaP Cement 
Calcium Phosphate cement consisted of 85% of α-Tricalcium Phosphate, 10% Dicalcium Phosphate Dihydrate 
and 5% Hydroxy Apatite. The cement powder was sterilized using gamma radiation with 25 kGy (Isotron B.V. , 
Ede, The Netherlands).  
PLGA Microspheres 
Poly (DL-Lactic-co-glycolic acid), (PURASORB, Purac, Gorinchem, The Netherlands) with a Lactic to Glycolic acid 
ratio of 50:50 and an average molecular weight of 4.55 ±0.03 kDa, was used for microparticle preparation. Acid 
terminated PLGA microparticles were prepared using a double-emulsion solvent-extraction technique. The 
average size of the microparticles, as determined with image analysis, was 20 ± 18 μm [18]. PLGA microparticles 
were mixed with the CaP cement powder in a proportion of 20  %wt/wt. 
  
Contrast Agent 
A customized dual contrast agent (DCA) was synthetized (Nano4Imaging GmbH, Aachen, Germany). The dual 
contrast agent particles were based on an inverse emulsion approach (patent WO2005/052581) using passive 
MRI responsive SPIO nanoparticles with a mean size of 200 nm and gold nanoparticles of 4 nm as embedded 
within a silica matrix at an end concentration of 40 wt/wt%. The wt% ratio between SPIO and gold 
nanoparticles was set at 4:1. The silica carrier particles containing the embedded iron oxide and gold 
nanoparticles had a mean size of 1.2 µm. They were sealed with an additional layer of silica synthesized using a 
modified Stoeber method [19] and dried by dry-freezing. The obtained solid phase of dual contrast agent 
particles was then mixed with the hydroxyapatite to reach a final end concentration of 5% (wt/wt) within the 
bone cement composition.  
Composite preparation 
The cement was created by adding a filtered sterilized (0.2 µm filter) 2% acqueous solution of sodium 
phosphate (Na2HPO4) to the PLGA/CaP or PLGA/CaP/DCA  powder mixture using a 2-mL syringe (BD Plastipak, 
Becton Dickinson S.A., Madrid, Spain) with a closed tip. The components were shaken for 20 seconds using a 
mixing apparatus (Silamat Vivadent, Schaan, Liechtenstein). 
CaP cement/DCA Characterization 
To ensure proper handling properties of the cement, the following parameters were assessed: 
- Gillmore test: Initial and final setting times for the different cement formulations were assessed using 
custom available Gillmore needles (ASTM C266). A plastic mould of 3 mm (diameter) x 6 mm (height) was 
used to prepare scaffolds. At least four samples from each formulation were mixed and injected into the 
mould and both initial and final setting times were determined. Tests were performed at room 
temperature. 
- Compression Test: Samples were placed in a testing bench (858 MiniBionixII®, MTS, Eden Prairie, MN) and 
compressive strength in the longitudinal direction (parallel to the long axis) of the specimens was 
measured at 0.5 mm/min cross-head speed. 
- Morphology: The morphology of different cement formulations was determined by Scanning Electron 
Microscopy (SEM). For this purpose, destructed samples were obtained from the compression test. Images 
from each sample were obtained at 100x, 500x and 1000x magnification. 
2.2 In vitro assays 
Bone Blocks 
Bone blocks of approximately 1.5 cm
3
 were obtained from fresh pig bone. A 3 mm (depth and diameter) 
cylindrical defect was drilled using a dental bur and dental drills. The defects were (1) left unfilled, (2) filled with 
CaP/PLGA cement, (3) filled with CaP/PLGA cement mixed with 5% of  DCA. All samples were then scanned with 
both µCT and MR modalities.  
In vitro micro-CT 
Prior to scanning, all specimens were dehydrated in ethanol 70% and wrapped in Parafilm® (SERVA 
Electrophoresis GmbH, Heidelberg, Germany) to prevent the occurrence of drying artifacts during scanning. For 
  
3D analysis, the specimens were placed vertically onto the sample holder of a micro-CT imaging system 
(Skyscan 1072, Kontich, Belgium). Subsequently, samples were recorded at a 14.16 μm  resolution (X-ray 
Source 100kV/98µA; Magnification 20x; Exposure Time 3.9 sec; 1 mm filter applied). Then, using NRecon V1.4 
(SkyScan), a cone beam reconstruction was performed on the projected files. Reconstructed files were 
analyzed using CTAnalyser software (Version 1.10.1.0; SkyScan). Finally, 3D-reconstructions of the samples 
were also obtained (3D-DOCTOR 4.0, Able Software Corp, Lexington, MA). 
In vitro MRI 
All samples were embedded in 70% Etanol  and MR imaging of bone samples was performed on a 11.7T MR 
system (Biospec, Bruker, Germany) with a mouse brain surface coil. Zero Echo Time (ZTE) images were acquired 
at 200 kHz bandwidth, TR=4ms, flip angle=5°, FOV=50*50*50mm, matrix size 128*128*128, total acquisition 
time 3.27 minutes. 
2.3 In vivo assays 
Animal Model  
All in vivo work was conducted in accordance with standards and protocols of the Radboud University 
Nijmegen Medical Center, Nijmegen, The Netherlands. National guidelines for care and use of laboratory 
animals were obeyed and approval of the Experimental Animal Ethical Committee was obtained (RU-DEC 2010-
225). Eight healthy adult male Wistar rats, weighing 250-300 g were included as experimental animals. Surgery 
was performed under general inhalation anesthesia (Isoflurane) and aseptic conditions.  For the surgical 
procedure (Figure 1) animals were immobilized and both legs were shaved, washed and disinfected. The knee 
joint was exposed after a longitudinal parapatellar incision. At the femural intercondylar notch, a cylindrical 
defect (3.0 mm depth and diameter) was then prepared using a dental bur and continuous external cooling 
with saline. Defects were filled with the CPC material, or left untreated in control animals (Table 1), before the 
subcutaneous tissue and skin were closed by suturing in layers. In vivo CT and MRI scans were performed 
during time, up to 8 weeks post-surgery. Thereafter, animals were sacrificed and histology and micro-CT were 
performed. 
 
Figure 1. Surgical procedure of a femoral condyle defect in rats. The knee joint was exposed after a longitudinal 
parapatellar incision (a-b). At the femural intercondylar notch, a cylindrical defect (3.0 mm depth and diameter) was then 
prepared using a dental bur and continuous external cooling with saline (c-d). Defects were filled with the CPC material (e-
f), or left untreated in control animals (Table 1), before the subcutaneous tissue and skin were closed by suturing in layers. 
  
 
Table 1. Experimental groups and implantation schema. 
In vivo CT  
Animals were scanned after surgery and at 4 as well as 8 weeks after surgery, using a small animal CT scanner 
(Inveon, Siemens Preclinical Solutions, Knoxville, TN). Acquisitions were performed under general inhalation 
anesthesia (Isoflurane). Animals were placed in a supine position in the scanner and images were acquired over 
~6 minutes (spatial resolution 30 μm, 80 kV, 500 μA, exposure time 1000 ms, frame average by 1). Projected 
files were then reconstructed using a cone beam algorithm. 
In vivo MRI  
MR imaging was performed the day of the surgery and at 4 as well as 8 weeks after surgery using a 11.7T MR 
system (Biospec, Bruker, Germany) with a home-built bare Helmholtz coil with a size of 3*3 cm. Zero Echo Time 
imaging was performed at 200 kHz bandwidth, TE/TR = 0 ms/8 ms, flip angle = 5°, FOV = 50*50*50 mm, matrix 
size:128*128*128, 4 averages and a final acquisition time of 30.27 minutes. 
Micro-CT 
Eight weeks after surgery, the animals were sacrificed by CO2/O2 overdose. Femoral condyles were retrieved 
and surrounding soft tissue was removed. Bone samples were fixed in 10% Formalin for 48 hours and 
subsequently transferred to 70% Ethanol for the duration of the μCT scans. For 3D analysis, the specimens 
were placed vertically onto the sample holder of a micro-CT imaging system (Skyscan 1072, Kontich, Belgium). 
Subsequently, samples were recorded at a 15.30 μm  resolution (X-ray Source 100kV/98µA; Exposure Time 3.9 
sec; 1 mm filter applied). Then, using NRecon V1.4 (SkyScan), a cone beam reconstruction was performed on 
the projected files. Finally, 3D-reconstructions of the samples were obtained (3D-DOCTOR 4.0, Able Software 
Corp, Lexington, MA). 
2.4 Histology 
After scanning, all specimens were decalcified in 5% formic acid at 37ºC for 5 days with daily solution 
replacement. Samples were then dehydrated in gradual series of ethanol (70%-100%) and embedded in 
Paraffin. Sections of 6 µm thickness were cut in a plane parallel to the long axis of the femur using a Leica 
RM2165 Microtome (Leica Microsystems, Rijswijk, The Netherlands). The sections were stained with 
Haematoxylin/Eosin and trichrome Elastin van Gieson (EVG); at least three sections of each specimen were 
analyzed.  
  
2.5 Bone Quantification 
EVG-stained slides were quantitatively scored using computer-based image analysis techniques (Leica Qwin 
Pro-image, Leica, Wetzlar, Germany). From digitalized images (magnification 5X), the percentage of bone tissue 
was determined within the area of interest, positioned between the growth plates and the cortical bone layer.   
2.6 Statistical Analysis 
Statistical analysis for bone quantification was performed using SPSS, version 16.0 (SPSS Inc., Chicago, IL). 
Statistical comparisons were performed by one-way analysis of variance with a Tukey multiple comparison 
post-test. For setting time and compression tests, data are presented as mean ± standard deviation and 
significant differences were determined by analysis of variance (ANOVA). Grey values distributions were 
validated by Wilcoxon matched-pairs signed-ranks test. Calculations were performed using GraphPad Instat® 
(GraphPad Software, San Diego, CA). All differences were considered significant at P-values <0.05.  
3. Results 
Initial observations 
After freeze-drying, increasing concentrations of DCA, ranging from 1 to 10% (wt/wt%) were incorporated 
within the CaP/PLGA powder. The lowest concentration required for imaging was reached at 5%. At higher 
concentrations the physico-mechanical properties of the material were altered. Consequently 5% was 
maintained throughout (data not shown).  
CaP cement/DCA Characterization 
In order to exclude eventual interactions between the DCA and CaP/PLGA matrix, physico-mechanical as well as 
morphological tests were performed. Figure 2a shows the initial and final setting times of the two cements, 
with and without DCA. The Gillmore test showed no significant differences between the two groups. Initial 
setting time required around 9 minutes, while for the final setting time 21-22 minutes were needed. The 
contrast was uniformly mixed with the cement powder, providing a uniform light brown color. Measurements 
of the peak load (compression strength) and E-Modulus for CPC, with and without contrast agent, are 
presented in Figure 2b and 2c respectively. Both parameters appear slightly altered by the incorporation of the 
contrast agent, namely, the strength of the resulting material is increased, even though the difference cannot 
be considered statistically significant.  
From the morphological point-of-view, Figure 3 shows representative SEM micrographs of CPC and CPC plus 
the DCA. In both samples, PLGA particles were easily recognizable, dispersed evenly in the Calcium Phosphate 
matrix. The overall structure appeared uniform between the samples and the presence of the contrast agent 
did not affect the internal structure of the cement upon visual inspection.  
  
 
Figure 2. Mechanical properties of CPC vs CPC/DCA. a. Gillmore test for initial and final setting times measurements.; for 
both composites initial setting time required 8-9 minutes, while for the final setting time 21-22 minutes was required. b. 
and c. respectively show E-Modulus and Peak Load as measures of the mechanical strength of the two materials. All data 
are showed as mean value ± standard deviation. 
 
  
Figure 3. Figure 3. SEM micrographs. a. CPC containing PLGA microsphere at 500X and 1000X magnification; b. CPC 
containing PLGA microspheres and DCA at 500X and 1000X magnification. Red arrows indicate PLGA microspheres. 
In vitro assays 
At visual inspection, no differences emerged during both preparation and injection of the cements, with and 
without 5% wt/wt contrast, into the pre-made bone blocks. After final setting all samples were scanned with 
both MRI and µCT. 
-MRI 
After mixing with the DCA, the cement was immediately injected to fill the defects created into the cortical 
layer of the bone blocks (Figure 4a). 
While the untreated defect was easily identifiable in the upper part of the specimen, within the cortical layer 
(Figure 4b), in case of defect filled with plain CPC, the visual inspection did not allow localization of the defect 
area within the surrounding cortical bone (Figure 4d).  
 
Figure 4. In vitro MRI. a. A 5 ml syringe filled with CPC/DCA composite used to fill a bone defect created in the cortical part 
of approximatively 1.5 cm3 bone blocks (4b), which reveals the brownish color of the CPC. The following images are 
representative slides from the acquired 3D dataset of the bone blocks with: c. empty defect; d. defect filled with plain CPC; 
e. defect filled with CPC/DCA cement. The evident blooming effect caused by the presence of the contrast is recognizable. 
The bone samples were embedded in 70% Ethanol. Red arrows indicate the location of the defects. 
When the DCA was added to the cement, the presence of SPIO particles made the defect easily  identifiable as 
well as characterized by the presence of an artifact known as blooming effect (result of the dipolar behavior of 
the iron particles). Although the defect area was easy to localize, the blooming artifact caused an 
overestimation of the defect size, complicating possible quantification methods (Figure 4e).    
-CT 
Based on the images, it was already possible to visually identify a clear difference between plain CPC and CPC 
with the DCA. Plain CPC could not be discerned from the surrounding cortical bone (Figure 5a), while with the 
contrast (5b), the difference between the material and bone was evident. Figure 5c shows the unfilled defect as 
control. The contrast agent was distributed evenly through the cement matrix. Quantitatively, the analysis of 
grey values revealed two different curves for CPC and CPC/DCA. The curve generated from the empty defect is 
also included. As shown in Figure 5d, plain CPC gave a distribution peak corresponding to grey values of 100-
  
120. The incorporation of the DCA caused a shift of the population to the left part of the scale, toward grey 
values ranging from 80 to 90. No peak was found the empty defect. 
 
Figure 5. In vitro CT. 2D (les) and 3D (right) CT images of a. plain CPC; b. CPC/DCA cement injected into 3 mm defects in 
pig bone blocks; c. Untreated empty defect. CPC/PLGA filling become clearly identifiable after incorporation of the DCA (in 
red in the CT model of the whole bone block) . d. Grey values curve distributons for the two composite materials and the 
empty defect. The shift of the DCA population towards the left side of the graph is significant with p < 0.05. 
In vivo 
- Animal Model 
The surgical procedure (Figure 1) did not lead to any adverse and unexpected reactions. All animals recovered 
within a few hours post-surgery and none were restricted in their movements. Rats were monitored during the 
whole experimental period and no evident signs of discomfort nor weight loss were observed. Based on in vitro 
explorative data, the concentration of the DCA to be mixed with the cement powder was set at 5% wt/wt. After 
8 weeks, all femoral condyles were retrieved, at macroscopical inspection no clear differences were detectable 
between the different groups.  
-MRI 
In line with in vitro results, injected plain CPC were not detectable in the femoral condyles at any time point 
and  the resulting images were comparable to those obtained from untreated femoral condyles defects.  In 
contrast, the visibility of the CPC was enhanced by the presence of DCA (Figure 6) at all evaluation times. The 
addition of DCA caused a similar blooming effect as in the in vitro assay. However, it was observed that visibility 
and contrast clearly decreased with the increasing implantation time. 
  
 
Figure 6. In vivo MRI. Representative slides selected from 3D-acquired datasets of rat femoral condyle defects filled with 
plain CPC ( first column), CPC/DCA cement (second column) or empty untreated defects (third column) acquired by Zero 
Echo Time sequence at day 0, 4 weeks and 8 weeks following cement installation. Red arrows indicate the location of the 
defect. 
-CT  
Figure 7 shows that, in agreement with in vitro data, no differences in terms of grey values were measured 
between plain CPC and surrounding bone tissue at any evaluation time. However, the incorporation of the DCA 
provided a significant enhancement of the radiopacity, resulting in a good contrast between the bright CPC-
treated defect and the surrounding tissues. Moreover, bone healing was observed within the untreated defect 
within the 8 weeks evaluation. Grey values distributions in Figure 7b highlighted a shift of the population from 
grey values of 100-120 for plain CPC, to values ranging from 80 to 90 when DCA was incorporated. This effect 
was only detectable at the first time point, while 8 weeks post-surgery the grey value distributions for the two 
cements were mostly overlapping (Figure 7c).  Grey values from untreated defects are always shown as control. 
  
 
Figure 7. In vivo CT. a. 2D-CT images of rat femoral condyle defects filled with plain CPC, CPC/DCA cement or empty 
untreated defects. Upper images were taken immediately after implantation, while bottom images were taken 8 weeks 
post-implantation. Red arrows indicate the defect. b. Grey values curve distributions of the two composite materials at day 
0. The shift of the DCA population towards the left side of the graph was considered significant with p < 0.05. c. 8 weeks 
post-surgery, the differences between the two curves were no longer significant. Grey value curves from untreated defects 
is also shown as control. 
Histology and Bone Quantification 
In none of the histological sections an adverse tissue reaction or signs of inflammation were found (Figure 8). 
Both HE and EVG staining showed a uniform bone reaction in all groups. Due to decalcification of the 
specimens before paraffin embedding, the CPC no longer was detectable within the stained sections. Still, a 
round-shaped area could be recognized, which was used to localize the original defect site within the condyle. 
Upon light microscopical inspection, all defect areas appeared to be filled by newly formed trabecular bone. 
Bone marrow-like tissue was observed in between the bone voids and fibrotic tissue was absent.  
 
  
Figure 8. Qualitative histological evaluation. Elastin van Gieson representative histological sections after 8 weeks of 
implantation. a. Empty defect; b. CPC- filled defect; c. Sham-operated, no defect was created; d. CPC/DCA- filled efect. A 
black dashed circle indicates the location of the defect. After decalcification of the samples no traces of CPC remained 
visible. 
The defect location, between the cortical bone layer and the growth plates, was selected to quantify the bone 
tissue percentage (Figure 9a). Eight weeks after implantation, results from the 4 experimental groups did not 
reveal statistically significant differences in bone content, which was found to be around 50% in the selected 
area in all groups (Figure 9 b).  
 
Figure 9. Quantitative evaluation of bone formation. Bone formation was measured within the yellow highlighted region of 
interest in the four experimental groups, 8 weeks after implantation. Bone percentage in all groups was around 50%, 
without statistically significant differences (p < 0.05). 
4. Discussion  
The present study aimed to test the feasibility of a dual contrast agent as enhancer for the visualization of CPC 
in terms of bone contrast using CT and MR imaging. Both in vitro and in vivo assays were done. The DCA, as 
used, was a nanocomposite of silica beads in which two different nanoparticle types are structurally integrated. 
For our study, colloidal gold and superparamagnetic iron oxide nanoparticles were incorporated. The gold/iron 
ratio content per bead is predetermined by the detection equipment and knowledge of the individual (not 
dual) products already applied clinically. Following explorative pilot experiments with scans at different DCA in 
gradual steps from 1-10%, it was  shown that below 4% no quantifiable CT contrast was obtainable. Data also 
show that the higher ranges result in improper cement hardening is hampered. Thus, final concentration within 
our cement was set at 5% wt/wt. Mixing of the two components was homogeneous conferring a uniform 
brown color to the cement, and indeed the cement’s preparation and injection procedure did not differ from 
control groups. Setting time and compressive strength are of great interest to surgeons, as these data directly 
affect the selection of operation procedure and post-operative care. The presence of DCA did not induce 
significant changes of those parameters, or even accounted for a slight enhancement of the mechanical 
strength. Thus, the handling remained acceptable within a defined range. [15, 20] 
The animal model (non-critical size femoral condyle defect in rat) is a well-established defect model for testing 
injectable as well as pre-set bone substitute materials [21, 22]. The relatively easy surgical procedure, together 
with the easily accessible location for imaging procedures, makes this model optimal for the purposes of our 
study. 
Post-implantation imaging was evident in both techniques, which could be of great benefit to surgeons to 
verify proper implant placing directly post-operatively. Long term contrast enhancement was only achievable 
  
by MRI , which signal decay over the experimental period could be assessed, thus aiding quantification of the 
biomaterial degradation process.  
At 8 weeks after injection, CPC/DCA implants were still detectable by MRI, while CT contrast had become 
negligible. This indicates that also temporal degradation of the nanocomposite occurs and could allow kinetic 
studies with the DCA, since the contrast disappears during remodeling of the cement. The disappearance of CT 
signal with time could be explained as result of the degradation of the outer shell of the silica beads [23, 24], 
resulting in a dilution of the gold nanoparticles. Instead, iron nanoparticles were placed on the inside of the 
bead, which degrade much slower. Although the location of the two embedded agents (either in the core or in 
the shell) does not affect directly the imaging properties of the DCA, results proved that it could become a 
valuable parameter when performing longitudinal studies where a long lasting contrast is needed. Finally, 
histological sections and histomorphometry proved biocompatibility and no interference of the contrast agent 
with the healing rate and bone ingrowth compared to plain CPC and control groups. As shown in figure 8, the 
whole defect area was not located within the selected region of interest. However, the goal of the study was to 
test the influence of the DCA on bone growth rate and quality compared with plain CPC. Therefore, as following 
decalcification procedures CPC was degraded and impossible to be accurately localized, we still assume 
defining a well-delimited area the most accurate method. Here, the influence of the defect on bone quantity 
could be considered constant between all samples. Still, information regarding osteoinductive performance 
and degradation of CPC/DCA were precluded by the dissolution of the cement and will require further 
investigation. 
Micro X-ray Computed Tomography (µCT) is often employed to evaluate the outcome of bone regeneration 
studies, as it provides qualitative as well as quantitative information based on differences in grey values 
between different tissues. However, visualization of CPC is still challenging and several radiopacifying materials 
are currently employed (bismuth, strontium, barium, colloidal gold, a.o.) [25]. In a recent study by Camilleri and 
Gandolfi [26], an adequate radiopacity was achieved with the use of 30% zinc oxide and similar results were 
obtained by the group of Húngaro Duarte [27] with zirconium oxide. However, very high concentrations of 
embedded material will always (negatively) influence the handling properties of a cement in terms of setting 
time and mechanical outcome. A strategy to decrease the concentration of contrast agent in order to avoid 
interferences with physico-mechanical performances of the cement [28]  is to choose high atomic number 
compounds [29]. In the study of Aguilar et al [25] bismuth oxide showed good contrast enhancing properties at 
a concentration of 20%, while choosing an even higher atomic mass compound as nanometric particulate of 
tantalum oxide, Hoekstra et al [30] were able to decrease the concentration up to 10% wt/wt. Still, the problem 
arising from the use of such heavy metal compounds, besides unspecific reactivity,  is the lack of information 
about their metabolic destiny, possible accumulation and toxicity after being released after CPC degradation 
[16, 17, 31, 32]. In the current study, the concentration of both radiopacifiers was set at 5% wt/wt. The 
structural embedding of two nanoparticles types into the silica carrier beads prevents/inhibits their release as 
free metal ions, and allows even the encapsulation of much higher concentrations while avoiding the above 
mentioned side effects. The advantage is that after dissolution of the organic silica matrix, the inert 
nanoparticles can be cleared through intestinal macrophages and renal filtration. [33, 34].  
As a second approach MR Imaging was selected as means of visualization. MRI is the gold standard for soft 
tissue imaging such breast and prostate, but has recently started to be exploited for hard tissue applications 
too. The development of short Echo Time acquisition sequences, like Ultra Short Echo Time (UTE) and Zero 
Echo Time (ZTE) [8, 9, 10, 35], opened the way to new possibilities for bone related applications.  
In a recent study, Sun et al [36] aimed to evaluate the feasibility of ZTE acquisition for CPC visualization. Gd-
DTPA (Magnevist
®
)  and USPIO (Sinerem
®
) were used as in vitro and in vivo enhancers of CPC contrast. Despite 
the positive results in terms of contrast enhancement, both compounds negatively affected the physical and 
mechanical properties of CPC, even at concentrations as low as 1% wt/wt. This precludes their further clinical 
application. The hereby proposed  Dual Contrast approach allows, by encapsulation and isolation of the 
contrast agents, to prevent unspecific reactivity. If  CT acquisition could be directly translated into clinical 
applications, MR bone imaging is still undergoing developmental and optimization steps at a preclinical level. 
  
Although Zero Echo Time acquisition represents a valuable tool for hard tissue imaging, the integration within 
clinical instruments is still an ongoing process as specific instruments as well as software requirements must be 
fulfilled.  
In the present study, SPIO particles and colloidal gold nanoparticles were jointly encapsulated into the silica 
beads. Although gadolinium-chelates [37, 38] have been described earlier, SPIO currently appear to be 
preferred as MRI contrast agents. Such particle labeling is considered favorable because: (1) SPIO  account for 
the highest change in signal per unit of metal, in particular on T2*-weighted images. Since SPIO are composed 
of thousands of iron atoms they defeat the inherent low contrast agent sensitivity of MRI; (2) SPIO are 
biocompatible and biodegradable and can be reused/recycled by cells using normal biochemical pathways for 
iron metabolism; (3) SPIO can be magnetically manipulated while their magnetic properties differ according to 
size, as well as their structural conformation (eg. free vs. bound state). [39] 
Gold nanoparticles have been shown to be superior compared to several other radiopacifiers (eg. Iodinated 
compounds). The application of Gold results in higher absorption with less bone and tissue interference 
achieving better contrast with lower X-ray dose [40]. In fact, imaging gold at 80–100 keV reduces interference 
from bone absorption and takes advantage of lower soft tissue absorption helping to reduce patient radiation 
doses [41]. 
The encapsulation of both compounds into a silica matrix appeared to be a good strategy to prevent side 
reactions between CPC and contrast agents. A major drawback of iron oxide particles as MR-T2* contrast 
enhancer is the resulting so called “blooming effect”, often caused by overload or simple clustering of iron 
oxide particles within the tissue [42].  
Possible strategies to reduce the blooming effect are suggested by recent studies and consist in reducing the 
concentration of nanoparticles, in the tuning and modification of the MR acquisition parameters [43, 44], or 
incorporation of MR contrast agents like gadolinium or fluorine. Morover, MRI contrast agents are usually 
employed in Gradient Echo scans at 1.5 Tesla in which blooming effects are less evident. Despite, what needs 
to be taken in consideration is that the effect of the contrast agents also strongly depends on the MRI 
technique employed. In our case, in contrast with Gradient Echo techniques, with the ZTE  the affected signal is 
not lost but blurred as well as dislocated, contributing to a further signal intensity increasment. The localization 
of our CPC/DCA resulted, therefore, more obvious but, at the same time, a direct signal quantification was 
hampered. Still, recent literature has already shown that quantification of the iron particle-signal is possible by 
means of novel susceptibility mapping techniques in combination with relaxation time mapping techniques. 
However, these methods have to be developed further, as only preliminary studies are currently reported [45, 
46]. 
The hereby presented formulation allowed the clear verification of proper implant placing with both methods. 
The long term contrast enhancement provided by MRI opens longitudinal quantification possibilities. The 
contrast degradation, proved  by disappearance of CT contrast enhancement, suggested that degratation 
analisys would also be possible and tailoring degradation and contrast persistance is a way that will be surely 
explored in future studies. 
Furthermore, due to the inhert behaviour of the carrier, we assume that the DCA could be incorporated within 
virtually any kind of material, i.e. different ceramic or polymer-based materials. Finally, we envision that 
besides contrast-enhancing agents, the hereby proposed bead-carrier can ideally also be employed for the 
incapsulation of different molecules (i.e. bioactive molecules, drugs, growth factors, etc.) for regenerative 
medicine applications. In conclusion, the combination of two different contrast agents within one silica bead 
carrier product allows to obtain complementary information from multiple imaging modalities, without 
changing overall biomaterial performance in calcium phosphate ceramic. 
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Introduction 
The growing need for bone treatment procedures keeps a high pressure on the development and optimization 
of artificial substitutes for bone regeneration. Calcium Phosphate (CaP) based materials are amongst the most 
commonly used, as they closely resemble structure and composition of the natural bone. Especially, injectable 
CaP-based cements (CPCs) have the advantage of optimal bone defect filling capacity, and are applicable 
through minimally invasive surgery [1]. The osteoinductivity of such materials can be enhanced by 
incorporating biologically active molecules, like BMP-2, either via adsorbtion onto pre-set CPC scaffolds [2], or 
via loading before the CPC setting. 
At the same time, assessment of tissue regeneration is essential to optimize the stages of bone healing. Most 
commonly, bone healing is assessed with x-ray or computed tomography (CT) assessments. Recently, also Zero 
Echo Time (ZTE) Magnetic Resonance Imaging (MRI) [3], has proved to be a powerful tool for bone tissue 
imaging.  However, all commonly used techniques for bone imaging lack sensitivity to detect the presence of 
synthetic bone substitutes, without additional contrast enhancement.  Advances in the fields of material 
science, imaging and formulation development lead to the development of theranostics, which aims at 
combining both therapeutic (e.g. the BMP-2) and diagnostic (e.g. the MR detection) functions within a single 
product. Theranostic medicine is currently explored to enhance the quality of cancer treatments, 
atherosclerosis, infections, and a variety of regenerative medicine applications [4]. In this study, we have 
developed a theranostic agent (TA), a silica-based nanocomposite MR contrast agent, which also functions  as 
carrier for BMP-2 release. The specific formulation of such a composite, combined with the biocompatibility of 
silica, is meant to provide imaging contrast enhancement, while reducing unspecific reactivity and improving 
the osteogenic performance of CPCs. After in vitro characterization, the developed TA was tested in vivo, in a 
femoral condyle defect model in rats. Imaging properties were monitored by MRI, while osteogenic 
performance were measured by histomorphometry, up to 8 weeks post-implantation.   
1. Materials and Methods 
2.1 CaP  cement with PLGA Microspheres 
Calcium phosphate cement consisted of 85% of α-Tricalcium Phosphate, 10% Dicalcium Phosphate Dihydrate 
and 5% Hydroxy Apatite [5]. The cement powder was sterilized using gamma radiation with 25 kGy (Isotron 
B.V., Ede, The Netherlands). As a porogen, acid-terminated PLGA microparticles were prepared using a double-
emulsion solvent-extraction technique. Poly (DL-Lactic-co-glycolic acid), (PURASORB, Purac, Gorinchem, The 
Netherlands) with a Lactic to Glycolic acid ratio of 50:50 and an average molecular weight of 4.55 ±0.03 kDa, 
was used for microparticle preparation. The average size of the microparticles, as determined with image 
analysis, was 96 ± 16 μm [6]. PLGA microparticles were mixed with the CaP cement powder in a proportion of 
20  %wt/wt. 
2.2 Theranostic Agent 
A customized theranostic agent (TA) was synthetized. The contrast agent particles were prepared by an inverse 
emulsion approach (patent WO2005/052581; Nano4Imaging GmbH, Aachen, Germany) using MRI responsive 
Ultra Small Iron Particles (USPIO) embedded within a mesoporous silica matrix. Two contrast agent 
formulations were tested: (i) MRI-1 with an iron oxide core size range of 200-300 nm at an end concentration 
of 40 wt/wt%, and (ii) MRI-2 with an iron oxide core size range between 0.5 and 1.2 µm at an end 
concentration of 30 wt/wt%.  
BMP-2 (Pfizer, InductOs® former Wyeth Europe Ltd., Berkshire, UK) was immobilized onto the surface of the 
beads, functionalized with silane linkers carrying amino functions (3-aminopropyl-trimethoxysilane), as 
described by Elhert et al [7]. A solution containing 10 µg of BMP-2 was mixed with a suspension of beads (12.5 
µL at a concentration of 20mg/mL) in Phosphate-Buffered Saline (PBS) buffer (pH 6.8). PBS was then removed 
  
and the beads were resuspended in in 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 5.5) and 
placed at 4 °C, overnight. 
Finally, the TA beads were given a calcium phosphate coating. For this, 500 µL of a 5 mg/mL contrast agent 
suspension, containing 10 µg of BMP-2,  was mixed with 54 µL of 40 mM CaCl2 , 77 µL of 3.9 mM Na2HPO4  and 
60 µL of 1 mM NH3. The mixture was placed at 4 °C for 1 hour. After pH had reached 7.9, 60 µL of 1 mM  NH3 
was added into the solution, and again placed at 4 °C for 1 hour. When pH was 8.5, again 80 µL 1 mM NH3 was 
added and the solution remained at 4 °C for 1.5 hours. The final pH was 9.5. The suspension was maintained 
under continuous rotation throughout the entire procedure. The resulting coated beads were magnetically 
separated and washed 4 times in PBS. The precipitate was then diluted to an end concentration of 20 mg/mL. 
Control samples were treated the same way, with exception that the beads did not contain BMP-2. After 
freeze-drying, the obtained solid phase was then mixed to reach a final end concentration of 0.1% (wt/wt) 
within the bone cement/PLGA composite.  
2.3 Composite preparation 
The cement was created by adding a filtered sterilized (0.2 µm filter) 2% aqueous solution of sodium phosphate 
(Na2HPO4) to the PLGA/CaP or PLGA/CaP/TA  powder mixture using a 2-mL syringe (BD Plastipak, Becton 
Dickinson S.A., Madrid, Spain) with a closed tip. The components were shaken for 20 seconds using a mixing 
apparatus (Silamat Vivadent, Schaan, Liechtenstein). 
2.4 Characterization of CPC and TA 
Theranostic agent-beads 
The morphology of the TA beads was determined by SEM and Transmission Electron Microscopy (TEM). SEM 
images were obtained at 2000x, 5000x and 10000x magnification, while TEM images were obtained at 30K and 
50K.  
Elemental analysis was performed using a scanning electron microscope (SEM, Philips XL30, Eindhoven, The 
Netherlands) coupled with an energy dispersive x-ray spectrometer (EDS, EDAX, AMETEK Materials Analysis 
Division, Mahwah, NJ). Samples were sputtered with a thin layer of Gold using a common sputtering 
instrument (Cressington 108A, Watford, UK) to improve the surface conductivity. The EDS elemental maps 
were taken at accelerating voltage of 15 KeV and working distance of 10 mm. 
CPC 
- Cement setting time: Initial and final setting times for the different cement formulations were assessed 
using custom available Gillmore needles (ASTM C266). A plastic mould of 3 mm (diameter) x 6 mm (height) 
was used to prepare the scaffolds. Both initial and final setting times were determined and tests were 
performed at room temperature. 
- Mechanical testing: Samples were placed on a 858 MiniBionixII® testing bench (MTS, Eden Prairie, MN) and 
the compressive strength in the longitudinal direction of the specimens was measured at 0.5 mm/min 
cross-head speed. 
- Morphology: All different cement formulations were assessed by Scanning Electron Microscopy (SEM). For 
this purpose, destructed samples were obtained from the compression test. Images were obtained at 
500x, 1000x and 2000x magnification. 
Ex vivo MRI 
Sixteen explanted rat femoral condyles were collected, which were left-over material from unrelated 
experiments (RU-DEC 2012-317). In each condyle, a cylindrical defect was made of 3.0 mm depth and diameter; 
  
and filled bearing either the contrast agent MRI-1 or MRI-2 mixed into the CPC, at a concentration of both 0.1 
and 0.5% wt/wt (n=4 for each condition). After 30 minutes, condyles were immersed in in 70% Ethanol and MR 
imaging was performed on a 11.7T MR system (Biospec, Bruker, Germany) with a mouse brain surface coil. 
Zero Echo Time (ZTE) images were acquired for all samples at the same time and settings, to avoid confouding 
effects of individual calibration or thresholding, at 200 kHz bandwidth, TR=4ms, flip angle=5°, 
FOV=50*50*50mm, matrix size 128*128*128, total acquisition time 3.27 minutes. 
BMP-2 immobilization and release 
Following BMP-2 immobilization, the amount of BMP-2 effectively bound to the surface of the beads was 
measured. Thereafter, BMP-2 release tests were performed and the protein concentration was measured by 
both ELISA, to quantify all released BMP-2, and BRE-Luc assay, to specifically quantify the fraction of bioactive 
BMP-2. 
Quantification of effectively bound BMP-2 
The fraction of BMP-2 bound to the silica beads was determined by enzyme-linked immunosorbent assay ELISA 
assays, with a Quantikine® BMP-2 Immunoassay kit (R&D Systems, Minneapolis, MN) following the 
manufacturer’s instructions. The assay was performed for all process steps, i.e. (i) on the MES buffer used for 
the immobilization, and removed during the first washing step, (ii) on the PBS collected after the following 
washing steps, and finally (iii) on the resulting beads.  
Quantification of released BMP-2  
A 12.5 µL aliquot of the bead suspensions, loaded with BMP-2 was resuspended in 500 μl of Minimum Essential 
Medium Alpha (MEM-α). Both coated and non coated samples  remained in the medium for 2 hours, 3 days 
and 7 days. The amount of BMP-2 released into the supernatants was determined using ELISA (R&D Systems) 
and BRE-luc assay, described below.  
BRE-Luc assay 
M3T3-BRE-Luc cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 5% Fetal Bovine 
Serum (FBS) and 800 ug/ml neomycine, at 37 °C in a humidified atmosphere of 5 % CO2. Cells were trypsinized 
and seeded at a concentration of 2*10
4 
in 100 µl of 5% FCS-DMEM in a flatbottomed transparent plate for 24 
hours. After removing the culture medium, 100 µL of the samples medium, containing the released BMP-2, 
were added into the wells, together with 2% FBS. To estimate BMP-2 release, a standard curve obtained with 
soluble BMP-2 in dilutions from 0.4 untill 50 ng/ml (100 µl/well) was performed in parallel. Following the 
incubation time of 16-20 hours, the medium was removed and replaced by 25 µl of reporter lysis buffer 
(Promega, Madison, WI ).  The icubation was done at -80 ºC for at least 1 hour. After defrosting, 25 µl of Bright 
glow (Promega) were added to each well and the luciferase intensity was measured (LUMIstar Omega, BMG 
LABTECH GmbH, Ortenberg, Germany).  
2.5 In vivo assays 
Animal Model  
All in vivo work was conducted in accordance with standards and protocols of the Radboud University Medical 
Center, Nijmegen, The Netherlands. National guidelines for care and use of laboratory animals were obeyed 
and approval of the Experimental Animal Ethical Committee was obtained (RU-DEC 2012-060). Ten healthy 
adult male Wistar rats, weighing 250-300 g were included as experimental animals. Surgery was performed 
  
under general inhalation anesthesia (Isoflurane) and aseptic conditions.  For the surgical procedure animals 
were immobilized and both legs were shaved, washed and disinfected. The knee joint was exposed after a 
longitudinal parapatellar incision. At the femural intercondylar notch, a cylindrical defect (3.0 mm depth and 
diameter) was then prepared using a dental bur and continuous external cooling with saline. Defects were filled 
with the various CPC materials, or left untreated in control animals (Table 1), before the subcutaneous tissue 
and skin were closed by suturing in layers. In vivo MR scans were performed 4 and 8 weeks post-surgery. 
Thereafter, animals were sacrificed and histology and micro-CT were performed.  
 
Table 1.  Experimental groups and implantation scheme. With the aim of testing both the MR contrast agent and BMP-2 
performance, four experimental groups were selected: (i) Empy – untreated defect, (ii) CPC –defect filled with injectable 
calcium CPC, (iii) MRI - defect filled with injectable CPC incorporating the MR contrast agent and (iv) MRI/BMP2 - defect 
filled with injectable CPC incorporating the MR contrast agent and BMP-2. 
In vivo MRI  
MR imaging was performed 4 and 8 weeks after surgery using a 11.7T MR system (Biospec, Bruker, Germany) 
with a home-built bare Helmholtz coil with a size of 3*3 cm. Zero Echo Time imaging was performed at 200 kHz 
bandwidth, TE/TR = 0 ms/8 ms, flip angle = 5°, FOV = 50*50*50 mm, matrix size:128*128*128, 4 averages and a 
final acquisition time of 30.27 minutes. 
Micro-CT 
Eight weeks after surgery, the animals were sacrificed by CO2/O2 overdose. Femoral condyles were retrieved 
and surrounding soft tissue was removed. Bone samples were fixed in 10% Formalin for 48 hours and 
subsequently transferred to 70% Ethanol for the duration of the μCT scans. For 3D analysis, the specimens 
were placed vertically onto the sample holder of a micro-CT imaging system (Skyscan 1072, Kontich, Belgium). 
Subsequently, samples were recorded at a 11.10 μm  resolution (X-ray Source 100kV/98µA; Exposure Time 3.9 
sec; 1 mm filter applied). Then, using NRecon V1.4 (SkyScan), a cone beam reconstruction was performed on 
the projected files. Finally, 3D-reconstructions of the samples were obtained (3D-DOCTOR 4.0, Able Software 
Corp, Lexington, MA). 
Histology 
After scanning, all specimens were decalcified for 72 hours in 10% ETDA. Samples were then dehydrated in 
gradual series of ethanol (70%-100%) and embedded in Paraffin. Sections of 6 µm thickness were cut in a plane 
parallel to the long axis of the femur using a Leica RM2165 Microtome (Leica Microsystems, Rijswijk, The 
  
Netherlands). The sections were stained with Haematoxylin/Eosin and trichrome Elastin van Gieson (EVG); at 
least six sections of each specimen were analyzed.  
Bone Quantification 
The EVG-stained slides were quantitatively assessed using computer-based image analysis techniques (Leica 
Qwin Pro-image, Leica, Wetzlar, Germany). From digitalized images (magnification 2.5X), the percentage of 
bone tissue was determined within the area of interest, positioned accordingly to the original size and position 
of the created defect.   
2.6 Statistical Analysis 
Statistical analysis for bone quantification was performed using GraphPad Instat® (GraphPad Software, San 
Diego, CA). Statistical comparisons were performed by one-way analysis of variance with a Tukey multiple 
comparison post-test. For setting time and compression tests, data are presented as mean ± standard deviation 
and significant differences were determined by analysis of variance (ANOVA). All differences were considered 
significant at P-values <0.05.  
2. Results  
Characterization of TA beads 
As evident from the SEM micrographies, the beads presented a uniform size distribution (Figure 1a), with a 
mean value of 1.68 ± 0.86 for MRI-1 and 1.65 ± 0.78 µm for MRI-2. From the TEM image it was possible to 
identify the inner iron core which appears darker, as more electrondense, surrounded by the silica matrix 
(Figure 1b). As shown in Figure 1c,  five principal elements could be detected: silicon (Si) and oxigen (O) as 
components of the silica matrix, phosphorus (P) and calcium (Ca) from the most superficial coating layer, and 
iron (Fe) from the inner core. The spatial distribution of Fe, O and Si was homogeneous throughout the entire 
field of view, delimited by the SEM micrography. Differently, despite being well-distributed throughout the 
whole sample, presence of Ca and P showed evident variability even within the single beads. 
  
 
Figure 1. Morphological characterization of the TA beads. a. SEM micrograph of the TA particles at 1000X magnification; b. 
TEM image of a single TA particle before CaP coating, at a magnification of 50K. The more electrondense inner iron core 
appears darker, while the surrounding silica matrix appears lighter. c. Elemental analysis of the final TA performed using 
SEM coupled with an EDS. Spatial distribution maps and relative abundance of the single elements are herein presented as 
atomic percentage. The upper right image shows the overlap of all detected elements. 
Characterization of CPC/TA 
All formulations showed a uniformly distributed appearance of the TA within the cement powder (Figure 2a). 
At both the 0.1 and 0.5 % wt/wt concentrations, no differences were measured in initial or final setting time 
with the incorporation of MRI-1. The addition of  MRI-2 caused a significant increase of the final setting time 
from approximately 18 to 20 minutes. When assessing  the material compression strength , only the highest 
concentration of MRI-2 caused a significant decrease (Table 2).  
 
  
Figure 2. Characterization of CPC/TA composite a. SEM micrograph of TA particles (indicated by red arrows) mixed within 
the CPC matrix at 1000X magnification. Note that the TA is uniformally distributed within the cement matrix. b. Ex vivo MR 
imaging performance of smaller diamter / higher concentration MRI-1 vs. larger diameter / lower concentration MRI-2 
agents, at two different concentrations. Note that 0.1 % w/w MRI-2 was the optimal combination providing MR-contrast 
enhancement. 
 
Table 2. Comparison of size of the TA beads and effect on setting time. Two sets of beads incorporating different contrast 
agents formulations, namely MRI-1 and MRI-2, at both 0.1 and 0.5% w/w concentrations, were  tested. (* = P < 0.05). 
Ex vivo MRI 
Obvious CPC-to-bone contrast enhancement was seen in all samples. For the MRI-1 formulation with a lower 
core diameter, yet higher iron concentration, contrast was mostly  characterized by the presence of a so-called 
blooming artifact. Further, at the settings used both applied concentrations led to a considerable visual 
overestimation of the size, with regards to the original defect perimeter. In contrast, the higher core diameter, 
lower iron  concentration MRI-2 formulation proved to be optimal, as by visual inspection the contrast 
enhancement was corroborating closely with the original defect morphology (Figure 2b). Based on this 
evidence,  MRI-2 at a concentration of  0.1 % wt/wt was selected only for the following tests and the final in 
vivo evaluation. 
BMP-2 immobilization and release 
The amount of BMP-2 immobilized on the surface of the beads was measured by ELISA. The assay showed that 
it was possible to immobilize relatively high amounts of BMP-2 on the substrates using an amino-silane linker. 
The measured amount was about 4.97 ± 0,86 µg of BMP-2 per 12.5 µL bead suspension, i.e. approximately 50% 
of the originally added 10 µg. The remaining 1,98 ± 0,72.µg were measured in the supernatant and 2,54 ± 1,81 
in the washing medium.  
To quantify the released BMP-2 and its biological activity, the complementary ELISA and BRE-Luc tests were 
carried out. Both detection methods showed a progressive release during the observational period of 7 days. 
The presence of the hydroxyapatite coating induced a double amount of growth factor to be released after 
both 3 and 7 days, compared to the non-coated beads (Figure 3a). BRE-Luc data (Figure 3b) showed that at 
least half of the released protein measured by ELISA remained biologically active.  
  
 
Figure 3. In vitro BMP-2 release measured by a. ELISA and b. BRE-Luc assay. Both graphs compare the release from HA-
coated beads against not coated beads. Results from both assays showed enhanced BMP-2 release in the presence of the 
coating. The BRE-Luc assay showed that, in the presence of the coating, the amount of bioactive released BMP-2 was 
relatively higher compared to the release in absence of coating. 
In vivo MRI 
The surgical procedure did not lead to any adverse and unexpected reactions. All animals recovered within a 
few hours post-surgery and none were restricted in their movements. Rats were monitored during the whole 
experimental period and no evident signs of discomfort nor weight loss were observed. Eight weeks post-
implantation, all femoral condyles were retrieved. At a macroscopical visual inspection, no clear differences 
were observed between the Empty, CPC and MRI groups, whereas obvious areas of new bone formation were 
detected in the group containing BMP-2. MR images obtained 4 weeks post-implantation showed a partial 
healing of the untreated bone  defects, which appeared to be progressed at week 8. No reliable observations 
could be made within the CPC group without additives, as the implanted material could not be reliably localized 
among the surrounding natural bone at either time point. In contrast, the incorporation of the MRI-2 contrast 
agent provided information about the correct localization of the injected material. Interestingly, also one 
undesired event could immediately be found, i.e. the formation of an evident crack in the centre of one of the 
implanted cements. In this group, the MRI-2 contrast enhancement could still be detected 8 weeks following 
the implantation. Finally, similar contrast was observed at 4 weeks in the presence of the MRI-2/BMP-2 sample. 
This contrast had disappeared at week 8. Moreover, in this group an obvious region of newly formed bone 
could be localized inside, as well as outside the site of CPC injection (Figure 4). 
  
 
Figure 4. In vivo MRI. Representative 2D slides selected from 3D-acquired datasets of rat femoral condyle defects from the 
four experimental groups, acquired by Zero Echo Time MRI sequence at 4 and 8 weeks post-implantation. Red arrows 
indicate the location of the defect. 
Histology and microCT for bone volume quantification 
In none of the histological sections an adverse tissue reaction or signs of severe inflammation were found. 
Micro CT observation as well as HE and EVG staining showed a uniform bone reaction in all groups, and 
combined information from histological slides and microCT (Figure 5a) allowed the location of the original 
defect site within the condyle. Upon light microscopical inspection, all defect areas appeared to be filled by 
newly formed trabecular bone. Bone marrow-like tissue was observed in between the bone voids and fibrotic 
tissue was absent. Despite the decalcification procedure, still traces of the implanted CPC were present in both 
CPC and MRI groups, whereas they could not be found in samples from the MRI/BMP2 group. The original 3X3 
mm defect area was selected to quantify the bone volume percentage. Eight weeks after implantation, the 
results showed significantly enhanced bone formation only in the presence of BMP-2, whereas no differences 
were detected between the other three groups (Figure 5b).  
  
 
Figure 5. microCT and histology for bone volume quantification. a. Qualitative µCT and histological evaluation. 
Representative 2D-µCT and corresponding H&E stainined sections from the CPC group 8 weeks post-implantation. The 
dashed circle indicated the original defect area. b. Quantitative evaluation of bone formation. Bone formation was 
measured within the original defect area, in the four experimental groups, 8 weeks after implantation. Bone percentage in 
all groups was around 60 to 70%, while the MRI/BMP2 group showed a significantly enhanced bone formation (P < 0.05). 
3. Discussion  
The present study aimed to test the feasibility of a theranostic agent, i.e. an agent which simultaneously is 
capable to enhance the MR bone contrast, as well as enhance the osteogenic properties of CaP bone cement. 
Both in vitro and in vivo assays were performed. The TA as used, was a nanocomposite of silica beads, in which 
an iron oxide core and a silane linker-modified and calcium phosphate coated surface for BMP-2 immobilization 
were structurally integrated. The main in vivo implantation results showed a long-term MR contrast 
enhancement, as well as improved osteogenic capacity, by means of new bone formation.  
Theranostic agents are a class of imaging probes explored for the simultaneous visualization of drug delivery 
and therapeutic outcomes [8]. Conveniently, many imaging agents can be easily upgraded to theranostic 
agents. For example, iron particles, currently the most popular MR contrast agents[9], have been often 
selected for theranostic applications, as their surface coating allows straightforward chemical linkage and 
bioactive molecules loading [10]. In an initial study from our group, USPIOs were directly incorporated into 
CaP-based scaffolds, as enhancers of the implant-to-bone contrast. Despite providing sufficient imaging 
contrast, this approach had many practical drawbacks. Mainly, the Ultra Small Iron Oxide Particles (USPIOs) 
negatively affected the setting and mechanical properties of the injectable material [11]. Therefore, in a follow-
up study, USPIOs were encapsulated into inert silica, with the purpose to reduce aspecific reactivity in the 
cement setting reaction [12]. In the present study, the same approach was used to synthesize two sets of silica 
particles, both encapsulating iron oxide, but differing by core size and iron particles-to-silica ratio. Besides the 
advantage of reducing unspecific reactivity, mesoporous silica has been extensively studied with regard to its 
applications for drug delivery and loading of bioactive molecules [13, 14,15].  
  
As first principal results of this study, the charasterization of the particles and ex vivo MRI data were used for 
the selection of one TA composition for the final animal work. Although the MRI-2 showed a significant 
increase in final cement setting time, we regarded this effect of lesser importance, as the increase from 18 to 
20 minutes would be irrelevant for clinical handling. In stead, the MRI-2 by visual inspection exhibited a region 
of hypointensity, which at the MRI settings used more closely resembled the original area of the CPC-filled 
defect. It is important though to realize that shape measurements with any iron-containing MRI contrast agent 
will always be irreliable, as such agents are always be suspectible to so-called blooming effects. This type of 
artifact indeed was seen at both MRI-1 and MRI-2. It would ideally be possible to perform quantitative 
assessments on this effect with phantom studies, combined with proper calibration of the image thresholding. 
Such quantification however was not the aim for the current work, where image settings were always kept 
constant. After proper imaging contrast was achieved, we focused on the osteogenic protein. A recent study 
from Elhert et al. [16] sought to investigate the immobilization methods of BMP-2 on ceramic bone 
replacement materials. Only in the presence of the aminosilane linker notable amounts of BMP-2 could be 
immobilized. Considering these results, in the present study, the same approach was used to immobilize BMP-2 
on the surface of the MRI-2 silica particles. Of course, also the amount of BMP-2 provided at the implant site is 
determining for its function [17, 18, 19], and furthermore appropriate amounts can vary among different 
scaffold materials. For CPCs ranges from 2 to 30 μg have been investigated [20, 21], while several studies 
report enhanced bone formation already at the lowest doses [22, 23, 24]. In the present study therefore a final 
concentration of ~5 µg per defect was adsorbed onto the beads and incorporated into each CPC scaffold.  
The possibilities to further modulate BMP-2 release in terms of kinetics and concentration ranges, have been 
extensively explored. One options to modulate release is to provide the carrier with a coating. In the present 
study, the silica particles were coated by precipitated hydroxyapatite, following BMP-2 adsorption. The study of 
Boix et al. showed that BMP-2 has high affinity for hydroxyapatite, mainly influenced by the abundance of 
calcium or phosphate ions, especially at low pHs [25]. These results support the hypothesis that in our study, 
BMP-2 might have higher affinity for the coating rather than the functionalized silica support. It is therefore 
realistic to expect a fast release of the coating from the silica surface, together with the attached BMP-2. Based 
on the BRE-Luc assays results, upon release, the coating also contributed to preserve higher concentrations of 
bioactive BMP-2. 
Finally, we tested in vitro the setting time and compressive strength of the CPC. Such  handling properties are 
often overlooked but of critical interest to surgeons. It was shown that handling was not significantly affected 
by the incorporation of the TA, corroborating the data of our previous study [12]. The material handling 
remained acceptable within a range which still meets the clinical demands when repairing non-loading sites 
[24]. 
The TA-CPC was thereafter also tested in vivo, upon injection in a femoral condyle defect model in rats. The 
animal model is a well-established defect model for testing injectable as well as pre-set bone substitute 
materials [26, 27]. The relatively easy surgical procedure, together with the easily accessible location for 
imaging procedures, makes this model optimal for the purposes of our study. Again corroborating our previous 
data [12], standard non modiefied CPC was not distinguishable from the surrounding bone tissue. In contrast, 
the TA-CPC remained detectable by MRI up to eight weeks post-implantation. However, in most samples from 
the MRI/BMP2 group, contrast was seen at 4 weeks, but no longer observable after 8 weeks. Such observation 
is not due to a decay of the generated signal, but rather indicative that CPC remodeling and degradation was 
accelerated by the activity of BMP-2. Moreover, the results of this group evidenced that the TA was released 
from the CPC upon its degradation, but not incorporated into the newly formed bone, as the contrast 
enhancement would still be detectable otherwise. This property makes the TA particularly attractive for 
longitudinal and material degradation studies. Furthermore, for these type of beads is has been described that 
upon release from the scaffold, they can be cleared through intestinal macrophages and, due to their size, 
renal filtration [28, 29], overcoming toxic accumulation issues. Finally, also the histological evaluations proved 
that no traces of the implanted CPC could be retrieved in the MRI-BMP/2 group, supporting the notion that 
indeed the MR contrast disappearance 8 weeks post-implantation was solely due to the CPC scaffold 
degradation. 
  
4. Conclusions 
Multimodal and multifunctional theranostic probes are forming a cutting-edge technology, in which the 
advantages of both advanced imaging and therapeutic strategies can be combined. In the present study, we 
have described a bead-based formulation composed of an iron oxide core for MR contrast enhancement, 
embedded in a mesoporous silica matrix on which BMP-2 was immobilized. Our strategy allowed to overcome 
negative interference of the addition of a contrast agent to the biomaterial properties. Furthermore, bioactive 
BMP-2 could be efficiently released from the carrier-beads, leading to localized and effective bone 
regeneration. The desribed TA was shown to be suitable for longitudinal material degradation and bone healing 
studies.  
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Introduction 
Bone diseases account for half of all chronic conditions in people over 65 years old and osteoporotic fractures 
have doubled in the last decade (Tanner, 2000). Many of these cases require bone graft substitutes. Thus, 
together with the increasing request for bone trauma treatments, there is an increasing need for sensitive and 
non-invasive follow-up techniques (Hoekstra et al, 2011). For clinical use, X-rays and Computed Tomography 
(CT) are considered the gold standard for visualization and follow-up of bone regenerative therapies, providing 
excellent structural and anatomical information. Still, these techniques lack sensitivity to detect early bone 
healing processes, and functional studies cannot be performed. The problem becomes even more evident 
when a bone substitute is used to enhance/accelerate bone healing. In this case, anatomical information is also 
missing as many frequently used bone substitutes are made of, or contain,  calcium phosphates with similar 
radiopacity to the bone. Therefore, such substitutes are difficult to distinguish from the surrounding natural 
tissue by means of conventional techniques (Pekkan et al, 2012), even though recent attempts have been 
made using high resolution micro-CT or X-ray microdiffraction analysis (i.e. synchrotron radiation) (Gauthier et 
al, 2005; Mastrogiacomo et al, 2005; Komlev et al, 2010; Papadimitropoulos et al, 2007.). Histology can also be 
employed to evaluate the outcomes of preclinical studies although the invasiveness of the procedure and the 
time consuming protocols are still important limitations. The use of non-invasive imaging modalities could lead 
to a reduction of the number of experimental animals, to an increased statistical power and significance of 
preclinical studies and facilitate the translation from preclinical to clinical applications. 
Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) could be 
valuable imaging modalities to monitor the bone regeneration process. For bone-related studies, specific 
tracers are currently available. For SPECT, 
99m
Technetium (
99m
Tc-labeled diphosphonates such as 
hydroxymethylene diphosphonate (HDP)) selectively accumulate in bone tissue via chemical adsorption onto 
the crystalline structure of hydroxyapatite (Horiuchi-Suzuki et al, 2004). For PET, the 
18
F-fluoride ion deposits 
preferentially into newly formed matrix (Blau et al, 1962) through ion exchange with hydroxyl groups of the 
hydroxyapatite to form fluoroapatite (Hsu et al, 2007). Both tracers show enhanced accumulation in areas of 
high bone turnover, like newly formed bone matrix (Iagaru et al, 2011). Both modalities are clinically used for 
bone scanning,  mainly focusing on the detection and metabolic activity of bone metastases, while offering the 
advantages of total body examination, low cost, and high sensitivity. In particular, in the pathogenesis of bone 
metastases, tumor cells proliferating in bone interact with the local environment stimulating or inhibiting 
osteoclast and osteoblast activity. Because 
18
F-Fluorodeoxyglucose is taken up by tumor cells and 
99m
Technetium is taken up in areas of osteoblastic activity or osteoblastic healing reaction, both modalities 
appear to be complementary (Brenner et al, 2012). In the present study we test whether they can be used to 
monitor bone regeneration, especially in the presence of a radiopaque biomaterial.  
In regards to preclinical instruments, PET is well-known for its higher sensitivity and more accurate 
quantification, while SPECT has a higher spatial resolution. The latter should not be underestimated when 
studying small lesions. Moreover, 
99m
Tc has a longer half-life, is less expensive and more widely available than 
18
F (Rahmim et al, 2008).  Thus, this study aimed to compare and determine the utility of SPECT scans with 
99m
Tc-HDP versus PET scans with 
18
F-fluoride to quantify bone healing in a rat calvarial defect model. The best 
performing method was then validated in the presence of different Calcium Phosphate Cement (CPC) bone 
substitutes. Two scaffold materials of different density and porosity were used in order to assess the sensitivity 
of the method to quantitatively discriminate different bone ingrowth outcomes. Such a model could then, at a 
later stage, be used to compare in vivo performance of other radiodense bone fillers and tissue engineered 
constructs, in a non-invasive and quantitative way. 
1. Materials and Methods 
2.1 Animal model 
  
All in vivo procedures were performed in accordance with the standards and protocols of the Radboud 
University Nijmegen Medical Centre, Nijmegen, the Netherlands. National guidelines for care and use of 
laboratory animals were obeyed and approval of the Experimental Animal Ethical Committee was obtained 
(RU-DEC 2010-066).  
A bilateral calvarial defect was made in adult male 250-300 g Wistar rats (10-12 weeks old). First, to compare 
the two techniques, the defects were left untreated and animals were divided into two subgroups based on 
imaging modality: (1) SPECT/CT and (2) PET/CT. Due to a different location of the two instruments, SPECT and 
PET scans could not be performed on the same animals. Thereafter, to validate the selected technique, two 
more experimental groups were created and the two defects were filled with pre-set CPC scaffolds, either (3) 
dense or (4) with 40% porosity (Table 1). Sample size calculation was performed in line with the existing 
literature and previous experience of our research group. Power calculations were based on the following 
formula [n=1+2C(s/d)
2
], (Dell et al, 2002) where s is the standard deviation, d is the difference to be detected, 
and C is a constant dependent on the selected value of α (power of the study - the probability that the effect 
will be detected) and ß (1-power - the chance of obtaining a false-negative result). A power of 0.9 and the level 
of significance of 0.05 were chosen for the study, and the calculation resulted in n=4 repetitions per modality 
and/or material group. 
 
Table 1. In vivo study setup. The table describes the treatment applied to each bone defect, and the imaging schedule. 
During the surgical procedure animals were anesthetized by intubation with Isoflurane inhalation anesthesia, in 
order to prevent any eventual respiratory depressions that may occur during the procedures. The skin of the 
head was shaved and disinfected and a midline longitudinal incision was made from the nasofrontal area to the 
external occipital protuberance along the mid-sagittal suture (Figure 1a-e). Skin and underlying tissues were 
reflected bilaterally to expose the calvaria and two symmetrical 4 mm wide full-thickness bone defects were 
created in both parietal bones lateral to the midsagittal suture using a dental drill (ELCOMED 100, W&H Dental 
Work Bürmoos GmbH, Bürmoos, Austria) and a trephine bur (ACE Dental Implant System, Brockton, MA) under 
constant saline coolant irrigation. Special care was taken to prevent damage of the dura mater. Defects were 
left untreated or filled with the pre-set scaffolds (Figure 1f), depending on the group. Finally, the periosteum 
and the scalp were closed with 3.0 and 4.0 Vicryl
®
 resorbable sutures (Johnson & Johnson, St. Stevens-Woluwe, 
Belgium).  
  
 
Figure 1 (a-e). Surgical procedure of a bilateral calvarial defect in rats. Skin and underlying tissues were reflected bilaterally 
to expose the calvaria and two symmetrical 4 mm wide full-thickness bone defects were created in both parietal bones 
lateral to the midsagittal suture using a dental drill and a trephine bur under constant saline coolant irrigation. (f). Dense 
(left) and porous (right) pre-set CPC scaffolds were implanted into the defect areas before closing in layers periosteum and 
skin. 
2.2 Scaffold preparation 
PLGA microspheres 
Poly (DL-Lactic-co-glycolic acid), (PURASORB, Purac, Gorinchem, the Netherlands) with a Lactic-to-Glycolic acid 
ratio of 50:50 and an average molecular weight of 4.55 ± 0.03 kDa, was used for microparticle preparation. 
Acid-terminated dense PLGA microparticles were prepared using a double-emulsion solvent-extraction 
technique (Habraken et al, 2008). The morphology and size distribution of the PLGA microspheres was 
determined by light microscopy. Spheres were suspended in H2O and optical micrographs were made 
(Leica/Leitz DM RBE Microscope system, Leica Microsystems AG, Wetzlar, Germany). The size distribution of 
the microspheres was determined by digital image software (Leica Qwin®, Leica Microsystems AG, Wetzlar, 
Germany) using a sample size of 200 microspheres and resulted in an average size of 192 ± 58 μm. PLGA 
microparticles were mixed with the CaP cement powder in a proportion of 40% w/w. 
CaP cement 
Calcium phosphate cement consisted of 85% α-Tricalcium Phosphate, 10% Dicalcium Phosphate Dihydrate and 
5% Hydroxy Apatite. The cement was created by adding a filtered sterilized (0.2 µm filter) 2% aqueous solution 
of sodium phosphate (Na2HPO4) to the CaP powder mixture (with or without PLGA particles) using a 2-mL 
syringe (BD Plastipak, Becton Dickinson S.A., Madrid, Spain) with a closed tip. The components were shaken for 
20 seconds using a mixing apparatus (Silamat Vivadent, Schaan, Liechtenstein) and the composite was injected 
into a 4 mm diameter x 1 mm height cylindrical plastic mould. After setting, a constant temperature of 650°C 
for two hours was used to burn off the polymer template from the scaffold. The rate of temperature increase 
and decrease during the process was 1.5 °C/min.  
2.3 Micro-Computed tomography 
The pre-set scaffolds were placed vertically onto the sample holder of a micro-CT imaging system (Skyscan 
1072, Kontich, Belgium). Subsequently, samples were recorded at a 11.09 μm  resolution (X-ray Source 
100kV/98µA; Exposure Time 3.9 sec; 1 mm filter applied). Then, using NRecon V1.4 (SkyScan), a cone beam 
reconstruction was performed on the projected files. Reconstructed files were analyzed using CTAnalyser 
  
software (Version 1.10.1.0; SkyScan). Finally, 3D-reconstructions of the samples (n=5 per group) were also 
obtained (3D-DOCTOR 4.0, Able Software Corp, Lexington, MA). 
2.4 In vivo imaging  
SPECT/CT and PET/CT data acquisition for groups 1 and 2, respectively, of empty defects was performed at 12 
time points: before the surgery, one day after surgery and then once a week for a total period of 10 weeks. 
PET/CT scans of groups 3 and 4 were performed before surgery, one day after and then every two weeks, 
starting from week 2 up to week 10 after surgery. 
SPECT/CT images were acquired 2 hours post-injection of ~150 MBq/rat of Technescan 
99m
Tc-HDP (Covidien, 
Petten, The Netherlands) with an in vivo small-animal U-SPECT/CT scanner (MILabs, Utrecht, The Netherlands) 
with a spatial resolution of 0.8 mm (van der Have et al, 2009). Animals were scanned for 45 minutes in total (3 
frames of 15 minutes each) using the 1.0-mm-diameter pinhole rat collimator tube. SPECT scans were followed 
by CT images acquisition for anatomical reference (55 kV, 615 μA, Normal Scan Mode, Full Scan Angle).  PET/CT 
data were acquired 1 hour after injecting ~15 MBq/rat of
 18
F (BV Cyclotron VU, Amsterdam, The Netherlands), 
with  an Inveon small-animal PET/CT scanner (Siemens Preclinical Solutions, Knoxville, TN) with a spatial 
resolution of 1.5 mm. PET emission scans were acquired for 15 min, followed by CT acquisitions for anatomic 
correlation (spatial resolution 113 μm, 80 kV, 500μA, exposure time 300 ms). 
2.5 Quantitative analysis of the images 
SPECT/CT data were reconstructed with MILabs reconstruction software, using an ordered-expectation 
maximization algorithm, with a voxel size of 0.375 mm.  
PET/CT data were reconstructed using Inveon Acquisition Workplace software version 1.2 (Siemens Preclinical 
Solutions), using an ordered subset expectation maximization 3-D/maximum a posteriori (OSEM3D/fMAP) 
algorithm with the following parameters: matrix 256×256×159, pixel size 0.43×0.43×0.8. In PET scanning, the 
relation between distance and spatial interactions of the emitted positron will change according to the beta 
exponent, with a high beta indicating significant influence of the distance, whereas a low beta indicates no 
effects of distance. For the current experiment a relatively low beta value of 0.1 was set.   
Both SPECT/CT and PET/CT data were analyzed by drawing a 3D Region of Interest (ROI) over the defect areas. 
The nearby brain tissue was used as reference region (Figure 2). The Partial Volume effect has to be taken into 
account when measuring the uptake of small lesions and, as soon as the volume gets smaller than 3 times the 
resolution, partial volume effects play a significant role. Therefore, the ROI was designed considering PET 
resolution (1-2 mm) as the limiting factor, and measured 5 mm in diameter and 3 mm in depth. Defect-to-brain 
uptake ratios were determined using mean pixel values by AMIDE version 1.0.1 (A Medical Image Data 
Examiner, Stanford University, Stanford, CA) (Loening et al, 2003). Also, visual 3D models from CT scans were 
obtained by using a 3D creator software (3D-DOCTOR 4.0, Able Software Corp, Lexington, MA). 
  
 
Figure 2. Uptake ratio quantification. Transverse, coronal and sagittal view of: (a). SPECT (red) and CT (white) images 
overlap; (b). 3D-ROI placed on both defect areas; (c). an identical 3D-ROI was placed in the brain area and used as 
normalization reference. The same procedure was applied to analyze PET data. 
2.6 Histology 
At week 10, animals were euthanized by CO2/O2. The upper part of the skulls was retrieved, 
surrounding soft tissue was removed and bone samples were fixed in 10% Formalin for 48 hours, and 
dehydrated in gradual series of Ethanol (70%-100%). Samples that did not contain pre-set scaffolds (groups 1 
and 2) were decalcified for 72 h in 10% EDTA, and embedded in Paraffin. Sections of 6 µm thickness were cut 
following the coronal plane of the skull, using a Leica RM2165 Microtome (Leica Microsystems, Rijswijk, The 
Netherlands). Sections were stained with Haematoxylin/Eosin and at least three sections of each specimen 
were analyzed. The samples containing pre-set scaffolds (groups 3 and 4) could not be decalcified as such 
procedure would also cause scaffold degradation. Instead, the specimens were embedded in 
methylmethacrylate (MMA) after the dehydration step. Following the coronal plane of the skull, sections of 10 
µm thickness were cut using a microtome with a diamond blade (Leica Microsystems SP 1600, Nussloch, 
Germany). The sections were stained with methylene blue and basic fuchsin and a minimum of three sections 
from each specimen were analyzed by light microscopy (Leica Microsystems). 
2.7 Statistical Analysis  
For each experiment, data was reported as a mean ± standard deviation. Statistical significance was assessed 
using  a repeated measurements two way ANOVA (with Bonferroni correction for multiple comparisons) to 
  
detect differences in time and between the two types of scaffold.  Results were considered significant when P < 
0.05.  
2. Results 
3.1 Animal model 
All animals completely recovered from the surgical procedure and remained in good health. No signs of 
unexpected tissue response, inflammation or wound-healing complications were detected during the 
experimental period. Also, no changes in the normal behavior of animals were noticed. 
3.2 Pre-set scaffolds 
Micro-CT analysis was used to determine topology and 3D characteristics of the scaffolds ( porosity, 
interconnectivity, degree of anisotropy and structure model index, among others) as shown in Figure 3a. 
Resulting values encouraged, from a theoretical point of view, the use of 40% porosity scaffold. Such porosity 
should give a higher amount of bone ingrowth if compared with the dense scaffold, thus be most suitable as 
positive control for PET measurements. Moreover, the morphological aspect of dense and porous pre-set CPC 
scaffolds was visualized using micro-CT (Figure 3b-c). 
 
Figure 3. (a). Topology and 3D analysis of pre-set scaffolds. (b). Micro-CT representative 3D images showing the volumetric 
and morphological aspect of dense and (c). porous pre-set CPC scaffolds before implantation. 
3.3 In vivo CT imaging 
Both PET and SPECT acquisitions were accompanied by CT scans at every time point, in order to provide 
anatomical references and identify the defects, while analysing the PET and SPECT images quantitatively. 
  
The 3D reconstruction of CT images allowed clear visualization of the bone healing process over time (Figure 4), 
revealing bone growth starting immediately post-surgery. New bone formation was visually detectable at each 
time point, starting from the edges of the defects and moving towards the centre, as shown by a close up 
image from the third week post-surgery (Figure 4g). Complete closure of the defects was observed 10 weeks 
post-surgery, confirming that the 4 mm calvarial defect is a non-critical sized model. In contrast, when CPC 
scaffolds were implanted, the value of the information provided by CT images was highly reduced. The 
localization of the defect area appeared less obvious, especially in middle and late stage scans, and visual 
detection of new bone ingrowth within the defects area was not possible. Moreover, based on visual 
inspection only, it was not possible to discriminate between porous and dense scaffolds (Figure 4h, i, j). 
 
  
Figure 4. 3D reconstruction of in vivo CT scans showing the empty bone defects at (a). Day 0 before surgery (b). Day 1 post-
surgery (c). Week 1 post-surgery (d). Week 2 post-surgery (e). Week 4 post-surgery (f). Week 10 post-surgery. (g). Close-up 
of healing defects at 3 weeks post-surgery. 3D scans following pre-set scaffolds implantation at (h). 1 day post-implantation 
(i). 4 weeks post-implantation and (j). 10 weeks post-implantation. 
3.4 SPECT and PET imaging of untreated defects  
The 
99m
Tc-HDP activity was detected in sites of physiological uptake along the skeletal system, i.e. in the growth 
plates. Even after surgery, the activity in the defect area was noticeably lower compared to that in the growth 
plates, but still in all cases a specific activity was found, in the bone defect area (Figure 5b). The 
99m
Tc-HDP 
SPECT activity appeared to be specifically located at the edges of the defects, apparently in the area where new 
bone deposition was occurring. Quantitative measurements showed significantly enhanced tracer uptake at 
four weeks post-surgery (Figure 5a), followed by an activity reduction already detectable one week later. For 
SPECT however, no statistically significant differences were detected between all the other time points.  
The  physiological uptake of 
18
F assessed with PET also showed high tracer uptake within the skeletal system, 
especially in the growth plates areas. However, in sharp contrast to the SPECT, for the PET a significantly 
enhanced 
18
F uptake was registered as quickly as one day after surgery. The activity reached the maximal 
intensity  at the fourth week post-surgery and then slowly decreased until the last time point, still maintaining 
a significant difference from the basal activity (Figure 5c). 
 
Figure 5 (a). SPECT/ 
99m
Tc-HDP uptake ratio; note that activity was significantly increased only at the 4 
weeks time point, followed by a significant reduction 5 weeks post-surgery. No statistically significant differences were 
present at any other time point. (b). PET/ 
18
F uptake ratio; note that activity significantly increases from one day post-
surgery, reaching the maximal peak at week 4. From week 5 on the activity decreases while remaining significantly  higher 
than the basal value at the last time point. (c). SPECT and CT image overlay. Specific tracer uptake is seen around the 
borders of the empty defects (arrow). (d). PET/CT overlay showing a preferential uptake within the porous scaffold. As 
indicated by the arrow, the activity is specifically localized along the edges of the implanted scaffold. (e). Quantification of 
18
F uptake ratio within porous and dense scaffolds showing a significantly higher tracer uptake from porous implants with 
  
respect to the dense material. (f). Cumulative graph for the discrepancy between 
18
F uptake of porous and dense scaffolds, 
thus reflecting the overall cumulative bone ingrowth activity into the scaffold porosity. The scatter of the longitudinal data 
in both SPECT and PET data, can be associated to the variation in uptake ratios between different animals. 
3.5 PET imaging of CPC-filled defects 
Based on the results of the untreated defects, PET was considered to reveal more accurate information than 
SPECT. Therefore, this method was validated in the presence of synthetic bone substitutes. CPC dense and 
porous scaffolds were used as negative and positive controls, by respectively preventing or promoting new 
bone matrix deposition, to validate the technique and to confirm its feasibility in the presence of synthetic 
bone substitutes.  
Again, 
18
F-fluoride was preferentially taken up at the edges of the defects (Figure 5d). Quantitatively, the 
previously described metabolic trend was observed in both scaffolds.  In this study a significantly enhanced 
activity was detected starting at week 2 until week 6  post-implantation. At visual inspection, the PET activity 
appeared higher within the porous scaffold, compared to the controlateral side of the skull, where the dense 
scaffold was placed. The uptake of the tracer in the porous scaffolds was significantly higher compared with the 
dense material (Figure 5e). This temporal variation in signal, can be assessed easily by calculating the 
discrepancy between the dense and porous material (Figure 5f), and suggests a possible correlation to the 
healing capacity (i.e. rate of bone ingrowth) which would need further investigation. Apparently, ingrowth 
started after week 1, and was maximal until week 5/6. 
3.6 Histology 
Figure 6a presents an overview of histological sections of the empty defects ten weeks post-surgery. At low 
magnification (5X) the full closure of both defects with new bone matrix bridging the defect areas was clearly 
visible, again confirming that the defect is non-critically sized. Higher magnification, as shown in Figure 6b and 
c, showed ongoing bone tissue formation with clear demarcation lines between old and new bone, which 
stained darker and contained large osteocytes, indicative for woven bone and active remodeling. Figure 6d-f 
show representative histological slides of groups 3 and 4 after 10 weeks of implantation. As expected from the 
short experimental time, both scaffolds did not present visual signs of degradation. The dense construct 
showed a compact and uniform matrix, while evenly distributed pores could be easily identified throughout the 
structure of the porous material. A direct bone contact existed between these implants and the pre-existing 
edges of the defects without any intervening fibrous tissue, nor was any inflammatory cell infiltration detected. 
Newly formed bone was observed as both scaffolds resulted in osteoconduction and bone growing 
underneath. While the dense scaffold did not allow any new bone deposition within the material, in the porous 
scaffold, ingrowth of newly formed bone was also detected. Newly deposited matrix was only present in areas 
exhibiting interconnected pores.  
  
 
Figure 6 (a). Representative paraffin section (H&E staining), 10 weeks post-surgery showing complete healing of the empty 
bone defects at 2.5X magnification. (b) and (c) show the left and right defect area, respectively, at 20X magnification. (d). 
Representative MMA section (methylene blue and basic fuchsin staining), 10 weeks post-implantation of the pre-set 
scaffolds at 2.5X magnification. A further magnification (20X) from the lower part of dense and porous scaffolds is shown in 
part (e) and (f) respectively. 
3. Discussion 
Currently available techniques for the evaluation of bone tissue regenerative studies are X-ray, CT imaging and, 
when referring to preclinical studies, histology. Despite wide knowledge and long-time experience supporting 
these methods, important limitations remain when studying new bone substitute materials. Often, the similar 
radiopacity of the surrounding natural tissue results in unreliable X-ray and CT data, whereas the methods do 
not provide metabolic information. In this study, we investigated whether SPECT and PET could be used to 
study tissue healing, and whether PET could still be helpful in the presence of such a commonly used bone 
substitute. With SPECT and PET the maximal matrix deposition rate was observed quantitatively four weeks 
post-surgery, the time when bone callus starts to mineralize and the bone remodeling process begins (Einhorn 
et al, 1998; Greenbaum et al 1993), decreasing to a slow activity reduction until the last time point. Tracer 
uptake increased up to 4 weeks post-surgery and declined thereafter, until the last time point. However, PET 
scans provided statistically significant measurements for all time-points, whereas SPECT only provided 
  
significant data at the maximum bone metabolic activity interval at week 4. In other words, for our purpose, 
PET proved to be more sensitive than SPECT.   
The power of these functional imaging methods is emphasized by the results; namely during the 10-week 
healing period, the earliest visual signs of new bone tissue deposition by in vivo CT scans were detectable from 
the second week post-surgery, while PET scans revealed an increased metabolic activity as early as one day 
after surgery. Thus PET visualized  the activation of a healing response-to-trauma far before being anatomically 
visible. Still, CT scans provided essential information for the validation of the model, allowing a clear 
visualization of the healing process over time and, most importantly, confirming, through co-registration with 
PET (and SPECT), the site-specific tracer uptake along the edges of the defect. However, when CPC scaffolds 
were implanted, the use of CT was limited. It even was impossible to visually distinguish the solid scaffold from 
the porous scaffold, due to the resolution of the in vivo CT scans.  
Regarding the validation of the model, our aim was not to focus on the characteristics of the implanted 
scaffold, but to obtain a scaffold which would work as negative control  for the PET signal not allowing any 
bone healing, vs.  a scaffold which would work as positive control, by facilitating maximal bone ingrowth. 
Adequate pore volume and size alone are not sufficient for achieving osteoconduction. Pore connectivity may 
determine the effectiveness of porosity and, in general, biomaterials with interconnected pores are considered 
to be superior to biomaterials containing closed pores. Indication about the presence of interconnectivity thus 
were obtained through the Euler Number. Furthermore, the Structure Model Index (SMI) indicated the relative 
prevalence of rods and plates in the 3D structure of the material and involved a measurement of surface 
convexity. Concave surfaces of enclosed cavities represent negative convexity to the SMI parameter which is, 
overall, related to total porosity, open porosity, and closed porosity.  
Some practical considerations have to be taken into account for PET imaging: the presence of calcium 
phosphate-based materials caused a two-fold increase of 
18
F uptake at each time point. This result could be 
due to unspecific binding of the tracer to the scaffolds and could lead to an overestimation of the regeneration 
process. Still, the metabolic profile was maintained (excluding any effect on the final results) and a significantly 
higher 
18
F activity was detected within the porous scaffolds compared with the dense one. Furthermore, by 
assessing the discrepancy between solid and porous materials, it was possible to correlate the observed 
temporal variations in signal to the extent or rate of bone formation, i.e. such approach  will provide for a 
similar key outcome for bone regeneration, as compared to well-accepted histological measuring parameters. 
The choice of the animal model was crucial to determine the potential value of SPECT and PET for bone healing 
follow-up. As well established in literature, both employed tracers (
99m
Tc-HDP and 
18
F fluoride) exhibit high 
affinity for bone tissue and preferential accumulate in areas of high bone turnover and matrix deposition, such 
as the growth plates. To avoid interference of the background activity during measurements, our bone defect 
had to be as far as possible from these areas of high tracer uptake. For the purpose of the study, we needed a 
model to induce spontaneous bone healing and, taking into account future applications, a reliable model to 
test bone substitutes’ performances in vivo. The rat was the smallest suitable model. Among the non-critical 
size defects described in literature (Yasko et al, 1992; Nasseri et al, 2011; Schouten et al, 2009; Kondo et al, 
2005; Jones et al, 2007), bilateral calvarial defects appeared to be the most suitable, due to the negligible 
physiological tracer uptake of the area. A limitation of the study though is that the measured activity remained 
very weak even after the creation of the defects. This could be due to the low vascularization of flat bones, as 
several studies dealing with long bones fracture repair showed higher activity uptakes (Blokhuis et al, 2003; 
Blake et al, 2001).  
Coming to the quantification, literature offers no consensus on how to present the data. While in some studies 
results are presented as %ID/g [percentage of injected dose per gram of tissue] (Groot-Wassink et al, 2004; 
Carlson et al, 2006), others are shown as a ratio of radiotracer accumulation in the target site versus that of 
reference tissues, taken as background (Siddiqui et al, 2007). The latter has the advantage of accounting for 
background values and is therefore less likely to be susceptible to individual experimental artifacts. 
While quantifying the activity, the choice of reference tissues for background corrections was also relevant 
because there is currently no consensus in the literature: while some studies suggest non-damaged bone as 
control, [i.e. controlateral site of the defect area (Blake et al, 2009; Ogawa et al, 2011)], the majority of the 
  
studies  recommend soft tissue uptake as reference signal [i.e. muscular tissue surrounding bone defects (Hsu 
et al, 2007; Groot-Wassink et al, 2004)]. However, it could be debated if in the presence of a bone defect the 
whole skeletal system could experience an enhanced basal metabolism.  This effect could be evaluated by 
measuring skeletal uptake of both tracers in a bony area distant to the calvarial defect and it will be worth 
further investigation in future studies.  
For the present study, however, bone tissue seemed an unreliable reference, masking the regenerative rate of 
the bone within the ROI. Therefore, the reference area was drawn directly underneath the defect site, in the 
area of the brain. The use of brain tissue as reference tissue could be regarded unusual. Still, it allowed 
correction for aspecific activity of the circulating tracer. From literature, a more commonly used reference 
tissue for bone scans appears to be muscle tissue. The use of muscular tissue as reference was also considered 
in the present study, however, muscle areas of adequate size were not present in the considered field of view. 
The selected reference specifically referring to our goal, did not introduce any bias in the final results. The brain 
as a reference thus allowed to effectively assess bone healing potential over time, and to assess a significant 
up-regulation when in presence of an osteoconductive biomaterial scaffold. 
As the main outcome of our experiment, PET proved to produce significant data over the entire time range and 
thus be more suitable than SPECT , which did not reveal any significant increase of metabolic activity until 4 
weeks post-surgery. This may be caused by the properties of the tracers: previous studies have shown that 
18
F-
Fluoride exhibits superior pharmacokinetic properties compared to 
99m
Tc-labeled diphosphonates (Toegel et al, 
2006; Mitterhauser et al, 2005; Hawkins et al, 1992; Schwartz et al, 1993). Although the difference is negligible 
in regions of normal uptake, it could become crucial in areas of low vascularization and poor tracer distribution 
such as our bone defects.  
In a clinical setting, different groups have evaluated bone formation around allogenic bone grafts with help of 
18Fluoride PET measurements (Piert et al, 1999; Sorensen et al, 2003; Temmerman et al, 2008). The regional 
bone metabolism after hip replacement operations was mainly evaluated and expressed as bone blood flow 
rate through kinetic 18F-fluoride PET and related to the peri-implant bone formation, underlying the essential 
role of blood flow in determining the metabolic fate of allogenic bone grafts. Still, preclinical models for the 
screening of allogenic graft performance over time could represent a fast and reliable tool for the selection of 
highly performant materials even before clinical implantation. 
Finally, it might be of concern whether the repeated exposure to irradiation may have affected the 
spontaneous bone healing process. Indeed, the effects of repeated irradiation on bone are debated, either 
when dealing with depositions of radioactive isotopes which localize in the bone (γ-rays) or in repeated X-ray 
exposures (O’Donovan et al, 2001; Gevorgyan et al, 2007; Costantino et al, 1995; Takahashi et al, 1994; 
Casarett et al, 1968). Although we did not include reference specimens with no exposure, the histological 
evaluation of our samples, retrieved after the completed experimental period, did not reveal signs of delayed 
or incorrect bone healing. Still, the X-rays dose applied during image acquisition is of special concern in small 
animal CT, especially if follow-up examinations of the same animal are necessary. The effect of ionizing 
radiation in small animals has been well studied after micro-CT and the lethal dose in rodents is in the range 5 
to 7.6 Gy. The typical whole-body radiation dose for a 3D scan is far below the lethal dose and ranges from 
0.017 to 0.78 Gy.  
In the present study, the quantification of new bone formation by an independent gold standard technique, 
together with correlation analysis between PET, SPECT and gold standard results is lacking. Whereas CT would 
have been the most valuable comparison,  the resolution of preclinical scanners is not comparable to the 
resolution of “ex-vivo” micro-CT devices and would not allow such an accurate quantification of bone growth, 
and especially a clear distinction between not radiopaque scaffolds and newly formed bone. For 
musculoskeletal applications, higher resolutions are often required, resulting in increased exposures (Boyd SK 
et al, 2006). Depending on the diagnostic demand, however, X-ray dose can be decreased while maintaining 
high spatial resolution by reducing other image quality parameters such as image noise and soft-tissue 
contrast, which is commonly accepted in case of bone imaging.  
  
4. Conclusions 
PET provided significantly superior metabolic data on new bone matrix deposition compared to SPECT. Tracer 
uptake increased up to 4 weeks post-surgery and declined thereafter, until the last time point. Significantly 
higher values were registered within the porous scaffolds compared to the dense. In conclusion, PET is a 
valuable tool for qualitative and quantitative follow-up of bone healing in presence of radiopaque synthetic 
bone substitutes in vivo. 
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1. Introduction   
The release of osteoinductive growth factors plays an important role in bone regenerative medicinal 
strategies [1, 2]. A pre-requisite for the release of such proteins is a suitable scaffold material, as the 
delivery vector. Among many candidate materials especially porous ceramics, like calcium phosphate 
cement (CPC), are promising because of the good characterization and proven beneficial effects on 
bone healing. To introduce osteogenic properties, mostly proteins from the Transforming Growth 
Factor β (TGFβ) super family are chosen, like Bone Morphogenic Protein 2 (BMP-2). BMP-2 can be 
incorporated onto CPC via mixing into the ceramic starting powders, as the hardening takes place at 
ambient temperature, and thus the risk of thermal denaturation or loss of activity during preparation 
is minimal. Alternatively, BMP-2 can be adsorbed onto the surface after the cement has set [4]. 
Several studies have already shown that both of these incorporation modes actually result in a rather 
similar release profile [5-7]: i.e. an initial burst release followed by a stable sustained release. Blom et 
al. attributed the initial burst to the release of non-bound proteins from the surface of the material, 
while the steady stage was attributed to the strong binding affinity of TGF family proteins to the CPC 
[8]. Such data were also confirmed by the  van de Watering et al. using a highly porous CPC 
formulation. Also in this study, surface-loaded BMP-2 showed initial burst release within 1 day 
(~40%), followed by sustained release up to day 28. Moreover, despite the similar release profiles, 
surface-loaded CPC produced better outcomes in terms of osteogenic capacity  [10]. Further 
evidence about the use of surface-loaded CPCs as local BMP-2 delivery system, have been reported, 
both in vitro [9] and in vivo [10-14].  
Investigation of the protein release profile from CPCs usually is performed with scintigraphic imaging 
of radiolabeled proteins. For such purpose, BMP-2 is labeled with Iodine-125 or 131 (125I – 131I) to 
trace its release longitudinally. However, besides pure spatial information no data on the biological 
effect of BMP-2 (i.e. bone formation) can be extrapolated, and thus histological evaluation at various 
time points is always required. And although histology still remains the gold standard to provide 
decisive evidence, it also is obvious that early and non-destructive detection methods would be 
desirable. Thus, it could be postulated that a metabolic activity measurement like Positron Emission 
Tomography (PET), would be optimal, especially since our previous studies showed that neither 
Computed Tomography (CT), nor Magnetic Resonance (MR) imaging are suitable to visualize and 
quantify newly formed bone in the presence of CPC material [8]. 
Therefore, we currently propose that PET scanning could be a valid alternative to monitor the 
effectiveness of BMP-2-releasing CPC scaffolds over time. PET is routinely used for clinical bone 
scans, as specific bone-seeking tracers are available. Concerning bone applications, the standard 
tracer is 18F-Fluoride. Its specific and rapid bone uptake results in a high bone-to-background ratio 
following intravenous administration [15], thus, areas of increased 18F-Fluoride uptake reflect sites 
of enhanced osteoblast activity and osteoid production [16]. Moreover, our previous study showed 
that PET is a valuable tool for the qualitative and quantitative follow-up of bone healing around 
radiopaque bone substitutes, in vivo [17]. The present study sought to follow the osteogenic 
performance of one of a frequently used and well-characterized BMP-2 releasing system (i.e. the 
surface-loaded CPC) with PET, for a non-invasive and real-time functional evaluation. Pre-set CPCs,  
either dense or highly porous, were used as negative and positive controls, respectively. 
Furthermore, autograft implants were also included as these are a clinical standard control for bone 
regeneration studies. Following in vitro characterization, the scaffolds were implanted in a bilateral 
calvarial defect model in rats and monitored by PET once every two weeks, up to 8 weeks post-
  
implantation. CT was performed simultaneously for anatomical reference, and further PET activity 
was correlated to the efficacy (i.e. bone volume percentage) measured by histology. 
2. Materials and Methods 
Scaffold preparation 
Acid-terminated poly (DL-Lactic-co-glycolic acid) (PLGA, PURASORB, Purac, Gorinchem, the Netherlands) with a 
Lactic-to-Glycolic acid ratio of 50:50 and an average molecular weight of 4.55 ± 0.03 kDa, was used for 
microparticle preparation using a double-emulsion solvent-extraction technique as described before [18]. The 
morphology and size distribution of the PLGA microspheres was determined by light microscopy. Spheres were 
suspended in H2O and optical micrographs were made (Leica/Leitz DM RBE Microscope system, Leica 
Microsystems AG, Wetzlar, Germany). The size distribution of the microspheres was determined by digital 
image software (Leica Qwin®, Leica Microsystems AG, Wetzlar, Germany) using a sample size of 200 
microspheres and resulted in an average size of 175 ± 69 μm. PLGA microparticles were mixed with the CaP 
cement powder in a proportion of 40% wt/wt. 
Thereafter calcium phosphate cement was prepared, consisting of 85% α-Tricalcium Phosphate, 10% Dicalcium 
Phosphate Dihydrate and 5% Hydroxy Apatite [19]. The cement was created by adding a filtered sterilized (0.2 
Sm filter) 2% aqueous solution of sodium phosphate (Na2HPO4) to the CaP powder mixture (with or without 
PLGA particles) using a 2-mL syringe (Plastipak, Becton Dickinson, Madrid, Spain) with a closed tip. The 
components were shaken for 20 seconds using a Silamat mixing apparatus (Vivadent, Schaan, Liechtenstein) 
and the composite was injected into a 4 mm diameter x 1 mm height cylindrical plastic mould. After setting, a 
constant temperature of 650°C for two hours was used to burn off the PLGA from the scaffold. The rate of 
temperature increase and decrease during the process was 1.5 °C/min. 
Loading of BMP-2 
BMP-2 (Pﬁzer, InductOs® former Wyeth Europe Ltd., Berkshire, UK), containing glycine, sucrose and glutamic 
acid, was reconstituted in sterile water. A stock solution of BMP-2 at a concentration of 1.5 mg/ml was 
prepared and stored at 4 °C. Following the method also described by van de Watering et al. [10], a volume of 
15 μl water solution of growth factor, containing 5 μg BMP-2 was applied to the surface of each side of the pre-
set porous scaffolds to obtain 10 μg BMP-2/scaffold. Thereafter, the scaffolds were lyophilized. 
Characterization of scaffold material 
The scaffolds (n=5 per group) were placed vertically into a micro-CT imaging system (Skyscan 1072, Kontich, 
Belgium) and recorded at a 11.09 μm resolution (X-ray Source 100kV/98SA; Exposure Time 3.9 sec; 1 mm 
filter). Using NRecon V1.4 (SkyScan), a cone beam reconstruction was performed on the projected files. 
Reconstructed files were analyzed using CTAnalyser software (v1.10.1.0; SkyScan). Finally, 3D-reconstructions 
of the samples were also assessed in 3D-DOCTOR (V4.0, Able Software Corp, Lexington, MA) on porosity, pore 
size and Euler number, as indication of pore interconnectivity.  
Animal model 
All in vivo procedures were performed in accordance with the standards and protocols of the Radboud 
University Medical Centre, Nijmegen, the Netherlands. National guidelines for care and use of laboratory 
animals were obeyed and approval of the Experimental Animal Ethical Committee was obtained (RU-DEC 2012-
289). A bilateral calvarial defect was made in 32 adult male 250-300 g Wistar rats (10-12 weeks old). Besides 
the experimental CPC/BMP-2 material, three control were included in the study, i.e. a porous CPC scaffolds 
without BMP-2, a dense CPC scaffold, and autograft bone. Sample size calculation was performed in line with 
the existing literature and previous experience of our research group. Power calculations were based on the 
  
following formula [n=1+2C(s/d)2] [20], where s is the standard deviation, d is the difference to be detected, 
and C is a constant dependent on the selected value of α (power of the study - the probability that the effect 
will be detected) and ß (1-power - the chance of obtaining a false-negative result). A power of 0.9 and the level 
of significance of 0.05 were chosen for the study, and the calculation resulted in n=4 repetitions per group. 
During the surgical procedure animals were anesthetized by intubation with Isoflurane inhalation anesthesia, in 
order to prevent any eventual respiratory depressions that may occur during the procedures. The skin of the 
head was shaved and disinfected and a midline longitudinal incision was made from the nasofrontal area to the 
external occipital protuberance along the mid-sagittal suture. Skin and underlying tissues were reflected 
bilaterally to expose the calvaria and two symmetrical 4 mm wide full-thickness bone defects were created in 
both parietal bones lateral to the midsagittal suture using a dental drill (ELCOMED 100, W&H Dental Work 
Bürmoos GmbH, Bürmoos, Austria) and a trephine bur (ACE Dental Implant System, Brockton, MA) under 
constant saline coolant irrigation. Special care was taken to prevent damage to the dura mater. For the 
autograft group, the removed 4 mm bone discs were placed back, as such, into their original position. The 
remaining defects were filled with the scaffolds depending on the group. Finally, the periosteum and the scalp 
were closed with 3.0 and 4.0 Vicryl® resorbable sutures (Johnson & Johnson, St. Stevens-Woluwe, Belgium). 
In vivo imaging 
Imaging was performed before surgery, at day 2, and then every two weeks, starting from week 2 up to week 8 
post-surgery. PET/CT data were acquired 1 hour after injecting ~15 MBq/rat of 18F (BV Cyclotron VU, 
Amsterdam, The Netherlands), with an Inveon small-animal PET/CT scanner (Siemens Preclinical Solutions, 
Knoxville, TN). PET emission scans were acquired for 15 min, followed by CT acquisitions for anatomic 
correlation (spatial resolution 113 μm, 80 kV, 500μA, exposure time 300 ms).  
Following the in vivo imaging, 8 animals were euthanized at the time points 2, 4, 6 and 8 weeks post-surgery by 
CO2/O2 overdose. The top part of the skull was retrieved and the surrounding soft tissues were removed. 
Samples were fixed in 10% formalin for 48 hours and subsequently transferred to 70%  ethanol. Although the in 
vivo CT scans were used for anatomical reference, for visualization then also higher resolution μCT scans were 
made at a 14.5 μm resolution (X-ray Source 100kV/98µA; Exposure Time 3.9 sec; 1 mm filter applied) and 
reconstructed as mentioned above. 
Analysis of the PET/CT images 
PET/CT data were reconstructed using Inveon Acquisition Workplace (v1.2, Siemens), using an ordered subset 
expectation maximization 3-D/maximum a posteriori (OSEM3D/fMAP) algorithm with the following 
parameters: matrix 256×256×159, pixel size 0.43×0.43×0.8. For the current experiment a relatively low beta 
value of 0.1 was set. PET/CT data were analyzed by drawing a cylindrical-shaped 3D Region of Interest (ROI) 
over the defect areas. The Partial Volume effect has to be taken into account when measuring the uptake of 
small lesions and, as soon as the volume gets smaller than 3 times the resolution, partial volume effects play a 
significant role. Therefore, the ROI was designed considering PET resolution (1-2 mm) as the limiting factor, and 
measured 5 mm in diameter and 3 mm in depth. The mean Standardized Uptake Values (SUV) were 
determined using mean pixel values by AMIDE (v1.0.1, Stanford University, Stanford, CA). Also, visual 3D 
models from CT scans were obtained using  3D Doctor (v4.0, Able Software Corp, Lexington, MA). 
Histology 
All specimens were decalcified for 72 hours in 10% ETDA, dehydrated in gradual series of ethanol (70%-100%), 
and embedded in paraffin. Starting from the centre of the implants, and following the coronal plane of the 
skull, sections of 6 µm thickness were cut using a microtome with a diamond blade (Leica Microsystems SP 
1600, Nussloch, Germany). The sections were stained with Haematoxylin/Eosin and trichrome Elastin van 
Gieson (EVG); at least six sections of each specimen were analyzed. 
  
Bone volume quantification 
EVG-stained slides were quantitatively scored using computer-based image analysis (Qwin Pro-image, Leica, 
Wetzlar, Germany). From digitalized images (magnification 2.5X), the percentage of bone tissue was 
determined within the area of interest, designed and positioned accordingly to the size and position of the 5x3 
mm ROI previously described for PET-SUV quantification. 
 Statistical Analysis 
Data was reported as means ± standard deviation. Statistical significance was assessed using a repeated 
measurements two-way ANOVA with Bonferroni correction for multiple comparisons, to detect differences in 
time and between the different groups of scaffold. Results were considered significant when P < 0.05. 
Correlation analysis was performed by comparing the PET dataset with the histomorphometric bone volume 
quantification dataset as a whole, without differentiating between the experimental groups. For PET data, the 
mean value between 2 adjacent time points was calculated, and correlated to the difference in bone volume 
between the same adjacent time points, i.e. [(PET uptake week 4 + PET uptake week 2)/2] correlated to (bone 
volume week 4 – bone volume week 2)], using Prism (v5.00, GraphPad, San Diego, CA). 
3. Results 
Characterization of scaffold material 
Micro-CT analysis was used to determine topology and 3D characteristics of the scaffolds (Figure 1a). The 
porous scaffolds had large, interconnected pores as indicated by a negative Euler number, and the porosity 
seemed to be uniformly present throughout the entire porous scaffold (Figure 1b). In contrast, the dense 
scaffolds (Figure 1b) did not show macro-porosity.  
                             
Figure 1. Morphological analysis of pre-set calcium phosphase cement scaffolds. a. Topology and 3D analysis of the 
scaffolds calculated from µCT analysis. b. Representative 3D morphological aspect of porous and, c. dense scaffolds before 
implantation. 
PET imaging 
All animals recovered from the surgical procedure and remained in good health. No signs of unexpected tissue 
response, severe inflammation or wound-healing complications were detected during the experimental period. 
Also, no changes in the normal weight development or behavior of the animals were noticed. 18F-Fluoride PET 
showed specific tracer uptake within the skeletal system, especially in the area of the growth plates. 18F-
Fluoride uptake remained hardly noticeable only  in correspondence of the autograft implants at every time 
  
point, whereas a time-dependent uptake modulation was noticed in the presence of the other experimental 
groups. Figures 2a shows representative 2D-PET images taken four weeks post-surgery. At visual inspection, 
the signal intensity followed the order from high to low as BMP-2; porous, dense, and finally autograft. The 
same trend was maintained during the entire experimental period, with BMP-2 implants consequently 
exhibiting the highest signal intensities. Moreover it could be noticed that in all control groups 18F-Fluoride 
was preferentially taken up at the defect edges, whereas for BMP-2 containing scaffolds, the signal was well-
spread throughout the entire implant. 
 
                               
 
Figure 2. PET/CT imaging. a. Representative µCT images of the four experimental groups, 4 weeks post-implantation, and 
correspondent 18F-Fluoride PET uptake. Note that the BMP-2 loaded sample visually gives the highest signal, whereas the 
autograft is lowest. b. 3D reconstruction of in vivo CT scans, the right side shows a µCT close-up at 2 weeks post-surgery. 
Both the autograft (left) and dense CPC (right) are easily recognizable. 
Thereafter region of interest were selected in all directions of the PET scan signal (Figure 3a). Subsequently, 
quantitative data was extracted and presented as mean specific uptake values  (Figure 3b). Such data showed 
that the incorporation of BMP-2 promoted a statistically significant  post-surgical enhancement of the bone 
activity, maintained up to 4 weeks later. Thereafter, the signal was found to significantly decrease, while 
remaining significantly higher compared to the basal signal (at day 0). The same trend was shown by porous 
scaffolds, even though the overall signal uptake was significantly lower compared to the BMP-2 group, at all 
time points. Also dense implants and autografts showed a similar metabolic trend with a significant peak of 
signal uptake measured after implantation, followed by a significant signal decrease thereafter. These two 
groups still were always significantly lower than BMP-2 group, and also significantly lower compared to porous 
starting from week 4. All data were considered significant when P < 0.05. 
  
                  
Figure 3. PET Quantification. a. PET transverse, coronal and sagittal view of a rat skull. The 3D-ROI is represented by a blue 
dash line and positioned over the defect area. b. 18F-Fluoride PET uptake, mean SUV quantification. Note that dense and 
autograft implants show the same trend, with a rapid SUV increase post-surgery, and a rapid decrease thereafter. Both 
Porous and BMP-2 loaded scaffolds show enhanced uptake values maintained up to 4 weeks post-surgery, even though 
BMP-2–SUV remains significantly higher during the entire experimental period. 
Micro CT 
3D-CT images allowed localization of the defects area over time (Figure 2b). Four weeks post-surgery, regions 
of newly formed bone could be identified along the edges of the BMP-2 loaded and the porous scaffolds, even 
though no quantification was possible, solely based on the gray values. Dense scaffolds seemed fully integrated 
within the implantation area, with evident implant-to-bone contact, but showed no obvious signs of new bone 
formation. Finally, the bone gap surrounding the autograft seemed almost entirely repaired as soon as day 2 
post-surgery. Still, also for this group the borders of the defect remained evident throughout the entire 
experimental period. 
Histology 
After PET and µCT evaluation, the specimens were further processed for histology (Figure 4). From the first 
time point, 2 weeks post-implantation, the BMP-2 bearing scaffolds were characterized by large areas of new 
bone ingrowth. Over time the ingrowth mainly seemed to be conducted from the edges and continue 
throughout the entire sample. Still, also bone induction inside the sample porosity was found. By visual 
inspection, also a loss of material integrity was observed over time. In the porous scaffold group it was seen 
that samples were entirely surrounded by newly formed bone, while ingrowth continued towards the centre of 
the scaffold only through the interconnected pores of the material. In contrast, a thin fibrous capsule without 
the presence of inflammatory cells was surrounding the dense scaffolds. Consistently,  direct bone-to-implant 
contact was only seen in two out of eight specimens from this group. The structural integrity of the dense 
  
material was maintained over the entire period, and only osteoconductive mechanisms allowed limited bone 
growth along the intra-cranial side of the scaffolds. Around the autograft implant the histology showed full 
integration of the bone graft. As soon as the first time point, by visual inspection it was nearly impossible to 
distinguish the original defect from the surrounding bone. 
                         
Figure 4. Histological assessment. Representative paraffin EVG-stained sections (5X magnification) of a. BMP-2 loaded 
implants b. porous c. dense and d. autograft, 8 weeks post-surgery. The remaining panels (20X magnification) show a 
sequence of images from the centre of BMP-2 loaded scaffolds, at e. 2, f. 4, g. 6 and h. 8 weeks post-implantation, showing 
progressive bone ingrowth filling the material porosity. 
Histomorphometry and bone volume quantification 
New bone formation within the different scaffolds was quantified as bone volume percentage, considering a 
5x3 mm ROI as total area (Figure 5a-b), consistently with the ROI used for PET quantification. The highest bone 
volume percentage was recorded in the presence of the BMP-2 bearing scaffolds, where a significant 
enhancement could be detected already 4 weeks post-implantation. Differently, significant bone formation 
occurred within the porous scaffolds, only starting 6 weeks post-implantation. No significant bone formation 
was measured within the dense specimens. (Figure 5c). The autograft group was not included in the 
quantification, as from the first time point, the graft was completely integrated into the surrounding bone, 
hampering the location of the graft-to-bone area of new bone formation. Furthermore it was impossible to 
distinguigh existing vs. newly formed bone.  
  
                
Figure 5. Histomorphometry and bone volume quantification. Representative EVG stained section (5X magnification) of a 
BMP-2 loaded scaffold, 8 weeks post-implantation. a. a region of interest of 5x3 mm was designed and positioned over the 
defect area. b. within the designed ROI, only bone was selected based on color thresholding. The selected area is 
highlighted in green. c. Quantitative evaluation of bone formation. Bone volume % was measured within the original defect 
area, in the four experimental groups, 2, 4, 6 and 8 weeks post-implantation. Whereas no significant bone formation was 
measured within the dense specimens, both porous and BMP-2 loaded CPCs induced new bone formation, with the highest 
values measured within the BMP-2 group. Results were considered significant at P < 0.05. 
Correlation Analysis  
The correlation analysis showed a significant dependence between the two sets of data retrieved from the PET 
and Bone Volume measurements. The Pearson's correlation coefficient, which value is +1 in the case of a 
perfect positive (increasing) linear correlation, suggested a strong linear dependence between the two 
variables, i.e. PET signal and bone volume percentage (P < 0.05). As shown in the scatter plot (Figure 6), the 
dataset seemed to follow a normal distribution, where every point was close to the regression line, without 
evident outliers. 
  
                                     
Figure 6. Correlation analysis comparing mean intensity from 18F-Fluoride PET scans and bone volume percentage 
measured using histomorphometric analysis. A strong correlation was established between the data points, P < 0.05, 
Pearson coefficient (r) = 0.60. 
4. Discussion 
The present study sought to explore the osteogenic effects of a previously well-described BMP-2 in vivo release 
system, by using PET as non-invasive monitoring method. Results showed indeed that PET quantification 
revealed clear differences of bone inductive potential compared with a non-loaded control material. 
Histomorphometric analysis at each time point was also performed, and further corroborated  statistical 
correlation between 18F-Fluoride uptake as measured in PET, with the newly formed bone induced by the 
BMP-2 release.  
Regarding our study set-up we deliberately chose CPC as the delivery biomaterial, as the preclinical application 
of CPCs has already extensively been explored in vivo [19, 21, 22]. Most commonly, osteogenic performance, 
bone ingrowth, and material degradation are accelerated by the incorporation of bioactive molecules like BMP-
2. It is known that especially the concentration of BMP-2 provided at an implant site is a crucial choice to 
determine function [23, 24].  For CPCs, initial loading concentrations of BMP-2 commonly range from 2 to 30 μg 
[25, 26], and according to previous studies from our group [25, 27], 10 μg was loaded onto our scaffolds. The 
subsequent release of BMP-2 has also been described before, as monitored by radioactive tracing [10, 11, 13, 
27]. However, such methodology only gives indications about the presence of BMP-2 while direct evidence in 
terms of bone forming activity is missing. The aim of the current study was to validate a method to quantify, 
directly and in real-time, new bone formation following growth factor release from the scaffold.  
Another comment that should be made on the CPC material is the incorporation of a sufficient porosity. In this 
study, porosity was created by incorporating and then burning out PLGA microspheres. The so-formed porous 
CPC scaffolds showed an interconnected porous structure with a final porosity above 98% (v/v), and an average 
pore size of 156 µm. Among others, a study from Galois et al. suggests that cell colonization and bone ingrowth 
in ceramic-based materials only occur in the presence of a minimal macroporosity, defined as a pore size above 
80 μm [28], thus supporting the osteoconductive potential of our porous non-loaded control scaffolds. 
Accordingly, based on the same evidence, no bone ingrowth was expected in the presence of our dense control 
scaffold. Both PET and histology results confirmed such hypothesis.  
Regarding the imaging results, the in vivo CT scans proved to be useful for anatomical reference and location of 
the original defects. In particular, in the presence of the BMP-2 loaded scaffolds, supra-physiological amounts 
of newly formed bone were detectable, even though any quantification was hampered. CPC and natural bone 
  
are of equal radiopacity, thus resulting in overlapping CPC-to-bone gray values. Such bone substitutes are 
known to be difficult to distinguish from the surrounding natural tissue by means of conventional techniques, 
even though recent attempts have been made using high-resolution micro-CT or X-ray microdiffraction analysis 
(i.e. synchrotron radiation) [29, 30]. Alternatively, several groups have proposed the use of PET as validation 
method to assess different parameters linked to bone tissue engineering, such as the homing of transplanted 
cells, or early detection of fatigue-loading and/or osteoporosis -dependent microfractures [31-33]. The 
hypothesis that 18F-Fluoride uptake is indicative for the amount of bone formation was proven by statistical 
correlation analysis. An evident  correlation was established between PET median signal intensity and bone 
volume measured on histomorphometric analysis, validating this quantification method. Other studies have 
shown similar high correlations (P < 0.05) between 18F-Fluoride PET scans and histomorphometrical indices of 
bone formation, and in general a Pearson coefficient raging between 0.6-0.8 is regarded as very strong [34-37]. 
Thus, areas of increased uptake of 18F-Fluoride reflect sites of enhanced osteoblast activity and osteoid 
production, also when enhanced due to BMP-2 release. Results from the autograft group further confirmed the 
specificity of the measurements for areas of new bone formation, as simple remodeling, most probably 
occurring throughout the entire experimental period, could not be significantly detected, and thus 
measurements in the autograft group always presented a lower base line level. 
Despite the positive correlation, a temporal shift of about 2 weeks was found between 18F-Fluoride uptake 
data, and effective measurable new bone formation in histology. While our results showed enhanced PET 
signal at early time points, significant amounts of newly formed bone could only be measured a few weeks 
later. Such delay could be explained by the fact that a single PET scan only measures the concentration of bone 
crystalline matrix accumulated during the one hour occurring between tracer administration and imaging 
acquisition. Therefore, is it realistic to say that PET-SUV only indicates the speed, and not the absolute amount 
of new bone formation. In our results, the presence of BMP-2 lead to faster bone deposition, thus higher bone 
formation compared to the other groups at a selected time point. 
5. Conclusions 
In the present study we have validated a PET/CT method for the longitudinal screening of previously well 
described BMP-2 releasing scaffolds, in vivo, in a bilateral calvarial defect model in rats. In the presence of 
BMP-2 a significantly enhanced bone healing response could be quantified over time, starting from the second, 
and up to eight weeks post-implantation. PET data positively correlated with newly formed bone volume. 
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1. Introduction 
Bone fracture is a common event that affects both young and old individuals. Our own innate bone 
regeneration potential heals most of the fracture; however, larger defects could not be repaired by this 
process. Current methods to treat patients with large bone defects include autologous bone transplantation 
surgery with donor tissue obtained from another site such as the iliac crest of the same patient [1], or artificial 
fixation of bone in case of lack of available donor tissue [2]. Both of these procedures are painful, while the 
bone grafting often causes donor site morbidity and increases the risk of infection. Moreover, the overall 
success is also dependent on the quality of transplanted bone from the patient [3]. 
One of the alternative procedures involves bone regeneration utilizing growth factors (proteins) such as bone 
morphogenetic proteins (BMPs) that promotes differentiation of endogenous stem cells towards bone 
phenotype, mimicking the natural bone healing process. This method requires development of technologies to 
deliver such sensitive proteins at the defect site with minimal invasive procedures. BMPs were originally 
identified as key proteins required for skeletal development, maintenance of adult bone homeostasis and are 
known to play an important role in fracture healing [4], [5], [6] and [7]. BMPs are expressed in an inactive pro-
form, and proteolytic cleavage by proteases releases the mature BMP proteins [8]. Several groups including 
ours are working on designing efficient delivery vehicles for rhBMP-2, due to its short half-life in vivo. BMP-P is 
approved for clinical use by the FDA and the European Medicines Agency (EMEA) for specific clinical 
assessment in spinal fusion and facture healing [9]. A recent review on clinical use of rhBMP-2 shows an 
increasing concern over the safety of this protein due to serious complications observed in some cases [10]. It 
is due to the fact that rhBMP-2 is not functionally specific for osteoblasts and its high dose often resulted in 
soft tissue inflammation, native bone resorption and implant fracture. Thus finding ways to reduce the dose of 
BMP-2 in clinical practice will be of great significance. In order to find such methods to improve BMP-2 
function, in vivo, we need to understand proper handling conditions for this protein. A close survey of the 
published literature related to BMP-2 research reveals that several groups employ different parameters in their 
experiments such as different doses of protein, different reconstitution solutions, temperature, etc. as 
instructed by the manufacturer. These differences can have profound effect in protein bioactivity, which limits 
direct comparison of results from different experiments. We therefore decided to test how crucial such 
handling conditions are for in vitro and in vivo experiments. We performed basic study with clinically approved 
BMP-P and for comparison we tested commercially available BMP-R. Both of these BMPs were obtained from 
genetically modified Chinese hamster ovary (CHO) cells. We have recently reported injectable hydrazone 
crosslinked HA hydrogel as an efficient rhBMP-2 delivery vehicle that can promote bone regeneration at 
ectopic [11] and orthotopic sites [12] and [13] without adding any cells to the scaffold. HA is a natural 
extracellular matrix (ECM) glycosaminoglycan that is known to have diverse biological function which include 
proliferation and differentiation of stem cell, wound healing etc. [14] but can also retain BMP-2 and increase its 
stability in vivo [15]. These systems also recruit endogenous stem cells from the surrounding tissue and support 
BMP-2 mediated osteogenic differentiation [15]. 
In this article, we showed for the first time that the stability and bioactivity of BMPs from different commercial 
sources possess profound differences. We found that BMP-P has a higher stability at physiological pH and has a 
lower adhesive property towards polypropylene Eppendorf tube as compared to the BMP-R. The higher 
stability of BMP-P was also reflected in the in vivo experiments, which showed larger however less compact 
bone formation with BMP-P whereas smaller and compact bone, in the case of BMP-R. There were also visible 
differences in collagen orientation between two groups with BMP-P induced bone to have an ordered structure 
similar to the native bone while the BMP-R group had a disordered collagen orientation. 
2. Materials and methods 
Hyaluronic acid (HA, 150 kDa) was purchased from Lifecore Biomedical, LLC (Chaska, MN). All other reagents 
were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used as received. Dialysis membranes Spectra/Por 
6 (3500 g/mol cut off) were purchased from Spectrumlabs Europe. The NMR experiments (δ scale; J values are 
  
in Hz) were carried out on Jeol JNM-ECP Series FT NMR system at a magnetic field strength of 9.4 T, operating 
at 400 MHz for 1H. 
2.1. Synthesis of hydrazide and aldehyde modified hyaluronic acid 
For hydrogel preparation we have developed a new hydrazide derivative of HA using commercially available 
dihydrazide, namely carbohydrazide (CDH). The synthetic procedure were as follows: 400 mg HA (1 mmol of 
disaccharide repeating units) was dissolved in 50 ml de-ionized water, followed by 90 mg (1 mmol) of CDH 
linker. N-hydroxybenzotriazole (HOBt; 153 mg, 1 mmol) was dissolved separately in a 2 ml solution of 1:1 (v/v) 
mixture of acetonitrile–water and was added to the HA solution. The pH of the resultant solution was adjusted 
to 4.7 and to this solution 19.17 mg (0.1 mmol) of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) was 
added and stirred overnight. The solution was transferred to a dialysis tube (Mw cutoff 3500) and dialyzed first 
against dilute HCl (3.5 pH) containing 0.1 M NaCl for 48 h, and then against dilute HCl (3.5 pH) for 24 h. The 
solution was lyophilized to get 360 mg of hydrazide derivative of HA (HA hydrazide). The degree of modification 
was 7%, as determined by TNBS (2,4,6-trinitrobenzenesulfonic acid) assay [16]. 1H NMR analysis also showed 
clean product with no structural difference from native HA. The aldehyde modified HA (HA aldehyde) was 
prepared according to the recently reported procedure [13]. 
2.2. Cytotoxicity studies of HA-aldehyde and hydrazide derivatives 
To determine toxicity of HA hydrogel components Cell-Titer 96AQueous One Solution Cell Proliferation Assay 
(MTS, Promega), a tetrazolium salt assay was performed. First the mouse embryonic fibroblast cell line (NIH-
3T3, ATCC) was expanded in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS; PerBio Science), 100 U/l penicillin and 100 μg/l streptomycin (Sigma-Aldrich) (culture 
medium) in T75 flasks (Nunc, VWR International) until 80% confluence at 37 °C in a humidified atmosphere of 
5% CO2. The culture medium was changed every second day. The cells were detached by the addition of 
trypsin/ethylenediaminetetraacetic acid (EDTA) (Gibco, Invitrogen) and were suspended in culture medium. 
The cells were plated in flat-bottomed 96 well plates at 5 × 103 per well in 200 μl culture medium overnight. 
Components were dissolved in culture medium and add to the wells at concentrations 100 and 200 μg/ml (n = 
5) for 48 h. Then MTS substrate was added to the wells. After 4 h of incubation at 37 °C an absorbance at 450 
nm was measured. Cell viability was shown in percentage (standard deviation from three samples) with 
controls as cells only considered as 100%. 
2.3. Hydrogel preparation 
HA hydrazide (7% modification) and HA aldehyde derivatives (7% modification) were dissolved in sterile 
phosphate buffer saline (PBS, Sigma-Aldrich) at pH 7.4 to a final concentration of 16 mg/ml followed by sterile 
filtration using 0.45 μm syringe filter (Whatman). The reconstituted stock solutions of BMP-P or BMP-R were 
added to the HA-hydrazide solution to maintain final concentration of 16 mg/ml of polymer and 20 μg/ml of 
BMP-2s. HA hydrogel matrix was formed by mixing (20 times) equal volume of HA-aldehyde and HA-hydrazide 
solutions in two syringes linked by a connector under sterile conditions in a laminar flow hood. 
2.4. Rheological evaluation 
An AR2000 Advanced Rheometer (TA Instruments) was used to determine the shear storage modulus, G′. In a 
typical experiment 1 ml gel (1.6 wt.%) was prepared as mentioned earlier and injected to cylindrical mold 
immediately after mixing and kept for 24 h at room temperature. The hydrogels were then carefully 
transferred and applied to the bottom plate of AR2000 rheometer. The mechanical properties were measured 
at a frequency of 0.1 to 10 Hz at 25 °C using 8 mm aluminum plate geometry. The gap was adjusted starting 
from the original sample height and compressing the sample to reach a normal force of about 50 mN (gap sizes 
were between 7 and 8 mm). 
  
2.5. Stability studies of recombinant BMPs 
Growth factors were reconstituted according to the manufacturers' protocols. BMP-P (Pfizer, InductOs® former 
Wyeth Europe Ltd., Berkshire, UK) was reconstituted in sterile water. BMP-R (R&D System) was reconstituted in 
4 mM HCl (final pH is 0). Both proteins are delivered in lyophilized form containing glycine, sucrose and 
glutamic acid. The stock solution of BMP-P at a concentration of 1.5 mg/ml was prepared and stored at 4 °C, 
while the stock solution of BMP-R was prepared at the concentration of 100 μg/ml and stored at − 20 °C. We 
evaluated the stability effects of BMP-P and BMP-R at two pHs stored in two types of vials. For that purpose 
BMPs stock solutions were diluted in different buffers namely at 7.4 pH (PBS) and 4.5 pH (BMP-P formulation 
buffer recommended by Pfizer) till concentration of 100 ng/ml. Those samples in triplicate were stored either 
in glass or polypropylene tubes (Eppendorf) and incubated at two time point as, 24 and 0 h at room 
temperature. The 0 h time point was approximately 30 min and stated as ‘0 h’ throughout the text. The 
stability of the BMPs was quantified using an alkaline phosphatase activity (ALP) assay, which gives a measure 
of bioactivity for the BMP. 
2.6. ALP activity assay 
The mouse stromal cell line W20 clone 17 (W20-17) was obtained from the American Type Culture Collection 
(ATCC–LGC Standards, Sweden). The cells were expanded in DMEM supplemented with 10% FBS, 100 U/l 
penicillin and 100 μg/l streptomycin (Sigma-Aldrich) (culture medium) in T75 flasks (Nunc, VWR International) 
until 80% confluence at 37 °C in a humidified atmosphere of 5% CO2. The medium was changed every second 
day. The cells were detached by the addition of EDTA (Gibco, Invitrogen) and suspended in culture medium and 
counted using Trypan blue (Gibco, Invitrogen). Then the cells were seeded as a cell suspension at 5 × 103/ml in 
96-well plates with culture medium. After 24 h media was replaced with 100 μl of sample (preparation 
described in previous section) supplemented with 100 μl of culture medium. After 48 h the cells were washed 
with PBS (Sigma-Aldrich) and lysed by two freeze-thaw cycles (30 min − 80 °C, 20 min 37 °C). ALP actvity in this 
extracted solution was determined by calculating the p-nitrophenol (pNP) concentration obtained from 100 μl 
of substrate (p-nitrophenyl phosphate; Sigma-Aldrich) in 0.1 M glycine, 1 mM MgCl2, 1 mM ZnCl2, (10.4 pH) at 
37 °C. After 20 min reaction was stopped with 50 μl of 0.1 M NaOH. The absorbance at 405 nm, which 
corresponds to pNP concentration was determined using microplate reader (Kinetic Microplate Reader; 
Molecular Devices). ALP activities were measured in triplicate and the average of three values were used to 
determine the standard deviation in each group. 
2.7. Western blot analysis 
Samples with different amounts of BMP-P and BMP-R (100, 250, 500 ng) were mixed with sample buffer 
(ClearPAGE, CBS Scientific) and loaded on 5–10% SDS polyacrylamide gels (CBS Scientific) and transferred to 
polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences) under non-reducing conditions. 
Membranes were exposed to anti-BMP-2/4 (1:1000 dilutions, R&D System) antibody and incubated overnight 
at 4 °C. Thereafter, blots were treated with secondary rabbit anti-goat IgG (1:5000 dilutions, Abcam) antibody 
conjugated to horseradish peroxidise. Immunodetection was performed by chemiluminescence using Immuno 
Star™ WesternC™ Kit (Bio-Rad) in a ChemiDoc XRS system (Bio-Rad). 
2.8. Dynamic light scattering 
The particle size distribution was carried out using Malvern laser Zetasizer Nano ZS, United Kingdom. Both 
BMP-P and BMP-R were suspended either in PBS 7.4 pH or formulation buffer pH 4.5 recommended by Pfizer 
at 150 μg/ml concentration. Samples were analyzed immediately after suspension and the measurements were 
continued at different time points, up to 2 h. 
2.9. In vivo rat model 
  
2.9.1. Animal preparation and anesthesia 
All animal handling and surgical procedure were approved by the Uppsala (Sweden) local committee for 
experimental animal research ethics and conducted according to the Helsinki guideline for the use and care of 
laboratory animals and approved by institutional ethical protocol (246/8). Six adult male Sprague–Dawley rats 
(Taconic M&B, Lille Skensved, Denmark), 280–300 g in weight were housed with two rats per cage with 12/12 h 
light/dark cycles in a temperature (22 °C) and humidity (45 ± 10%) controlled environment with ad libitum 
access to food and water. All surgical procedures were performed in aseptic conditions. Animals were 
anesthetized by using isoflurane (4,5% induce; 2.5% maintain; Forene®, Abbott Scandinavia) starting with 4 l 
min− 1 oxygen and 4 l min− 1 isoﬂurane in an inducton chamber and then by mask at 1.5 l min− 1 oxygen, 1.5 l 
min− 1 air and 3 min− 1 isoﬂurane. 
2.9.2. Surgical technique 
The HA hydrogel matrices with either BMP-P or BMP-R (20 μg/ml) were prepared as described earlier. After 
incubating the gels for 3 h at room temperature, the lumbar region was shaved and surgically prepared with 
three washes of alcohol. Then hydrogel constructs of 0.2 ml volume containing physically loaded 4 μg of BMP-P 
(n = 6) or 4 μg of BMP-R (n = 6) or only hydrogel (n = 6) were injected subcutaneously with a 21 G needle, at a 
minimal distance of 15 mm apart. Immediately after intervention, animals were administered buprenorfin 
(Temgesic, Schering-Plough, 0.05 mg/kg) subcutaneously for pain mitigation. Rats were sacrificed after 7 weeks 
by CO2 asphyxiation. The implants were dissected, extracted and analyzed by micro computed tomography 
(micro CT). The samples were also retrieved for histological observation (n = 5 per group). 
2.10. Micro computed tomography (μCT) analysis 
To quantify ectopic bone formation, the harvested samples were placed in 4% paraformaldehyde in PBS, after 
24 h replaced by 70% ethanol, at room temperature. Micro CT analysis was performed using a Skyscan 1072 
(Kontich) with X-ray source of 100 kV/98 μA. For quantitative 3D analysis, the specimens were placed vertically 
onto the sample holder of a micro-CT imaging system. Subsequently, a high-resolution scan was recorded at a 
14.16-μm-voxel resolution (Magnification 20 ×; exposure time 3.9 s; 1 mm filter applied). Then, using Nrecon 
V1.4 (SkyScan), a cone beam reconstruction was performed on the projected files. Opaque tissue was 
calculated using CT Analyzer software (Version 1.10.1.0; SkyScan). Finally, by using 3D creator software (3D-
DOCTOR 4.0, Able Software Corp.), 3D-reconstructions of the samples were obtained. Tissue formation was 
assessed by analyzing reconstructed coronal cross-sectional images. In addition, bone volume/total volume 
(BV/TV) of ectopic bone was calculated with CT-based morphometric analysis. 
2.11. Statistical analysis 
All experiments were performed in triplicate, and data were expressed as the means ± standard deviation, 
unless otherwise noted. Statistical analysis was performed with PASW Statistics 16.0 (SPSS Inc.). Student t-test 
was used to analyze the statistical differences between two groups (BMP-P and BMP-R) with consideration that 
p-value less than 0.05 was significant. 
2.12. Histological evaluation 
Specimens were stored in 70% ethanol, completely decalcified using an electrophoresis system (Tissue-Tek 
Miles scientific, Histolab) with formic acid, dehydrated, and embedded in paraffin wax. Serial cross sections 
were cut with a microtome to 5 μm, deparaffinized and stained. Representative slides were stained with 
hematoxylin/eosin (H&E, Merck), Masson's trichrome (Merck) [13], Sirius Red (Fluka) [17] as well as Alcian Blue 
(Sigma-Aldrich) solution [18]. For collagen observation the cross-sections (five sections per bone sample) were 
stained 0.1% Sirius Red dissolved in a saturated aqueous solution of picric acid (Fluka) for 1 h and then 
  
observed and photographed using polarized light microscopy with the slides inclined at 45° to the incident 
light. The amount of organized collagen fibers was quantified by measuring the area of green color using 
imaging software (BioPix AB). For Alcian Blue staining, sections were incubated in phosphate buffer (6.0 pH) or 
in presence of ovine testicular hyaluronidase (Sigma-Aldrich). The histological sections were photographed on a 
bright field microscope (Eclipse TE 2000U, Nikon). 
3. Results and discussion 
3.1. Synthesis of HA derivatives, hydrogel preparation and characterization 
Designing biomaterials for bone tissue engineering requires biocompatible 3D scaffold that could deliver 
sensitive growth factors such as BMP-2 in vivo. We have recently developed HA based injectable hydrogel using 
hydrazone chemistry and have also shown its use for bone augmentation in rat calvarial model [13]. In this 
work, we developed a novel hydrazone crosslinked HA hydrogel derived from CDH, anticipating a superior 
mechanical property and hydrogel stability. The synthesis of this HA hydrazide derivative was achieved by 
employing EDC coupling chemistry with 10-fold excess of commercially available CDH with respect to HA 
disaccharide units to obtain 7% modification of HA carboxylates. Next, we synthesized HA aldehyde following 
our previously described protocol with 7% modification [13]. This method is superior to conventional NaIO4 
oxidation of carbohydrates as the aldehyde units were grafted on HA backbone under mild conditions. The 
hydrogels were prepared by mixing the two components (HA-aldehyde and HA-hydrazide) between two 
syringes connected by luer-lock adapter and the two solutions were mixed for 20 cycles at room temperature 
(Scheme 1). The mixture was injected to cylinder mold immediately after mixing and was kept for 24 h at room 
temperature (gels were formed within 30 s). This method of hydrogel preparation is crucial to obtain 
reproducible data and also represents the scenario for material preparation during in vivo experiments. For 
gels with encapsulated BMP-2, the protein was added to HA hydrazide residue before mixing with the two-
syringe system. Rheological evaluation of this material showed the soft materials to have average storage 
modulus G′ and loss modulus G″ of 1196 ± 65 Pa and 3.1 ± 0.3 Pa respectively. This significantly higher storage 
modulus than the loss modulus (G′ > G″) implies that the material is elastic and has a typical gel like 
characteristics. This storage modulus also corresponds to an average molecular weight between crosslinks of ~ 
20 kg/mol forming stable networks [19] (Scheme 1). 
 
Scheme 1. Schematic representation of HA-hydrazide synthesis and hydrazone crosslinked hydrogel preparation. 
3.2. In vitro toxicity studies with HA derivatives 
We further decided to test the cytotoxicity studies of our chemically modified HA using MTS assay, which 
measures the mitochondrial activity of live cells. As shown in Fig. 1, HA derivatives did not show any toxicity on 
NIH-3T3 fibroblast cells at the concentrations tested. On the other hand we observed increase in cell 
proliferation upon addition of HA derivatives. This increase in cell proliferation with HA has been observed 
previously [20]. 
  
 
 
Fig. 1. Viability of NIH3T3 cells after 48 h of incubation in the presence of 100 and 200 μg/ml of HA aldehyde (HA-Ald) and 
HA hydrazide (HA-Hyd) derivatives, compared with 200 μg/ml HA and cells only (n = 5). 
3.3. In vitro stability studies of recombinant BMPs 
In order to evaluate critical aspects of handling BMPs, we decided to perform in vitro bioactivity assay (ALP) 
when they are stored under different conditions. We incubated BMPs at two pHs (physiological pH 7.4 and in 
pH 4.5 formulation buffer, recommended for BMP-P) and also in two different vials (glass and Eppendorf tube). 
The ALP levels were tested within 30 m and after 24 h under these conditions. We anticipate that the presence 
of hydrophobic residues in the protein will favor binding to hydrophobic surfaces (plastic), thereby reducing the 
protein concentration in the medium whereas hydrophilic surfaces (glass) will prevent such association. It has 
been reported earlier that BMP-P stability is pH dependent and aggregation occurs at pH 6.5 [21]. This is due to 
the change in pH that affects the net charge of the protein, resulting in its precipitation or aggregation [22]. The 
buffers with excess of acidic or basic residues can also affect hydrogen bonding between amino acids and 
consequently can disrupt the tertiary structure of protein causing biological de-activation [22]. Since in vitro 
ALP assay depends on BMP-2 binding to its cell-surface receptor and signaling, only bioactive BMPs are 
detected with this method. We employed this assay with W20-17 cells that are known to induce BMP-2 
dependent osteogenic differentiation [23] and [24]. 
Our in vitro results are shown in Fig. 2, which can be summarized as follows: (i) Both BMPs showed identical 
ALP activity at 0 h, indicating almost identical initial concentration of the two proteins. (ii) BMP-P remained 
bioactive under all conditions tested for up to 24 h. (iii) Bioactivity of BMP-R was found to depend on pH and 
hydrophilic/hydrophobic nature of the storage vial. Higher stability was observed at pH 4.5 and hydrophilic 
glass vials; however, at physiological pH the stability was instantaneously lost within 30 min (0 h). Increased 
binding of BMP-R on polypropylene Eppendorf tube probably suggests that there are more hydrophobic 
residues on BMP-R as compared to BMP-P. Since both proteins preferred glass surface and acidic pH indicates 
presence of basic amino acid residues (such as lysine and arginine) that require acidic pH for their protonation 
and solubility in aqueous medium. These differences in BMP-2 stability could also arise from differences in 
glycosylation pattern of BMP-2 as it was indicated recently that non-glycosylated BMP-2 has higher stability 
resulting in increased bioactivity [25]. 
  
 
 
Fig. 2. Stability of BMP-P and BMP-R was evaluated by an alkaline phosphatase (ALP) activity assay after 0 and 24 h of 
incubation at room temperature. The samples were dissolved in buffer at physiological pH (7.4) and at acidic pH (4.5) in (a) 
glass vials; (b) Eppendorf tubes. ALP activity was quantitatively measured at absorbance 405 nm. (*p < 0.05; error bars 
indicate SD for n = 3). 
3.3.1. Western blot analysis 
Since the BMP-R showed almost rapid aggregation at physiological pH, we decided to test if this difference 
could be observed using the Western blot analysis. Since this experiment was performed with basic running 
buffer (pH 8.5) we anticipated that BMP-R could be lost or aggregated during the experiment. As shown in Fig. 
3, we could detect BMP-P at all concentrations tested; however the density of BMP-R on the other hand were 
substantially lower. These experiments also demonstrated that one should be careful with sensitive proteins 
such as BMPs especially if they are from natural sources. 
 
Fig. 3. Western blot analysis of BMP-P and BMP-R loaded on SDS PAGE at concentration of 100, 250 and 500 ng; with anti-
BMP-2/4 as primary antibody in non reducing conditions. 
  
3.4. Dynamic light scattering studies of recombinant BMPs 
Since we observed substantial difference in the in vitro bioactivity assay, we decided to investigate protein 
aggregation behavior using dynamic light scattering technique, at two pHs (4.5 and 7.4). Interestingly, we 
observed a time dependent steady aggregation in BMP-R sample in both buffer conditions, while no 
aggregation was observed with BMP-P. In PBS 7.4, BMP-R acquired a size of 295 nm within 15 min, which 
gradually increased to 750 nm in nearly 2 h with good polydispersity of ~ 0.2 (Fig. 4a). After 15 h, this sample 
attained an average size of 2.7 μm. However, in formulation buffer (pH 4.5) the particle formed was bigger with 
an initial size of 700 nm, which gradually increased to 2.8 μm in nearly 2 h (Fig. 4b). This is presumably due to 
the presence of surfactant polysorbate 80 and other stabilizers present in formulation buffer, which form 
complex with BMP-2. This was evident upon analyzing the DLS of neat formulation buffer without any added 
protein, which showed presence of particles of ~ 700 nm unlike in PBS. When BMP-P was suspended in 
formulation buffer pH 4.5, we observed particles of ~ 1 μm, which did not change with time.  
 
Fig. 4. Dynamic light scattering studies of BMP-R in (a) PBS pH 7.4 and (b) BMP formulation buffer pH 4.5 showing linear 
aggregation with time. 
3.5. In vivo bone induction in a rat ectopic model 
3.5.1. Evaluation of total bone volume in the ectopic model 
After observing surprising difference in bioactivity of two proteins we decided to evaluate its in vivo efficacy by 
employing our HA hydrogel in a rat subcutaneous model. We used this model because it is quite 
straightforward and reproducible system to evaluate bone regenerative potential of BMPs. The subcutaneous 
surgical intervention also allows reducing the number of animals necessary for evaluation. We employed same 
amount (4 μg/implant) of BMPs from the two sources to compare its bioactivity. This is therefore the first study 
  
of direct comparison of BMP-2 with identical doses. In our experimental model, we injected 200 μl of hydrogel 
with either physically trapped BMP-P/BMP-R in gel or gel alone as negative control (n = 6). After 7 postsurgical 
weeks we sacrificed the animals and opened the implantation site for inspection. As expected, we did not 
observe any bone tissue at the implantation site in the control group lacking rhBMP-2. In the groups with 
BMPs, ectopic bone tissue was found. Our intraoperative observation revealed that ectopic bones were limited 
to the implantation site and firmly attached to the surrounding tissue with no sign of inflammation or fibrosis. 
To quantitatively determine their bone volume of the neo-bone, they were subjected to micro CT analysis. The 
3D reconstructions of one of the representative samples are shown in Fig. 5a (BMP-P) and 5b (BMP-R). Micro-
CT-based morphometric analysis showed that the average ectopic bone volume induced by BMP-P was 
significantly higher (almost twice) as compared to that observed for BMP-R group (Fig. 5c). The statistical 
analysis revealed the ratio of BV/TV to be 43.87 ± 6.38 mm3 for BMP-P group as compared to 27.48 ± 5.24 
mm3 for the BMP-R group (p < 0.01). The low standard deviations indicate that the experimental procedure to 
be highly reproducible.  
 
Fig. 5. Representative μCT images of 3D reconstruction of ectopic bones induced by (a) BMP-P and (b) BMP-R after 7 weeks 
of implantation. (c) Quantitative analysis of bone volume/total volume (BV/TV) showed a statistical significant difference 
between both groups (*p < 0.01; error bars indicate SD for n = 6). 
3.5.2. Histological evaluation of ectopic bone 
The morphology of ectopic bones induced by BMP-P and BMP-R after 7-week post-implantation was examined 
by histology (Fig. 6). The representative cross sections stained with H&E (Fig. 6a and b) and Masson's trichrome 
(Fig. 6c and d) showed woven bone distribution within newly formed tissue with no inflammatory cells. Both 
groups showed abundant bone marrow and collagen matrix (collagen is stained blue with Masson's trichrome). 
We however observed substantial differences within ectopic bone architecture. Ectopic bone in BMP-P group 
was larger in diameter with more cortical bone than trabecular bone as compared to BMP-R group. The BMP-P 
group also had larger void space towards the middle of the scaffold, unlike BMP-R group. This result is 
corroborated with the in vitro stability differences observed between the two BMPs. The more stable BMP-P 
presumably differentiated the recruited stem cells that formed mineralized outer surface. 
  
 
Fig. 6. Histological observation of paraffin-embedded cross sections of ectopic bone induced by BMP-P and BMP-R after 7 
weeks of implantation, (a,b) hematoxylin/eosin (H&E) stained and (c,d) Masson's trichrome stained. BMP-P represented by 
(a,c) and BMP-R by (b,d). In the magnified images: BM shows bone marrow; B shows trabecular bone structures. 
This could prevent migration of cells towards the core forming void space. The BMP-R on the other hand, being 
less stable did not differentiate cells on the scaffold periphery, which resulted in migration of cells to the core 
of the scaffold. Therefore BMP-R formed bone with smaller volume but with less void space. 
3.5.3. Qualitative and quantitative evaluation of collagen orientation 
Another important aspect to access the quality of regenerated tissue is the type of matrix laid down by the 
recruited cells. One of the main components of bone ECM is collagen that serves as the main structural protein 
of bone. During healing process newly formed callus tissue undergoes changes in its structural properties due 
to initial deposition of less oriented ECM, which is replaced by bone tissue with organized collagen fibrils [26]. 
The formation of a new layer is dependent on the pre-existing bone, which serves as an endogenous scaffold 
for lamellar matrix [27]. Moreover a higher degree of collagen organization also improves the mechanical load-
bearing capacity of the bone. We therefore decided to investigate the role of different BMPs on collagen fiber 
orientation within the newly formed bone tissue. We performed Sirius red staining of the histological sections, 
which enabled us to visualize natural birefringence of collagen in polarized light microscope [28]. As shown in 
Fig. 7a and b, the ectopic bone induced by BMP-P showed a homogenous green layer that indicates structured 
collagen orientation in the inner periphery of the new bone. The BMP-R group on the other hand showed red 
layer indicative of dispersed and disoriented collagen matrix within the mineralized tissue. Quantitative 
assessment (Fig. 7c) of the oriented collagen area demonstrated that bone formed by BMP-P had nearly 3 folds 
higher amount of oriented collagen as compared to the BMP-R group (n = 5). This striking difference could also 
be due to improved stability of BMP-P allowing controlled mineralization and matrix formation.  
  
                                        
Fig. 7. Sirius red staining of ectopic bone induced by (a) BMP-P and (b) BMP-R after 7 weeks implantation to show collagen 
orientation. Green color identified thicker and organized fibers while red-thinner fibers identified as unorganized collagen. 
(c) Quantitative analysis of green area representing organized collagen fibers. Results are shown as mean and standard 
error of minimum n = 5. 
3.5.4. Estimation of remaining HA-hydrogel within ectopic bone 
Finally, we attempted to elucidate the remnants of HA gel within the histological sections obtained from the 
two groups after 7 weeks in vivo implantation using Alcian blue staining. This reagent specifically stains 
glycosaminoglycan within the neo-tissue (Fig. 8). As observed in Fig. 8a the BMP-P group showed evidence of 
scaffold remaining in the inner part of specimen (red arrows in Fig. 8a). This observation was confirmed in 
control experiment where similar section was pre-treated with hyaluronidase (enzyme known to degrade HA) 
before staining with Alcian blue (Fig. 8c). The absence of staining in the control experiment unequivocally 
proves that HA gel was indeed remaining in this group. Similar experiment with samples obtained from the 
BMP-R (Fig. 8b and d) group however, did not show any remaining hydrogel. This observation also proves the 
above-mentioned hypothesis that stability of BMP-2 can result in efficient mineralization of the scaffold at the 
periphery that corroborate with limited tissue formation and scaffold degradation at the core.  
 
  
Fig. 8. Paraffin embedded cross sections of ectopic bone after 7 weeks of implantation stained with Alcian blue to 
demonstrate remaining hydrogel. (a) BMP-P group, red arrows shows remaining hydrogel; (b) BMP-R group; (c,d) controls 
respectively. 
4. Conclusions 
In this article we attempt to critically evaluate the bioactivity of two most common commercially available 
BMPs following standard assay conditions. As we are actively involved in developing hydrogel scaffold for 
delivery of BMP-2 for bone tissue regeneration, this evaluation is extremely important. We have discovered 
that bioactivity of BMP-2 is strongly influenced by storage conditions and pH. Our in vitro results show that 
there were significant differences in bioactivity between the two proteins with BMP-P being more stable under 
all conditions and also show lower binding to the plastic surfaces. On the other hand, BMP-R was extremely 
adhesive to hydrophobic surfaces and sensitive to pH as it almost lost its activity in less than 30 min at pH 7.4. 
This was also confirmed by dynamic light scattering studies of the two BMPs, which revealed gradual and 
progressive aggregation of BMP-R in both 4.5 and 7.4 pH conditions. To further understand the impact of this 
behavior in an in vivo setting, we developed hydrazone crosslinked hydrogel that was used as a BMP carrier. 
Same dose of BMPs was loaded in this carrier and in vivo experiments were performed in a rat ectopic model. 
Similar to in vitro observation, we found significant differences in bone formation in vivo between the two 
proteins. Higher stability of BMP-P resulted in bone formation with larger BV/TV ratio with void space at the 
core of the implant having remnants of hydrogel. The BMP-R groups, showed smaller but compact bone 
without any traces of gel. The BMP-P group also showed to be effective to form bone with an organized 
collagen matrix unlike BMP-R group. Our qualitative evaluation of trabecular/cortical bone and collagen 
supported with quantitative evaluation of bone volume and collagen fibers clearly suggest that BMP-P has also 
better in vivo bone induction capability. These experiments also indicate that rhBMP-2 mediated bone 
regeneration could be obtained if one can find ways to improve BMP-2 stability under physiological conditions 
and also that experimental results employing BMPs from different sources cannot be correlated by any means. 
These experiments also highlight the importance of handling techniques that are to be considered while 
performing BMP-2 related research. 
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CHAPTER 9 
 
Summary, closing remarks and future perspectives 
  
1. Summary and address to the aims 
 
Because of the aging of the population, the growing incidence of bone-affecting diseases like osteoporosis, or 
simply due to the incidence of bone traumas, the number of severe bone defects which are not capable of self-
healing is constantly increasing. Therefore, much effort is focused on the development of efficient treatments, 
as alternative to  overcome the limited availability of autografts, still regarded as gold standard treatment. 
Different classes of synthetic materials are available (i.e. polymer-based and ceramic-based) and some are 
already approved for clinical use. 
For calcium phosphate based materials, despite being well characterized and well-known for their 
osteoconductive properties, longitudinal data throughout the implantation period are usually partial and 
incomplete, due to the lack of follow-up methods. As alternative, pre-clinical imaging offers a wide variety of 
non-invasive and real-time tools which might contribute to fill the existing gaps in the evaluation of therapeutic 
outcomes.  
The aim of the present thesis was to explore imaging-based strategies to monitor bone healing and the bone 
healing response in the presence of synthetic bone substitutes, i.e. Calcium Phosphate cement. 
In chapter 1, a general introduction on imaging possibilities in bone tissue engineering and a description of the 
aims of this thesis are presented. Thereafter, the following chapters discuss a separate research question. 
  
1. What is the current state of the art in  bone  and biomaterial imaging? 
Since the discovery of X-rays in 1895, and the first radiological image of a hand, bone tissue has been the 
subject of detailed medical imaging. However, advances in bone engineering, including the increased 
complexity of implant scaffolds, currently also underline the limits of x-ray imaging. Therefore, advanced 
follow-up imaging methods are pivotal to develop. The field of non-invasive, high-sensitive and high-resolution 
anatomical and functional imaging techniques (optical, ultrasound, PET, SPECT, magnetic resonance, etc..) 
offers a wide variety of tools, which potentially could be considered as alternatives, or at least supportive, to 
the most commonly used X-ray Computed Tomography.  Moreover, dedicated preclinical scanners have 
become available, with sensitivity and resolution even higher than clinical scanners, thus favoring a quick 
translation from preclinical to clinical applications. Furthermore, the armamentarium of bone-specific probes 
and contrast agents for each of this imaging modalities is constantly growing. 
This chapter focuses on such preclinical imaging tools, each with its respective strengths and weaknesses, used 
alone or in combination. Especially multimodal imaging will dramatically contribute to improve the knowledge 
on bone healing regenerative processes.   
2. Is Magnetic Resonance Imaging suitable for bone and Calcium Phosphate-based 
materials imaging? 
Calcium Phosphate Cements (CPCs) are widely used bone substitutes. However, CPCs have similar radiopacity 
as natural bone, rendering them difficult to be differentiated in classical X-ray and CT imaging. As conventional 
MRI of bone is cumbersome, due to a low water content and very short T2 relaxation time, ultra-short echo 
time (UTE) and zero echo time (ZTE) MRI have been explored for bone visualization.  
In this chapter, the possibility to differentiate bone and CPC by MRI was explored. T1 and T2* values 
determined with UTE MRI showed little difference between bone and CPC, hence these materials were difficult 
to separate based on T1 or T2 alone. Incorporation of ultra-small particles of iron oxide (USPIO) and 
gadopentetate dimeglumine (Gd-DTPA) (1 wt% and 5 wt% respectively) into CPC resulted in visualization of CPC 
with decreased intensity on ZTE images in in-vitro and ex-vivo experiments. However, these additions had 
unfavorable effects on the solidification time and/or mechanical properties of the CPC, with the exception of 
1% Gd-DTPA alone. Therefore we tested this material in an in vivo experiment. The contrast of CPC was 
enhanced at an early stage post-implantation, and was significantly reduced in the 8 weeks thereafter. This 
  
indicates that ZTE imaging with Gd-DTPA as a contrast agent could be a valid radiation free method to visualize 
CPC degradation and bone regeneration in pre-clinical experiments. 
3. How can the Calcium Phosphate cement-to-bone contrast be enhanced in both CT and 
MRI? 
Calcium phosphate cements (CPCs) are commonly used bone substitute materials, which closely resemble the 
composition of the mineral phase of bone. However, this high similarity to natural bone also results in difficult 
discrimination from the bone tissue by common imaging modalities, i.e. plain X-ray radiography and 3D 
Computed Tomography (CT). In addition, new imaging techniques are introduced for bone tissue visualization, 
like Magnetic Resonance Imaging (MRI) face a similar problem. Even at high MRI resolution, the lack of contrast 
between CPCs and surrounding bone is evident. Therefore, this chapter aimed to evaluate the feasibility of a 
dual contrast agent, traceable with both CT and MRI as enhancer of CPC/bone tissue contrast. Our formulation 
is based on the use of silica beads as vectors, which encapsulate and carry contrast enhancing nanoparticles, in 
our case colloidal Gold and Superparamagnetic Iron oxide particles (SPIO). The bead suspension was 
incorporated within a calcium phosphate powder. The resultant cements were then tested both in vitro, and in 
vivo in a femoral condyle defect model in rats. Results showed that the mechanical properties of the cement 
were not significantly affected by the inclusion of the beads. Both in vitro and in vivo data proved the 
homogeneous incorporation of the contrast within the cement and its visual localization, characterized by short 
term CT contrast enhancement and long term MR effect recognizable by the characteristic blooming shape. 
Finally, no signs of adverse tissue reactions were noticed in vivo. In conclusion, this study proved the feasibility 
of a multimodal contrast agent as inert and biocompatible enhancer of CaP cement versus bone tissue 
contrast. 
4. How can an MR contrast agent be upgraded to theranostic agent to promote bone 
regeneration? 
With biomimetic biomaterials, like Calcium Phosphate Cements (CPCs), non-invasive assessment of tissue 
regeneration is challenging. This study describes a theranostic agent (TA) to simultaneously enhance both 
imaging and osteogenic properties of such a bone substitute material. For this purpose, mesoporous silica 
beads were produced containing an iron oxide core to enhance bone magnetic resonance (MR) contrast. The 
same beads were functionalized with silane linkers to immobilize the osteoinductive protein BMP-2, and finally 
received a calciumphosphate coating, before being embedded in the CPC. Both in vitro and in vivo tests were 
performed. In vitro testing showed that the TA beads did not interfere with essential material properties like 
cement setting. Furthermore, bioactive BMP-2 could be efficiently released from the carrier-beads. In vivo 
testing in a femoral condyle defect rat model showed long-term MR contrast enhancement, as well as 
improved osteogenic capacity. Moreover, the TA was released during CPC degradation and was not 
incorporated into the newly formed bone. In conclusion, the desribed TA was shown to be suitable for 
longitudinal material degradation and bone healing studies. 
5. Are Positron Computed Tomography and/or Single Photon Computed Tomography 
suitable to measure bone healing? 
Quantification of the bone healing processes by X-ray based methods becomes inaccurate in the presence of 
radiopaque synthetic materials. In this chapter, Single Photon Emission Computed Tomography (SPECT) and 
Positron Emission Tomography (PET) were compared as alternatives to follow in vivo bone healing in a rat 
calvarial defect model. SPECT/CT following administration of 99mTechnetium-labeled hydroxymethylene 
diphosphonate (
99m
Tc-HDP) and PET/CT data with 
18
F-fluoride were acquired up to 10 weeks post-surgery. New 
bone formation was then confirmed by histology. CT scans allowed visualization of untreated bone defect 
healing, however no information was gathered in presence of the ceramic. PET provided superior data 
  
compared to SPECT. 
18
F-fluoride uptake increased significantly up to 4 weeks post-surgery, declining thereafter 
until the last time point. In vivo performances of porous versus dense ceramic scaffolds were also evaluated by 
PET, with significantly higher uptake registered within the porous scaffolds. In conclusion, PET is a valuable tool 
for qualitative/quantitative follow-up of bone healing around radiopaque bone substitutes in vivo. 
6. Is Positron Computed Tomography suitable to discriminate bone healing response in the 
presence of different synthetic bone substitutes, as well as supra-physiological healing 
induced by growth factors (BMP-2) ? 
Bone morphogenetic protein-2 (BMP-2) releasing scaffolds are routinely used in bone tissue engineering to 
accelerate regeneration. Thus, assessing growth factor activity, and tissue regeneration around a biomaterial 
delivery system is extremely important to optimize the stages of bone healing. Such assessment commonly 
relies on histology. Non-invasive methods would allow longitudinal monitoring of the regeneration process. 
The present study sought to explore the feasibility of Positron Emission Tomography (PET) as non-invasive 
method to monitor the osteogenic potential of a BMP-2 releasing calcium phosphate cement (CPC) bone 
substitute. In a calvarial defect model in rats, 18F-Fluoride PET was used to quantify 18F-Fluoride uptake 
around the BMP-2/CPC material. As controls, non-loaded porous CPC, dense CPC and autograft samples were 
used. PET was performed every two weeks, during a period of 8 weeks post-implantation. In parallel, computed 
tomography (CT) imaging was performed for anatomical reference. The highest 18F-Fluoride signal intensity 
was measured in the BMP-2 group, followed by the controls in the order, from high to low, porous, dense and 
autograft. The same trend was maintained during the entire experimental period. Histology and measurements 
of the bone volume percentage confirmed the significantly higher new bone formation in the BMP-2 releasing 
group, compared to the controls. Moreover, 18F-Fluoride PET uptake showed a statistically significant positive 
correlation with the newly formed bone volume. In conclusion, our results support the use of a PET/CT method 
for the longitudinal monitoring of BMP-2 releasing scaffolds, in vivo.  
7. What is the influence of formulation and storage conditions on rhBMP-2 bioactivity? 
Understanding the influence of formulation and storage conditions on rhBMP-2 bioactivity is extremely 
important for its clinical application. Reports in the literature show that different research groups employ 
different parameters such as formulation conditions, storage, doses for in vivo applications etc. that makes it 
difficult to correlate results from different experiments. We therefore decided to rationalize these anomalies 
by performing a basic study on such parameters using two commercially available BMPs. Our in vitro 
experiments suggest that BMPs from different sources have significant differences in their bioactivity. The 
clinically approved rhBMP-2 (InductOs®; BMP-P) showed superior stability, compared to rhBMP-2 from R&D 
Systems (BMP-R) at physiological pH (determined by ALP assay). This BMP-P also showed lower binding to 
polypropylene Eppendorf tube. The BMP-R almost lost its bioactivity within 30 min at physiological pH and also 
shows more adhesion to plastic surfaces. This aggregation behavior was unequivocally ascertained by 
performing light scattering studies of the two BMPs, which revealed linear aggregation with time for BMP-R 
unlike BMP-P. The in vitro results were also reflected in the in vivo experiments, in a rat ectopic model with 
injectable hyaluronic acid (HA) hydrogel as BMP carrier. After 7 weeks post-implantation we observed larger 
bone volume with oriented collagen in the BMP-P group but a smaller bone with disoriented collagen in the 
BMP-R case. Our results highlight the large difference in activity between seemingly identical substances and 
also the importance of proper handling of such sensitive proteins. 
2. Closing remarks and future perspectives 
This thesis aimed to investigate the use of non-invasive imaging modalities for bone regenerative applications. 
Computed Tomography (CT) and, since recently, Magnetic Resonance Imaging (MRI) are the most commonly 
used imaging techniques for bone visualization. With both modalities, the use of contrast agents is required to 
  
enhance the visualization of implanted calcium phosphate-based bone substitutes. For this purpose a bead-
based dual contrast agent was initially designed, detectable with both CT and MRI. Following in vivo testing in a 
femoral condyle defect model in rats, the MR contrast was further optimized to reduce possible artifacts, and 
finally upgraded to a theranostic agent, by the incorporation of bone morphogenic protein BMP-2. Positron 
Emission Tomography and Single Proton Emission Tomography, which both are widely used for bone scans and 
for the quantification of functional processes in vivo. In our studies, PET proved to be the more suitable to 
quantitatively follow-up the metabolic activity of healing bone defects, as well as to differentiate the 
osteogenic performance of Calcium Phosphate-based bone substitute, in vivo.  
Whereas MRI results are promising, one major challenge remains for further applications of Zero Echo Time 
imaging. ZTE imaging with hard-pulse excitation is more demanding in terms of hardware requirements, 
implementation issues, and reconstruction effort, compared to conventional MRI. Therefore, a direct 
translation into clinical applications might not be achievable. As possible and improved alternative, Sweep 
Imaging With Fourier Transformation (SWIFT), might be explored. Still, the use of MRI has proved to be 
advantageous over CT imaging, not only because of its radiation-free nature, but also because of its higher 
sensitivity.  Despite being the less “user friendly” and one of the more complex imaging modalities, MRI is 
probably the only technique which could be used to monitor every step of the tissue engineering process, from 
anatomical imaging (a.o. cell tracking, implant location/degradation and neo-vascularization), to functional 
imaging to monitor tissue-specific metabolism or perfusion mechanisms. One big gap in bone tissue imaging 
remains the lack of specific bone-seeking tracers for MRI. Probably the main reason why the development of 
such tracer is still ongoing, is that the majority of the experimental work has been focused on the use of 
gadolinium as imaging agent. Bone targeting with gadolinium has resulted in products with optimal imaging 
properties, but usually exhibit slow clearance from the bone, thus resulting  in a high risk of local toxicity. One 
promising alternative might be the use of less toxic fluorinated probes. The resonance frequency of Fluorine-19 
(
19
F) is very similar to that for hydrogen (
1
H) which potentially allows for  the use of the existing 
1
H MR scanner 
infrastructure for 
19
F measurements. Furthermore, since 
19
F is essentially absent in the human body, the 
measurements do not suffer any interference from a background signal. The synthesis of a valid bone-seeking 
MR tracer truly holds the potential to cause a new revolution in bone imaging, for example by mimicking 
18
F- 
Fluoride PET scans, in a radiation free setting.  
Besides the necessity of more optimal tracers, the sensitivity of MRI is still too low when compared to PET. 
Thus, the most evident conclusion of this thesis is that every imaging modality has specific strengths and 
weaknesses, usually that modalities with the highest sensitivity have relatively poor resolution, while those 
with high resolution have relatively poor sensitivity.  Hence, the growing interest for multimodal imaging. For 
example, with dual probes for PET/MRI, the high sensitivity of PET can be used as a whole body screening 
method to identify regions of interest. This approach would then reduce the volume of tissue that needs to be 
scanned and the scan time required for high-resolution imaging by MRI. On the other hand, although 
multimodality surely gives complementary information, it also complicates the handling of data, and 
interpretation of the results. In the next years, pre-clinical imaging companies will have to keep up with the 
rapidly growing research field, by designing hybrid multimodality imaging instruments and optimizing the 
already existing ones (PET/CT, PET/SPECT/CT, PET/MRI, among others). As our results suggest, focusing on the 
design of smart contrast agents, while integrating different imaging modalities and thus obtaining 
complementary data, will dramatically contribute to improve the knowledge on bone healing and regenerative 
processes.       
  
 
Samenvatting, afsluitende opmerkingen en toekomstperspectief 
 
  
1. Samenvatting, en evaluatie van de doelstellingen  
In een vergrijzende samenleving komen problemen met botweefsel steeds vaker voor, bijvoorbeeld door 
osteoporose, of simpelweg door het toenemen van het aantal traumatische botbeschadigingen. Daarom wordt 
er veel aandacht besteed aan het ontwikkelen van efficiënte behandelingen. Autoloog donorbot vormt de 
gouden standaard bij het behandelen van grote, niet zelfhelende botdefecten, maar is helaas beperkt 
beschikbaar, waardoor alternatieven nodig zijn. Verschillende soorten synthetische botvervangers, gebaseerd 
op polymeren of keramiek, zijn al beschikbaar. Een aantal van deze alternatieven is ook al goedgekeurd voor 
klinisch gebruik.   
Ondanks de uitgebreide karakterisering van materialen gebaseerd op calciumfosfaatkeramiek, en de 
botgeleidende eigenschappen van dergelijke materialen, is het opmerkelijk dat er maar beperkte longitudinale 
data bestaat over het gedrag van deze materialen gedurende de periode van implanteren. Dit terwijl er 
voldoende preklinische niet-invasieve beeldvormende technieken zijn, die op elk moment direct kunnen 
bijdragen aan de evaluatie  van de therapeutische uitkomst.  
Het onderliggende doel van dit proefschrift was om beeldvormende technieken te onderzoeken bij het gebruik 
van een synthetisch bot substituut, nl. calciumfosfaatcement. In hoofdstuk 1, wordt eerst een algemene 
inleiding gegeven over beeldvormende technieken in botweefselregeneratie, en worden een aantal doelen en 
vraagstellingen geformuleerd. Elk van de hoofdstukken behandelt vervolgens een van deze vraagstellingen. 
  
1. Wat is de huidige status van beeldvormende technieken voor botweefsel en 
biomaterialen? 
Sinds de ontdekking van de röntgenstraling in 1895, en de eerste radiologische afbeelding van een menselijke 
hand, is botweefsel het onderwerp geweest van gedetailleerde studies op het gebied van medische 
beeldvorming. Recente vooruitgang bij het maken van kunstmatige botsubstituten, laten echter duidelijk de 
grenzen van röntgenologische beeldvorming zien. Het is momenteel van uiterst belang, om betere methoden 
te ontwikkelen waarmee genezend bot gevolgd kan worden. Het wetenschappelijke veld van medische 
beeldvorming biedt vele niet-invasieve, zeer gevoelige technieken, die met een groot oplossend vermogen 
anatomische structuren en functionele eigenschappen kunnen weergeven. Te denken valt aan optische 
beeldvorming, ultrageluid, PET, SPECT, MRI etc. Dergelijke technieken kunnen voor een deel dienen als 
alternatief, of zijn in elk geval complementair aan, de gangbare röntgen computertomografie. Bovendien zijn er 
tegenwoordig diverse apparaten specifiek beschikbaar voor preklinisch onderzoek, waarbij de gevoeligheid en 
het oplossend vermogen aanzienlijk hoger zijn ten opzichte van apparaten in de kliniek.  Zulke apparaten zullen 
het vertalen van experimentele gegevens naar klinische toepassing uiteindelijk versnellen. Tenslotte, neemt 
ook het aantal botspecifieke contrastmiddelen voor de diverse manieren van beeldvorming nog steeds toe. Dit 
eerste hoofdstuk richt zich op zulke preklinische beeldvormende technieken, elk met de bijbehorende sterktes 
en zwaktes. Deze technieken kunnen behalve zelfstandig, ook in combinatie toegepast worden. Multimodale 
beeldvorming zal een duidelijke bijdrage kunnen leveren aan de beschikbare kennis over het proces van 
botregeneratie.   
 
2. Is Magnetische Resonantie een geschikte techniek voor het afbeelden  van bot, en 
calciumfosfaatgebaseerde materialen? 
Calciumfosfaatcement (CPC) is een veel gebruikt botsubstituut materiaal. CPC heeft echter een vergelijkbare 
radiopaciteit met natuurlijk botweefsel, waardoor dit materiaal moeilijk onderscheiden kan worden in de 
klassieke röntgenfoto’s en CT scans. Ook conventionele MRI is lastig toepasbaar voor botweefsel, door het lage 
gehalte van water en de zeer korte T2 relaxatie tijd. Voor het afbeelden van botweefsel zijn echter recentelijk 
aparte technieken ontwikkeld; ultra-short echo time (UTE) en  zero echo time (ZTE) MRI. In dit hoofdstuk werd 
onderzocht of bot en CPC materiaal met een dergelijke aangepaste MRI techniek onderscheiden konden 
  
worden. T1 en T2* waarden, zoals bepaald met UTE MRI, lieten echter weinig verschil zien tussen het bot en 
het CPC materiaal.  Daardoor was het onmogelijk om CPC te detecteren op basis van alleen het T1 of T2 signaal. 
Na toevoegen van ultra kleine ijzeroxide deeltjes  (USPIO) of gadopentetaat dimeglumine (Gd-DTPA), in een 
hoeveelheid van 1 of 5 gewichtsprocent, kon het CPC materiaal wel duidelijk gezien worden als een gebied met 
een verlaagde intensiteit in de ZTE beelden, in zowel  in vitro als ex vivo experimenten. De toevoegingen 
hadden wel een negatieve invloed op de uithardingtijd  en/of de mechanische eigenschappen van het CPC, met 
uitzondering van de 1% concentratie Gd-DTPA. Daarom werd alleen deze samenstelling verder getest in een in 
vivo experiment. Hierin werd een verhoogd contrast voor CPC gezien direct na implantatie, en een significante 
afname in de 8 weken daarna. De resultaten laten dus zien dat ZTE met Gd-DTPA als contrastmiddel een 
geschikte stralingsvrije methode is om degradatie van CPC en regeneratie van bot te volgen in preklinische 
experimenten. 
 
3. Hoe kan het contrast tussen calciumfosfaatcement en bot verhoogd worden in zowel CT 
als MRI? 
Calciumfosfaatcement wordt vaak gebruikt als botsubstituut materiaal, aangezien dit materiaal gelijkenis 
vertoont met de samenstelling van de minerale fase van botweefsel. Deze gelijkenis met natuurlijk bot heeft 
echter tegelijkertijd als nadeel dat het erg moeilijk is om onderscheid te maken met botweefsel, in normale 
afbeeldingen met röntgenfoto’s of 3 dimensionale röntgen computertomografie (CT). Hetzelfde geldt voor 
nieuwe beeldvormende technieken voor botweefsel zoals MRI. Zelfs bij hoge resolutie opnamen is het gebrek 
aan contrast tussen CPC en het omliggende bot evident. Daarom werd in dit hoofdstuk gekeken of het mogelijk 
was een dubbel contrastmiddel te ontwerpen, waarmee het contrast tussen bot en cement detecteerbaar is 
met zowel CT als MRI. Nano-partikels van colloïdaal goud en superparamagnetisch ijzeroxide (SPIO) werden 
ingesloten in silica bolletjes. Een suspensie van zulke bolletjes werd toegevoegd aan calciumfosfaat poeder. Het 
cement dat met dit poeder werd gemaakt werd vervolgens in vitro, en in vivo getest in een defect in de 
femorale condyl van de rat. De resultaten lieten zien dat de mechanische eigenschappen van het cement niet 
significant veranderden door het toevoegen van de bolletjes. Zowel de in vitro als in vivo data lieten een 
homogene verdeling van het contrast zien door het cement. Het cement was visueel goed waarneembaar, en 
werd verder gekarakteriseerd door een duidelijk CT contrast op de korte termijn en MRI contrast op de langere 
termijn. Het MRI beeld vertoonde daarbij een karakteristieke uitgewaaierde vorm, het zgn. blooming effect. 
Tenslotte konden geen nadelige reacties op het weefsel worden gevonden. In conclusie, bewijst deze studie 
dat het mogelijk is een multimodaal inert en biocompatibel contrastmiddel te ontwikkelen om 
calciumfosfaatcement en botweefsel effectief onderling te kunnen onderscheiden.  
4. Kan een MRI contrastmiddel uitgebreid worden tot een theranositisch middel voor 
botregeneratie? 
Het is een uitdaging het om herstel van botweefsel in beeld te brengen rond biomimetische biomaterialen, 
zoals calciumfosfaatcement. Dit hoofdstuk beschrijft een theranostisch middel (TM) om gelijktijdig de 
beeldvorming, en de botinducerende eigenschappen van dergelijk botsubstituut te verbeteren. Voor dit doel 
werden mesoporeuze silica bolletjes vervaardigd, die een kern hadden van ijzeroxide om het MRI contrast te 
verhogen. Dezelfde bolletjes werden voorzien van silaan koppelingen om het bot-inducerende eiwit BMP-2 te 
immobiliseren. De bolletjes werden tenslotte afgedekt met een laagje calciumfosfaat, en toegevoegd aan CPC. 
Er werden zowel  in vitro als in vivo testen uitgevoerd. De in vitro experimenten liezen zien  dat het toevoegen 
van de TM bolletjes niet interfereerde met de essentiële materiaaleigenschappen, zoals de uitharding van het 
cement.  Verder kon bio-actief BMP-2 effectief vrijkomen van de drager bolletjes. In vivo experimenten in een 
femoraal condyl defectmodel in een rat lieten zien dat op lange termijn MRI contrast verkregen kon worden, en 
dat de botvorming bevorderd werd. Bovendien kwam het TM vrij gedurende de degradatie van het CPC 
materiaal, zonder ingebouwd te worden in het nieuwgevormde bot. Daaruit kan geconcludeerd worden dat het 
  
beschreven TM bruikbaar is om de degradatie van materialen en botheling rond die materialen longitudinaal te 
bestuderen.  
5. Zijn PET en/of SPECT geschikte technieken om botheling te meten? 
Het kwantificeren van botgenezing rond radiopake synthetische materialen is onbetrouwbaar wanneer 
meetmethoden worden gebruikt die gebaseerd zijn op röntgenstraling. In dit hoofdstuk werden Single Photon 
Emission Computed Tomography (SPECT) en Positron Emission Tomography (PET) onderling vergeleken als 
alternatieven om botheling te volgen in een schedeldak defectmodel in de rat. SPECT/CT werd uitgevoerd na 
toediening van 99mTechnetium-gelabeled hydroxymethyleen difosfonaat (
99m
Tc-HDP), en PET/CT werd 
uitgevoerd met 
18
F-fluoride, tot aan 10 weken na de operatie. De vorming van nieuw botweefsel werd ook 
bekeken met histologie. De CT scans gaven weliswaar informatie over het weefselherstel in niet-behandelde 
botdefecten, maar waren onbruikbaar bij de defecten gevuld met het keramiek. Het gebruik van de PET 
techniek gaf betere resultaten dan het gebruik van de SPECT. De opname van 
18
F-fluoride nam significant toe 
tot aan 4 weken na de operatie, en nam daarna weer af tot aan het laatste tijdspunt. In hetzelfde in vivo model 
werden vervolgens met PET ook dichte en poreuze keramische materialen vergeleken, waarbij het poreuze 
materiaal een significant hogere opname liet zien. In conclusie kan gesteld worden dat PET een geschikt 
hulpmiddel is om botheling kwalitatief en kwantitatief te volgen rond radiopake botsubstituten. 
6. Is PET geschikt om de heling rond verschillende botsubstituten, en de supra-fysiologische 
heling geïnduceerd door groeifactoren (BMP-2), te onderscheiden ? 
Om de regeneratie van botweefsel te bewerkstelligen, kunnen materialen gebruik worden die de groeifactor 
bone morphogenetic protein-2 (BMP-2) vrijgeven. Het kunnen bepalen van de activiteit van de groeifactoren, 
en de regeneratie rond het biomateriaal, is belangrijk om het botgenezingsproces verder te kunnen 
optimaliseren. Op dit moment wordt veelal afgegaan op histologische waarnemingen. Met niet-invasieve 
methodieken zou het ook mogelijk moeten zijn om longitudinale bepalingen in de tijd uit te voeren. In deze 
studie is er gekeken of Positron Emission Tomography (PET) gebruikt kan worden als een niet-invasieve 
methode om botvorming te bepalen rond een BMP-2-vrijgevend calciumfosfaatcement. In een defect in het 
calvarium van de rat werd het het BMP-2/CPC materiaal geplaatst, en vervolgens PET gebruikt om de 18F-
Fluoride opname te meten. As controle, werden niet-geladen poreus CPC, een volledig dicht CPC, en een 
autoloog bot transplantaat gebruikt. PET werd elke twee weken uitgevoerd, gedurende 8 weken na 
implantatie. Tegelijkertijd werden computer tomografie (CT) beelden gemaakt voor de anatomische referentie. 
De hoogste 18F-Fluoride signaalintensiteit werd gemeten in de BMP-2 groep, gevolgd door de controles in 
volgorde van hoog naar laag: poreus, dicht, en autoloog.  Deze zelfde trend bleef gedurende het hele 
experiment bestaan. Histologie, en metingen aan het bot volumepercentage bevestigden de  significant hogere 
nieuwe botvorming in de groep met BMP-2, in vergelijking met de controles. Bovendien vertoonde de 18F-
Fluoride PET opname een statistisch significante positieve correlatie met het volume van het nieuwgevormde 
bot zoals gemeten in de histologie. In conclusie, bevestigden deze resultaten de bruikbaarheid van PET/CT als 
een methode om BMP-2 vrijgevende biomaterialen in vivo te kunnen volgen in de tijd.  
7. Wat is de invloed van samenstelling en opslag op de bioactiviteit van rhBMP-2 ? 
Voor klinische toepassingen is het belangrijk om te begrijpen hoe de samenstelling en opslag van rhBMP-2 
bepalend kunnen zijn voor de uiteindelijke biologische activiteit. In de wetenschappelijke literatuur is te zien 
dat verschillende onderzoeksgroepen verschillende parameters gebruiken, zoals samenstelling, 
opslagcondities, de gebruikte doses bij toepassing in vivo, etc., waardoor het gecompliceerd is om resultaten 
onderling te vergelijken. Daarom werd besloten een basale studie te verrichten naar dergelijke parameters, 
waarbij zulke onderlinge afwijkingen vergeleken werden voor twee commercieel verkrijgbare BMPs. Onze in 
vitro experimenten lieten zien dat BMPs uit verschillende bronnen significant verschilden in bioactiviteit. Het 
  
klinisch toegestane rhBMP-2 (InductOs®; BMP-P) was superieur qua stabiliteit, in vergelijking met rhBMP-2 van 
R&D Systems (BMP-R) bij een fysiologische pH (bepaald met een ALP meting). Het BMP-P bond ook minder 
sterk aan een polypropyleen Eppendorf buisje. Het BMP-R verloor bijna alle bioactiviteit na 30 min in 
fysiologische pH, en verbond zich ook sterker aan plastic oppervlakken. Zulk aggregatiegedrag werd volledig 
bevestigd met lichtverstrooiing experimenten aan de twee BMPs, die een lineaire aggregatie in de tijd lieten 
zien voor BMP-R in tegenstelling tot BMP-P. De in vitro resultaten werden eveneens weerspiegeld in het in vivo 
werk, in een rat ectopisch model, waarbij een injecteerbare hyaluronzuur (HA) hydrogel werd gebruikt als 
drager voor de BMP. Zeven weken na de implantatie werd een groter botvolume, en georiënteerde collageen 
structuur gezien in de BMP-P groep, en een lager botvolume met ongeorganiseerd collageen bij BMP-R. Deze 
resultaten lieten dus grote verschillen in activiteit zien, tussen ogenschijnlijk identieke substanties, en 
onderlijnen daarmee het belang van de juiste behandeling van dergelijke gevoelige eiwitten.  
2. Afsluitende opmerkingen en toekomstperspectief 
Dit proefschrift had tot doel om niet-invasieve beeldvormende technieken te onderzoeken, binnen het veld van 
botregeneratie. Computertomografie (CT) en sinds kort ook Magnetische Resonantie, zijn veelgebruikte 
beeldvormingtechnieken voor bot. Met beide technieken is het gebruik van contrastmiddelen vereist om een 
kwalitatief goed beeld van calciumfosfaatgebaseerde botsubstituten te verkrijgen. Voor dit doel werd in eerste 
instantie een duaal contrastmiddel ontworpen, wat waarneembaar was met zowel CT als MRI. Na in vivo tests 
in een femoraal condyl defect in ratten, werd het MR contrast verder geoptimaliseerd om eventuele artefacten 
zoveel mogelijk te reduceren, en tenslotte zelfs tot een theranostisch middel door het toevoegen van bone 
morphogenic protein BMP-2. PET en SPECT zijn twee technieken die beide veel gebruikt worden voor het 
kwantificeren van functionele processen in botweefsel in vivo. In onze studies, bleek PET beter bruikbaar om de 
metabole activiteit van botheling te kwantificeren, en verder onderscheid te kunnen maken tussen het gedrag 
van verschillende calciumfosfaatgebaseerde botsubstituten.  
Alhoewel de MRI resultaten veelbelovend zijn, is het gebruik van Zero Echo Time nog uitdagend. Deze zgn. ZTE 
imaging with hard-pulse excitation, stelt hoge eisen op het gebied benodigde hardware, implementatie, en de 
moeite die in de reconstructie van de beelden moet worden gestoken, in vergelijking tot de conventionele MRI. 
Daarmee lijkt een directe vertaalslag naar klinische toepasbaarheid nog niet mogelijk. Als een eventueel beter 
alternatief, zou gekeken kunnen worden naar de zgn. Sweep Imaging With Fourier Transformation (SWIFT) 
techniek. Desondanks lijkt het bewezen dat het gebruik van  MRI toch een aantal voordelen heeft ten opzichte 
van de beeldvorming met  CT, niet alleen vanwege de stralingsvrije aard van de meting, maar ook vanwege de 
hoge gevoeligheid. Ondanks het lagere gebruikersgemak, inherent aan een meer complexe meetmethode, 
vormt de MRI waarschijnlijk de enige techniek die gebruikt kan worden om elke stap in het proces van 
weefselregeneratie in kaart te brengen, vanaf anatomische beeldvorming (o.a. het volgen van cellen, 
implantaat lokalisatie/degradatie, bloedvatvorming), tot aan functionele metingen aan het weefselspecifieke 
metabolisme of de perfusie mechanismen. Een groot hiaat in het afbeelden van botweefsel blijft het gebrek 
aan botbindende detectiemiddelen voor MRI. Een belangrijke reden dat zulke detectiemiddelen nog steeds in 
staat van ontwikkeling verkeren, is dat het grootste deel van de experimenten zich nog steeds richt op het 
gebruik van Gadolinium. Het detecteren van bot met Gadolinium heeft geresulteerd in een aantal producten 
met optimale beeldvormende eigenschappen, maar als nadeel verdwijnen zulke producten niet of nauwelijks 
meer uit het botweefsel, met een daaraan gekoppeld risico op locale toxiciteit. Een veelbelovend alternatief 
zou gevonden kunnen worden in het gebruik van veel minder toxische middelen gebaseerd op fluor. De 
resonantie frequentie van Fluor-19 (
19
F) is vrijwel gelijk aan die voor waterstof (
1
H) , waardoor wellicht de 
bestaande 
1
H MR scanner infrastructuur gebruikt kan worden voor 
19
F metingen. Omdat 
19
F in principe niet 
aanwezig is in het menselijk lichaam, is er bij een dergelijke meting geen sprake van interferentie met een 
achtergrondsignaal. De synthese van een geschikt botbindend MR detectiemiddel zou een revolutie kunnen 
veroorzaken in de beeldvorming van botweefsel, bijvoorbeeld door het nabootsen van 
18
F- Fluor PET scans, 
maar dan in een stralingsvrije omgeving.  
  
Behalve de behoefte aan verder geoptimaliseerde detectiemiddelen, kent MRI wel een lage gevoeligheid in 
vergelijking tot PET. Daarmee lijkt de duidelijkste conclusie van dit proefschrift dat elke beeldverwerkende 
techniek zijn eigen sterke punten en zwaktes kent: in het algemeen vertonen technieken met een hoge 
gevoeligheid een lage resolutie, en vice versa. Daarom neemt de interesse in multimodale beeldvorming toe. 
Bij het gebruik van duale PET/MRI detectiemiddelen kan bijvoorbeeld de hoge gevoeligheid van de PET 
gebruikt worden om binnen een geheel lichaam zeer specifiek de interessante gebieden op te sporen. Een 
dergelijke aanpak beperkt dan het volume, en dus de tijd, die nodig is voor een MRI scan met zeer hoge 
resolutie. Alhoewel zulke multimodale metingen zeker complementaire informatie opleveren, compliceren ze 
natuurlijk wel de verwerking van de data en interpretatie van de resultaten. In de komende jaren zullen 
bedrijven op het gebied van  preklinische beeldverwerking dan ook het snel groeiende onderzoek moeten 
bijbenen door hybride beeldinstrumenten te ontwikkelen, en de huidige generatie apparatuur geschikt te 
maken voor multimodale metingen (bv PET/CT, PET/SPECT/CT, PET/MRI). Zoals onze resultaten laten zien, kan 
het ontwikkelen van slimme contrastmiddelen, en het integreren van diverse beeldvormende technieken ter 
verkrijging van complementaire data, aanzienlijk gaan bijdragen aan de kennis over de heling van, en 
regeneratie technieken gebruikt bij botweefsel.  
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